Altria (MO) 10-Q 31 Oct 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 22, 2019
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	1-08940
Entity Registrant Name	Altria Group, Inc.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	13-3260245
Entity Address, Address Line One	6601 West Broad Street,
Entity Address, City or Town	Richmond,
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	23230
City Area Code	804
Local Phone Number	274-2200
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		1,868,126,510
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000764180
Current Fiscal Year End Date	--12-31
Common Stock, $0.33 1/3 par value [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $0.33 1/3 par value
Trading Symbol	MO
Security Exchange Name	NYSE
1.000% Notes due 2023 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2023
Trading Symbol	MO23A
Security Exchange Name	NYSE
1.700% Notes due 2025 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.700% Notes due 2025
Trading Symbol	MO25
Security Exchange Name	NYSE
2.200% Notes due 2027 [Member]
Entity Information [Line Items]
Title of 12(b) Security	2.200% Notes due 2027
Trading Symbol	MO27
Security Exchange Name	NYSE
3.125% Notes due 2031 [Member]
Entity Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2031
Trading Symbol	MO31
Security Exchange Name	NYSE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 1,604,000,000		$ 1,333,000,000
Receivables	165,000,000		142,000,000
Inventories:
Leaf tobacco	820,000,000		940,000,000
Other raw materials	201,000,000		186,000,000
Work in process	598,000,000		647,000,000
Finished product	569,000,000		558,000,000
Inventory, net	2,188,000,000		2,331,000,000
Income taxes	15,000,000		167,000,000
Other current assets	319,000,000		326,000,000
Total current assets	4,291,000,000		4,299,000,000
Property, plant and equipment, at cost	5,009,000,000		4,950,000,000
Less accumulated depreciation	3,047,000,000		3,012,000,000
Property, plant and equipment, net	1,962,000,000		1,938,000,000
Goodwill	5,262,000,000		5,196,000,000			$ 5,307,000,000
Other intangible assets, net	12,688,000,000		12,279,000,000			12,400,000,000
Investments in equity securities	27,346,000,000		30,496,000,000
Other assets	1,364,000,000		1,430,000,000
Total Assets	52,913,000,000		55,638,000,000
Liabilities
Short-term borrowings	0		12,704,000,000
Current portion of long-term debt	1,000,000,000		1,144,000,000
Accounts payable	246,000,000		399,000,000
Accrued liabilities:
Marketing	554,000,000		586,000,000
Settlement charges	3,094,000,000		3,454,000,000
Other	1,195,000,000		1,403,000,000
Dividends payable	1,573,000,000		1,503,000,000
Total current liabilities	7,662,000,000		21,193,000,000
Long-term debt	26,903,000,000		11,898,000,000
Deferred income taxes	5,240,000,000		5,172,000,000
Accrued pension costs	352,000,000		544,000,000
Accrued postretirement health care costs	1,764,000,000		1,749,000,000
Other liabilities	316,000,000		254,000,000
Total liabilities	42,237,000,000		40,810,000,000
Contingencies (Note 13)
Redeemable noncontrolling interest	39,000,000		39,000,000
Stockholders’ Equity
Common stock, par value $0.33 1/3 per share (2,805,961,317 shares issued)	935,000,000		935,000,000
Additional paid-in capital	5,960,000,000		5,961,000,000
Earnings reinvested in the business	39,910,000,000		43,962,000,000
Accumulated other comprehensive losses	(2,402,000,000)		(2,547,000,000)
Cost of repurchased stock (937,835,860 shares at September 30, 2019 and 931,903,722 shares at December 31, 2018)	(33,858,000,000)		(33,524,000,000)
Total stockholders’ equity attributable to Altria	10,545,000,000		14,787,000,000
Noncontrolling interests	92,000,000		2,000,000
Total stockholders’ equity	10,637,000,000	$ 14,466,000,000	14,789,000,000	$ 15,496,000,000	$ 15,798,000,000	$ 15,380,000,000
Total Liabilities and Stockholders’ Equity	$ 52,913,000,000		$ 55,638,000,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.3333	$ 0.3333
Common stock, shares issued (shares)	2,805,961,317	2,805,961,317
Shares repurchased (shares)	937,835,860	931,903,722

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Net revenues	$ 6,856	$ 6,837	$ 19,103	$ 19,250
Cost of sales	1,915	2,037	5,367	5,509
Excise taxes on products	1,444	1,545	4,109	4,409
Gross profit	3,497	3,255	9,627	9,332
Marketing, administration and research costs	552	700	1,654	1,959
Asset impairment and exit costs	1	(2)	74	2
Operating income (expense)	2,944	2,557	7,899	7,371
Interest and other debt expense, net	293	159	989	503
Net periodic benefit income, excluding service cost	(24)	(21)	(40)	(37)
Earnings from equity investments	(333)	(189)	(866)	(759)
Impairment of JUUL equity securities	4,500	0	4,500	0
Loss on Cronos-related financial instruments	636	0	1,327	0
Loss on ABI/SABMiller business combination	0	0	0	33
Earnings (losses) before income taxes and equity earnings of subsidiaries	(2,128)	2,608	1,989	7,631
Provision for income taxes	474	664	1,473	1,915
Net earnings (losses)	(2,602)	1,944	516	5,716
Net (earnings) losses attributable to noncontrolling interests	2	(1)	0	(3)
Net earnings (losses) attributable to Altria	$ (2,600)	$ 1,943	$ 516	$ 5,713
Per share data:
Basic and diluted earnings (losses) per share attributable to Altria (in usd per share)	$ (1.39)	$ 1.03	$ 0.27	$ 3.02

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Earnings - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net earnings (losses)	$ (2,602)	$ 1,944	$ 516	$ 5,716
Other comprehensive earnings (losses), net of deferred income taxes:
Benefit plans	26	39	84	126
ABI	221	(422)	53	(262)
Currency translation adjustments and other	(3)	1	8	(1)
Other comprehensive earnings (losses), net of deferred income taxes	244	(382)	145	(137)
Comprehensive earnings (losses)	(2,358)	1,562	661	5,579
Comprehensive (earnings) losses attributable to noncontrolling interests	2	(1)	0	(3)
Comprehensive earnings (losses) attributable to Altria	$ (2,356)	$ 1,561	$ 661	$ 5,576

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions		Total		Common Stock [Member]	Additional Paid-in Capital [Member]	Earnings Reinvested in the Business [Member]		Accumulated Other Comprehensive Losses [Member]	Cost of Repurchased Stock [Member]	Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2017		$ 15,380		$ 935	$ 5,952	$ 42,251		$ (1,897)	$ (31,864)	$ 3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (losses)	[1]	5,713				5,713
Other comprehensive earnings (losses), net of deferred income taxes		(137)						(137)
Stock award activity		17			7				10
Cash dividends declared		(4,159)				(4,159)
Repurchases of common stock		(1,317)							(1,317)
Other		(1)								(1)
Ending balance at Sep. 30, 2018		15,496		935	5,959	43,805		(2,034)	(33,171)	2
Beginning balance at Jun. 30, 2018		15,798		935	5,948	43,369		(1,652)	(32,804)	2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (losses)		1,943				1,943
Other comprehensive earnings (losses), net of deferred income taxes		(382)						(382)
Stock award activity		11			11
Cash dividends declared		(1,507)				(1,507)
Repurchases of common stock		(367)							(367)
Ending balance at Sep. 30, 2018		15,496		935	5,959	43,805		(2,034)	(33,171)	2
Beginning balance at Dec. 31, 2018		14,789		935	5,961	43,962		(2,547)	(33,524)	2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (losses)		513	[1]			516	[1]			(3)
Other comprehensive earnings (losses), net of deferred income taxes		145						145
Stock award activity		11			(1)				12
Cash dividends declared		(4,568)				(4,568)
Repurchases of common stock		(346)							(346)
Issuance of noncontrolling interest in Helix		88								88
Other		5								5
Ending balance at Sep. 30, 2019		10,637		935	5,960	39,910		(2,402)	(33,858)	92
Beginning balance at Jun. 30, 2019		14,466		935	5,953	44,081		(2,646)	(33,859)	2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (losses)		(2,603)				(2,600)				(3)
Other comprehensive earnings (losses), net of deferred income taxes		244						244
Stock award activity		8			7				1
Cash dividends declared		(1,571)				(1,571)
Repurchases of common stock		0
Issuance of noncontrolling interest in Helix		88								88
Other		5								5
Ending balance at Sep. 30, 2019		$ 10,637		$ 935	$ 5,960	$ 39,910		$ (2,402)	$ (33,858)	$ 92
[1]	Amounts attributable to noncontrolling interests for the nine months ended September 30, 2019 and 2018 exclude net earnings of $3 million due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars , which is reported in the mezzanine equity section on the condensed consolidated balance sheets.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Stockholders' Equity [Abstract]
Net earnings attributable to noncontrolling interests	$ 1	$ 1	$ 3	$ 3
Dividends declared (usd per share)	$ 0.84	$ 0.80	$ 2.44	$ 2.2

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Provided by (Used in) Operating Activities
Net earnings (losses)	$ 516	$ 5,716
Adjustments to reconcile net earnings (losses) to operating cash flows:
Depreciation and amortization	163	168
Deferred income tax provision (benefit)	(261)	215
Earnings from equity investments	(866)	(759)
Dividends from ABI	221	477
Loss on ABI/SABMiller business combination	0	33
Loss on Cronos-related financial instruments	1,327	0
Impairment of JUUL equity securities	4,500	0
Asset impairment and exit costs, net of cash paid	(33)	(24)
Cash effects of changes:
Receivables	(21)	(45)
Inventories	147	147
Accounts payable	(157)	(79)
Income taxes	174	308
Accrued liabilities and other current assets	(359)	(319)
Accrued settlement charges	(360)	757
Pension plan contributions	(51)	(19)
Pension provisions and postretirement, net	(42)	(19)
Other, net	376	9
Net cash provided by (used in) operating activities	5,274	6,566
Cash Provided by (Used in) Investing Activities
Capital expenditures	(160)	(132)
Investment in Cronos	(1,863)	0
Acquisition of businesses and assets	(421)	(15)
Other, net	32	10
Net cash provided by (used in) investing activities	(2,412)	(137)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	(12,800)	0
Long-term debt issued	16,265	0
Long-term debt repaid	(1,144)	0
Repurchases of common stock	(346)	(1,317)
Dividends paid on common stock	(4,498)	(3,909)
Other, net	(127)	(25)
Net cash provided by (used in) financing activities	(2,650)	(5,251)
Cash, cash equivalents and restricted cash:
Increase (decrease)	212	1,178
Balance at beginning of period	1,433	1,314
Balance at end of period	1,645	2,492
Cash, cash equivalents and restricted cash	$ 1,645	$ 1,314

Background and Basis of Present

Background and Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Basis of Presentation	Background and Basis of Presentation: Background At September 30, 2019 , Altria Group, Inc.’s (“Altria”) wholly-owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly-owned subsidiary of PM USA; Sherman Group Holdings, LLC and its subsidiaries (“Nat Sherman”), which are engaged in the manufacture and sale of super premium cigarettes and the sale of premium cigars; UST LLC (“UST”), which through its wholly-owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of smokeless tobacco products and wine; and Philip Morris Capital Corporation (“PMCC”), which maintains a portfolio of finance assets, substantially all of which are leveraged leases. In December 2018, Altria refocused its innovative product efforts, which included the discontinuation of production and distribution of all e-vapor products by Nu Mark LLC (“Nu Mark”). Prior to that time, Nu Mark was engaged in the manufacture and sale of innovative tobacco products. Other Altria wholly-owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to certain Altria operating subsidiaries, and Altria Client Services LLC, which provides various support services in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs to Altria and its subsidiaries. Altria’s access to the operating cash flows of its wholly-owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. At September 30, 2019 , Altria’s principal wholly-owned subsidiaries were not limited by long-term debt or other agreements in their ability to pay cash dividends or make other distributions with respect to their equity interests. At September 30, 2019 , Altria had a 10.1% economic and voting interest in Anheuser-Busch InBev SA/NV (“ABI”), which Altria accounts for under the equity method of accounting using a one-quarter lag. Altria receives cash dividends on its interest in ABI and will continue to do so as long as ABI pays dividends. During the third quarter of 2019, Helix Innovations LLC (“Helix”), a subsidiary of Altria, acquired Burger Söhne Holding and its subsidiaries as well as certain affiliated companies (the “Burger Group”) that commercialize on! oral nicotine pouches (tobacco-derived nicotine). At closing, Altria indirectly owns an 80% interest in Helix, for which Altria paid $353 million . The financial results of Helix are included in Altria’s condensed consolidated financial statements as part of its smokeless products segment, with the 20% ownership interest in Helix (held by the former shareholders of the Burger Group) included as a noncontrolling interest. The final purchase price allocation, which is subject to post-closing adjustments, will be completed by the third quarter of 2020. In December 2018, Altria, through a wholly-owned subsidiary, purchased shares of non-voting convertible common stock of JUUL Labs, Inc. (“JUUL”), representing a 35% economic interest for $12.8 billion . JUUL is engaged in the manufacture and sale of e-vapor products globally and is the U.S. leader in e-vapor. If and when antitrust clearance is obtained, Altria’s non-voting shares will automatically convert to voting shares (“Share Conversion”). In April 2019, Altria and JUUL received a request for additional information (commonly referred to as a “second request”) from the U.S. Federal Trade Commission (the “FTC”). As of October 30, 2019, Altria and JUUL have certified substantial compliance with the second request. Based on the timing agreement among Altria, JUUL and the FTC staff, Share Conversion will not occur before the end of the 70 th calendar day following certification of substantial compliance by Altria and JUUL unless the FTC completes its review prior to that day. At September 30, 2019 , Altria had a 35% economic interest in JUUL, which Altria accounts for as an investment in an equity security. Upon Share Conversion, Altria expects to account for its investment in JUUL under the equity method of accounting. Altria has agreed to non-competition obligations generally requiring that it participate in the e-vapor business only through JUUL as long as Altria is supplying JUUL services, which Altria is committed to doing until at least December 20, 2024. In March 2019, Altria, through a subsidiary, completed its acquisition of a 45% economic and voting interest in Cronos Group Inc. (“Cronos”), a global cannabinoid company headquartered in Toronto, Canada. At September 30, 2019 , Altria had an approximate 45% economic and voting interest in Cronos, which Altria accounts for under the equity method of accounting using a one-quarter lag. For further discussion of Altria’s investments in equity securities, see Note 5 . Investments in Equity Securities . Dividends and Share Repurchases During the third quarter of 2019, Altria’s Board of Directors (the “Board of Directors”) approved a 5% increase in the quarterly dividend rate to $0.84 per share of Altria common stock versus the previous rate of $0.80 per share. The current annualized dividend rate is $3.36 per share. Future dividend payments remain subject to the discretion of the Board of Directors. In July 2015, the Board of Directors authorized a $1.0 billion share repurchase program that it expanded to $3.0 billion in October 2016 and to $4.0 billion in July 2017 (as expanded, the “July 2015 share repurchase program”). In January 2018, Altria completed the July 2015 share repurchase program, under which it purchased a total of 58.7 million shares of its common stock at an average price of $68.15 per share. Following the completion of the July 2015 share repurchase program, the Board of Directors authorized a new $1.0 billion share repurchase program in January 2018 that it expanded to $2.0 billion in May 2018 (as expanded, the “January 2018 share repurchase program”). In June 2019, Altria completed the January 2018 share repurchase program, under which it purchased a total of 34.0 million shares of its common stock at an average price of $58.86 per share. In July 2019, the Board of Directors authorized a new $1.0 billion share repurchase program (the “July 2019 share repurchase program”). As of September 30, 2019, there have been no share repurchases under the July 2019 share repurchase program. Share repurchases under this program depend upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board of Directors. Altria’s share repurchase activity was as follows: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions, except per share data) Total number of shares repurchased 6.4 21.8 — 6.2 Aggregate cost of shares repurchased $ 346 $ 1,317 $ — $ 367 Average price per share of shares repurchased $ 54.36 $ 60.53 $ — $ 59.18 Basis of Presentation The interim condensed consolidated financial statements of Altria are unaudited. It is the opinion of Altria’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected in the interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year. These statements should be read in conjunction with the consolidated financial statements and related notes, which appear in Altria’s Annual Report on Form 10-K for the year ended December 31, 2018 . On January 1, 2019, Altria adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) and all related ASU amendments (collectively “ASU No. 2016-02”), which requires entities to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. Altria has elected to apply the guidance retrospectively at the beginning of the period of adoption. As a result, comparative periods prior to adoption will continue to be presented in accordance with prior lease guidance, including disclosures. The impact of the adoption was not material to Altria’s consolidated financial statements. As a result of the adoption, Altria and its subsidiaries, as lessees, recorded right-of-use assets and lease liabilities of $179 million at January 1, 2019 for its leases, which were all operating leases. There was no cumulative effect adjustment to the opening balance of earnings reinvested in the business. Right-of-use assets and lease liabilities on Altria’s condensed consolidated balance sheet at September 30, 2019 were not materially different than the amounts recorded upon adoption of ASU No. 2016-02. Additionally, in accordance with ASU No. 2016-02, lessor accounting for leveraged leases that commenced before the January 1, 2019 adoption date of ASU No. 2016-02 is unchanged unless there is a change in the scope of, or the consideration for, such leases. As a result, adoption of ASU No. 2016-02 as it relates to PMCC’s leveraged leases had no impact on Altria’s financial statements at the adoption date. During the first nine months of 2019, PMCC had no new leases nor any changes in the scope of or the consideration for its existing leveraged leases. For a description of issued accounting guidance applicable to, but not yet adopted by, Altria, see Note 15 . New Accounting Guidance Not Yet Adopted .

Revenues from Contracts with Cu

Revenues from Contracts with Customers	9 Months Ended
	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	Revenues from Contracts with Customers: Altria disaggregates net revenues based on product type. For further discussion, see Note 10 . Segment Reporting . Altria’s businesses offer cash discounts to customers for prompt payment and calculate cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Altria’s businesses record an allowance for cash discounts, which is included as a contra-asset against receivables on Altria’s condensed consolidated balance sheets. There was no allowance for cash discounts at September 30, 2019 and December 31, 2018 , and there were no differences between amounts recorded as an allowance for cash discounts and cash discounts subsequently given to customers. Altria’s businesses that receive payments in advance of product shipment record such payments as deferred revenue. These payments are included in other accrued liabilities on Altria’s condensed consolidated balance sheets until control of such products is obtained by the customer. Deferred revenue was $229 million and $288 million at September 30, 2019 and December 31, 2018 , respectively. When cash is received in advance of product shipment, Altria’s businesses satisfy their performance obligations within three days of receiving payment. At September 30, 2019 and December 31, 2018 , there were no differences between amounts recorded as deferred revenue and amounts subsequently recognized as revenue. Receivables, which primarily reflect sales of wine produced and/or distributed by Ste. Michelle, were $165 million and $142 million at September 30, 2019 and December 31, 2018 , respectively. At September 30, 2019 and December 31, 2018 , there were no expected differences between amounts recorded and subsequently received, and Altria’s businesses did not record an allowance for doubtful accounts against these receivables. Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s condensed consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, due to the limited shelf life of USSTC’s smokeless tobacco products it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return. Sales incentives include variable payments related to goods sold by Altria’s businesses. Altria’s businesses include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers. The sales incentives that require significant estimates and judgments are as follows: Price promotion payments- Altria’s businesses make price promotion payments, substantially all of which are made to their retail partners, to incent the promotion of certain product offerings in select geographic areas. Wholesale and retail participation payments- Altria’s businesses make payments to their wholesale and retail partners to incent merchandising and sharing of sales data in accordance with each business’s trade agreements. These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates. Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions. Differences between actual and estimated payments are reflected in the period such information becomes available. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements.

Asset Impairment, Exit and Impl

Asset Impairment, Exit and Implementation Costs	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Asset Impairment, Exit and Implementation Costs	Asset Impairment, Exit and Implementation Costs: Pre-tax asset impairment, exit and implementation costs consisted of the following: For the Nine Months Ended September 30, 2019 For the Nine Months Ended September 30, 2018 Asset Impairment and Exit Costs Implementation Costs (1) Total Asset Impairment and Exit Costs Implementation Costs (2) Total (in millions) Smokeable products $ 50 $ 29 $ 79 $ (4 ) $ 1 $ (3 ) Smokeless products 9 3 12 6 3 9 All other 14 (7 ) 7 — — — General corporate 1 — 1 — — — Total 74 25 99 2 4 6 Plus amounts included in net periodic benefit income, excluding (3) 12 — 12 — — — Total $ 86 $ 25 $ 111 $ 2 $ 4 $ 6 (1) Included in cost of sales ( $1 million cost reversal) and marketing, administration and research costs ( $26 million ) in Altria’s condensed consolidated statement of earnings. (2) Included in cost of sales in Altria’s condensed consolidated statements of earnings. (3) Represents curtailment costs. See Note 7 . Benefit Plans . For the Three Months Ended September 30, 2019 For the Three Months Ended September 30, 2018 Asset Impairment and Exit Costs Implementation Costs (1) Total Asset Impairment and Exit Costs Implementation Costs (2) Total (in millions) Smokeable products $ — $ 4 $ 4 $ (5 ) $ (1 ) $ (6 ) Smokeless products 1 — 1 3 — 3 Total $ 1 $ 4 $ 5 $ (2 ) $ (1 ) $ (3 ) (1) Included in cost of sales ( $1 million ) and marketing, administration and research costs ( $3 million ) in Altria’s condensed consolidated statement of earnings. (2) Included in cost of sales in Altria’s condensed consolidated statements of earnings. The 2019 pre-tax asset impairment, exit and implementation costs are related to the cost reduction program and the refocus of innovative product efforts discussed below. The movement in the restructuring liabilities, substantially all of which are severance liabilities, was as follows: For the Nine Months Ended September 30, 2019 (in millions) Balances at December 31, 2018 $ 155 Charges 52 Cash spent (119 ) Balances at September 30, 2019 $ 88 Cost Reduction Program In December 2018, Altria announced a cost reduction program that includes, among other things, reducing third-party spending and workforce reductions across the businesses. As a result of the cost reduction program, Altria expects to record total pre-tax restructuring charges of approximately $240 million , which includes employee benefit-related curtailment and settlement costs. Of this amount, Altria incurred pre-tax charges of $121 million in 2018 and expects to record the remainder in 2019. The total estimated charges, substantially all of which will result in cash expenditures, relate primarily to employee separation costs of approximately $210 million and other costs of approximately $30 million . For the nine and three months ended September 30, 2019 , total pre-tax asset impairment, exit and implementation costs were $99 million and $5 million , respectively. Total pre-tax charges incurred since the inception of this cost reduction program were $220 million at September 30, 2019 . Cash payments related to this cost reduction program of $110 million and $38 million were made during the nine and three months ended September 30, 2019 , respectively. There were no cash payments related to this program in 2018. Refocus of Innovative Product Efforts During the fourth quarter of 2018, Altria refocused its innovative product efforts, which included Nu Mark’s discontinuation of production and distribution of all e-vapor products . During the nine months ended September 30, 2019, Altria incurred pre-tax charges of $12 million , consisting of asset impairment, exit and implementation costs. During 2018, Altria incurred pre-tax charges of $272 million , consisting of asset impairment and exit costs of $209 million primarily related to the impairment of goodwill and other intangible assets, and other charges of $63 million related to inventory write-offs and accelerated depreciation. The pre-tax charges related to the refocus of innovative product efforts have been substantially completed. The majority of the charges related to these efforts did not result in cash payments.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, net	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, net	Goodwill and Other Intangible Assets, net Goodwill and other intangible assets, net, by segment were as follows: Goodwill Other Intangible Assets, net September 30, 2019 December 31, 2018 September 30, 2019 December 31, 2018 (in millions) Smokeable products $ 99 $ 99 $ 3,077 $ 3,037 Smokeless products 5,089 5,023 9,189 8,825 Wine 74 74 238 239 Other — — 184 178 Total $ 5,262 $ 5,196 $ 12,688 $ 12,279 The change in goodwill relates to the 2019 acquisition of the Burger Group. For additional information, see Note 1 . Background and Basis of Presentation . Other intangible assets consisted of the following: September 30, 2019 December 31, 2018 Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization (in millions) Indefinite-lived intangible assets $ 11,846 $ — $ 11,846 $ — Definite-lived intangible assets 1,090 248 654 221 Total other intangible assets $ 12,936 $ 248 $ 12,500 $ 221 At September 30, 2019 , indefinite-lived intangible assets consist substantially of trademarks from Altria’s 2009 acquisition of UST ( $9.0 billion ) and 2007 acquisition of Middleton ( $2.6 billion ). Definite-lived intangible assets, which consist primarily of intellectual property, customer relationships and certain cigarette trademarks, are amortized over a weighted-average period of 19 years . Pre-tax amortization expense for definite-lived intangible assets was $28 million and $30 million for the nine months ended September 30, 2019 and 2018 , respectively, and $12 million and $20 million for the three months ended September 30, 2019 and 2018 , respectively. Annual amortization expense for each of the next five years is estimated to be approximately $63 million , assuming no additional transactions occur that require the amortization of intangible assets. The changes in goodwill and net carrying amount of intangible assets were as follows: For the Nine Months Ended September 30, 2019 For the Year Ended December 31, 2018 Goodwill Other Intangible Assets, net Goodwill Other Intangible Assets, net (in millions) Balance at January 1 $ 5,196 $ 12,279 $ 5,307 $ 12,400 Changes due to: Acquisitions (1) 66 437 — 15 Asset impairment (2) — — (111 ) (98 ) Amortization — (28 ) — (38 ) Balance at End of Period $ 5,262 $ 12,688 $ 5,196 $ 12,279 (1) Substantially all of the 2019 changes reflect the acquisition of the Burger Group, which held assets consisting primarily of intellectual property. (2) Reflects asset impairment of goodwill and other intangible assets, net, related to e-vapor products and the Columbia Crest trademark.

Investments in Equity Securitie

Investments in Equity Securities	9 Months Ended
	Sep. 30, 2019
Investments [Abstract]
Investment	Investments in Equity Securities: Altria’s investments consisted of the following: Carrying Amount September 30, 2019 December 31, 2018 (in millions) ABI $ 17,950 $ 17,696 JUUL 8,305 12,800 Cronos (1) 1,091 — Total $ 27,346 $ 30,496 ( 1) Includes investment in Acquired Common Shares ( $673 million ), the Cronos warrant ( $315 million ) and the Fixed-price Preemptive Rights ( $103 million ) as discussed further below. Earnings from equity investments accounted for under the equity method of accounting consisted of the following: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) ABI $ 640 $ 759 $ 252 $ 189 Cronos (1) 226 — 81 — Total $ 866 $ 759 $ 333 $ 189 ( 1) Represents Altria’s share of Cronos’s earnings, substantially all of which relate to the change in fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares. Investment in ABI At September 30, 2019 , Altria had a 10.1% economic and voting interest in ABI, consisting of 185 million restricted shares of ABI (the “Restricted Shares”) and 12 million ordinary shares of ABI. Altria accounts for its investment in ABI under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI’s Board of Directors (“ABI Board”) and certain ABI Board committees. Through this representation, Altria participates in ABI policy making processes. In September 2019, ABI completed its initial public offering of a minority stake of its Asia Pacific subsidiary, Budweiser Brewing Company APAC Limited. Consistent with the one-quarter lag for reporting ABI’s results in Altria’s financial results, in the fourth quarter of 2019, Altria will record the financial statement impact, which has not yet been determined, related to this transaction. Altria reviews its investment in ABI for impairment by comparing the fair value of its investment to its carrying value. If the carrying value of Altria’s investment exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired and impairment is recognized in the period identified. The factors used to make this determination include the duration and magnitude of the fair value decline, ABI’s financial condition and near-term prospects, and Altria’s intent and ability to hold its investment in ABI until recovery. The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria may, in certain instances, pledge or otherwise grant a security interest in all or part of its Restricted Shares. In the event the pledgee or security interest holder forecloses on the Restricted Shares, the relevant Restricted Shares will be automatically converted, one-for-one, into ordinary shares. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share. The fair value of Altria’s equity investment in ABI at September 30, 2019 and December 31, 2018 was $18.8 billion and $13.1 billion , respectively, compared with its carrying value of $18.0 billion and $17.7 billion , respectively. At September 30, 2019 , the fair value of Altria’s equity investment in ABI exceeded its carrying value by 4% . The fair value of Altria’s equity investment in ABI was less than its carrying value by 26% at December 31, 2018 Investment in JUUL In December 2018, Altria, through a wholly-owned subsidiary, purchased shares of JUUL’s non-voting Class C-1 Common Stock for an aggregate price of $12.8 billion , which will convert automatically to shares of voting Class C Common Stock upon antitrust clearance, and for no additional payment a security convertible into additional shares of Class C-1 Common Stock or Class C Common Stock, as applicable, upon settlement or exercise of certain JUUL convertible securities (the “JUUL Transaction”). At September 30, 2019, Altria owned 35% of the issued and outstanding capital stock of JUUL. Upon Share Conversion, Altria will possess 35% of JUUL’s outstanding voting power, except to the extent that Altria’s percentage ownership has decreased, and have the right to designate one-third of the members of the JUUL Board of Directors, subject to proportionate downward adjustment if Altria’s percentage ownership falls below 30% . Altria received a broad preemptive right to purchase JUUL shares, exercisable each quarter upon dilution, to maintain its ownership percentage and is subject to a standstill restriction under which it may not acquire additional JUUL shares above its 35% interest. Furthermore, Altria agreed not to sell or transfer any of its JUUL shares until December 20, 2024. At September 30, 2019 , Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares do not have a readily determinable fair value, Altria has elected to measure its investment in JUUL at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There have been no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through September 30, 2019. Altria reviews its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators. If a qualitative assessment indicates that Altria’s investment in JUUL may be impaired, a quantitative assessment is performed. If the quantitative assessment indicates the fair value of the investment is less than its carrying value, the investment is written down to its fair value. Altria performed its qualitative assessment of potential impairment indicators for its investment in JUUL as part of the preparation of its financial statements for the period ended September 30, 2019 and determined that indicators of impairment exist, including recent significant adverse changes in both the e-vapor regulatory environment and the industry in which JUUL operates. While there was no single determinative event or factor, Altria considered in totality the following indicators of impairment: the increased likelihood of a United States Food and Drug Administration compliance policy prohibiting the sale of certain flavored e-vapor products in the U.S. market without a pre-market authorization; various e-vapor bans put in place by certain states and cities in the U.S. and in certain international markets, coupled with the increased potential for additional bans in the future; and the impact of heightened adverse publicity, including recent news reports and public health advisories concerning vaping-related lung injuries and deaths. Given the existence of these indicators, Altria performed a valuation of its investment in JUUL as of September 30, 2019 and determined that the fair value of its investment is $8.3 billion , which is less than its carrying value of $12.8 billion by approximately 35% . As a result, Altria recorded a non-cash pre-tax charge of $4.5 billion reported as impairment of JUUL equity securities in its condensed consolidated statements of earnings for the nine and three months ended September 30, 2019. The impairment charge was due primarily to lower e-vapor volume assumptions in the U.S. and international markets and a delay in achieving margin performance, as compared to the assumptions at the time of the JUUL Transaction. These assumption changes are a result of the factors discussed above. Altria used an income approach to estimate the fair value of its investment in JUUL. The income approach reflects the discounting of projected future cash flows for the U.S. and international markets at a rate of return that incorporates the risk-free rate for the use of those funds, the expected rate of inflation and the risks associated with realizing projected future cash flows. Projected future cash flows in the U.S. were based on a range of scenarios that consider various potential regulatory and market outcomes. In determining the fair value of its investment in JUUL, Altria made various judgments, estimates and assumptions, the most significant of which were volume, operating margins, discount rates and perpetual growth rates. Additionally, Altria made significant assumptions regarding the likelihood and extent of various potential regulatory actions and continued adverse public perception impacting the e-vapor category and specifically JUUL, as well as expectations of the future state of the e-vapor category. All significant inputs used in the valuation are classified in Level 3 of the fair value hierarchy. Upon Share Conversion, Altria expects to account for its investment in JUUL under the equity method of accounting. See Note 1 . Background and Basis of Presentation for a discussion of the status of antitrust clearance. Investment in Cronos In March 2019, Altria, through a subsidiary, completed its acquisition of: ▪ 149.8 million newly issued common shares of Cronos (“Acquired Common Shares”), which represented a 45% economic and voting interest; ▪ anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain its ownership percentage. Certain of the anti-dilution protections provide Altria the ability to purchase additional Cronos common shares at a per share exercise price of CAD $16.25 upon the occurrence of specified events (“Fixed-price Preemptive Rights”). Based on Altria’s assumptions as of September 30, 2019, Altria estimates the Fixed-price Preemptive Rights will allow Altria to purchase up to an additional approximately 37 million common shares of Cronos; and ▪ a warrant providing Altria the ability to purchase up to an additional 10% of common shares of Cronos (approximately 76 million common shares at September 30, 2019) at a per share exercise price of CAD $19.00 , which expires on March 8, 2023. The total purchase price for the Acquired Common Shares, Fixed-price Preemptive Rights and warrant (collectively, “Investment in Cronos”) was CAD $2.4 billion (USD $1.8 billion ). Upon full exercise of the Fixed-price Preemptive Rights, to the extent such rights become available, and the warrant, Altria would own a maximum of 55% of the outstanding common shares of Cronos. In accounting for the acquisition of these assets as of the date of closing, the Fixed-price Preemptive Rights and warrant were recorded at each of their fair values using Black-Scholes option-pricing models, based on the assumptions described in Note 6 . Financial Instruments . In addition, a deferred tax liability related to the Fixed-price Preemptive Rights and warrant was recorded. The residual of the purchase price was allocated to the Acquired Common Shares. Accordingly, the CAD $2.4 billion (USD $1.8 billion ) purchase price was recorded in USD as follows: ▪ $1.2 billion to the warrant; ▪ $0.5 billion to the Fixed-price Preemptive Rights; ▪ $0.4 billion to the Acquired Common Shares; and ▪ $0.3 billion to a deferred tax liability. For a discussion of derivatives related to Altria’s Investment in Cronos, including Altria’s accounting for changes in the fair value of these derivatives, see Note 6 . Financial Instruments . At September 30, 2019 , Altria had an approximate 45% economic and voting interest in Cronos, which Altria accounts for under the equity method of accounting. Altria reports its share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for Altria to record them in the concurrent period. Altria nominated four directors, including one director who is independent from Altria, who serve on Cronos’s seven -member Board of Directors.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments: Altria enters into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes. Altria’s investment in ABI, whose functional currency is the Euro, exposes Altria to foreign currency exchange risk on the carrying value of its investment. To manage this risk, Altria designates certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively “foreign currency contracts”), and Euro denominated notes (“foreign currency denominated debt”) as net investment hedges of Altria’s investment in ABI. At September 30, 2019 and December 31, 2018 , Altria had foreign currency contracts with aggregate notional amounts of $1,391 million and $1,226 million , respectively. At September 30, 2019 , Altria had foreign currency denominated debt with an aggregate fair value and carrying value of $4,937 million and $4,608 million , respectively. At December 31, 2018 , Altria had no foreign currency denominated debt. Altria’s estimates of the fair values of its foreign currency contracts are determined using valuation models with significant inputs that are readily available in public markets, or can be derived from observable market transactions, and therefore are classified in Level 2 of the fair value hierarchy. An adjustment for credit risk and nonperformance risk is included in the fair values of foreign currency contracts. See Note 11 . Debt for a discussion of the fair value hierarchy related to Altria’s debt. Altria’s Fixed-price Preemptive Rights and warrant related to its investment in Cronos, which is further discussed in Note 5 . Investments in Equity Securities , are derivative financial instruments, which are required to be recorded at fair value. The fair values of the Fixed-price Preemptive Rights and warrant are estimated using Black-Scholes option-pricing models, adjusted for unobservable inputs, including probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at: September 30, 2019 March 8, 2019 September 30, 2019 March 8, 2019 Fixed-price Preemptive Rights Warrant Expected life (1) 1.93 years 2.32 years 3.43 years 4 years Expected volatility (2) 81.55% 93.02% 81.55% 93.02% Risk-free interest rate (3)(4) 1.61% 1.61% 1.49% 1.67% Expected dividend yield (5) —% —% —% —% (1) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 1 year to 7 years at September 30, 2019 and March 8, 2019) and the March 8, 2023 expiration date of the warrant. (2) Based on a blend of historical volatility levels of the underlying equity security and peer companies. (3) Based on the implied yield currently available on Canadian Treasury zero coupon issues weighted for the remaining expected life of the Fixed-price Preemptive Rights. (4) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the warrant. (5) Based on Cronos’s expected dividend payments . The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and warrant, which are classified in Level 3 of the fair value hierarchy: (in millions) Balance at December 31, 2018 $ — Initial investment in Fixed-price Preemptive Rights and warrant 1,736 Exercise of Preemptive Rights (22 ) Pre-tax earnings (losses) recognized in net earnings (1,296 ) Balance at September 30, 2019 $ 418 Altria elects to record the gross assets and liabilities of derivative financial instruments executed with the same counterparty on its condensed consolidated balance sheets. The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows: Fair Value of Assets Fair Value of Liabilities Balance Sheet Classification September 30, 2019 December 31, 2018 Balance Sheet Classification September 30, 2019 December 31, 2018 Derivatives designated as hedging instruments: (in millions) Foreign currency contracts Other current assets $ 69 $ 37 Other accrued liabilities $ — $ — Foreign currency contracts Other assets 17 4 Other liabilities — 4 Total $ 86 $ 41 $ — $ 4 Derivatives not designated as hedging instruments: Cronos warrant Investments in equity securities $ 315 $ — Fixed-price Preemptive Rights Investments in equity securities 103 — Total $ 418 $ — Total derivatives $ 504 $ 41 $ — $ 4 Altria records in its condensed consolidated statements of earnings any changes in the fair values of the Fixed-price Preemptive Rights and warrant as gains or losses on Cronos-related financial instruments in the periods in which the changes occur. For the nine months ended September 30, 2019 , Altria recognized pre-tax unrealized losses of $1,296 million , consisting of $400 million and $896 million , representing the changes in the fair values of the Fixed-price Preemptive Rights and warrant, respectively. For the three months ended September 30, 2019 , Altria recognized pre-tax unrealized losses of $636 million , consisting of $188 million and $448 million , representing the changes in the fair values of the Fixed-price Preemptive Rights and warrant, respectively. In January and February 2019, Altria entered into derivative financial instruments in the form of forward contracts, which were settled on March 7, 2019, to hedge Altria’s exposure to CAD to USD foreign currency exchange rate movements, in relation to the CAD $2.4 billion purchase price for the Cronos transaction. The aggregate notional amounts of the forward contracts were USD $1.8 billion (CAD $2.4 billion ). The forward contracts did not qualify for hedge accounting; therefore, in the first quarter of 2019, pre-tax losses of USD $31 million representing changes in the fair values of the forward contracts were recorded in loss on Cronos-related financial instruments in Altria’s condensed consolidated statement of earnings. Counterparties to Altria’s foreign currency contracts are domestic and international financial institutions. Altria is exposed to potential losses due to non-performance by these counterparties. Altria manages its credit risk by entering into transactions with counterparties with investment grade credit ratings, limiting the amount of exposure Altria has with each counterparty, and monitoring the financial condition of each counterparty. No amounts of collateral were received or posted related to derivative assets and liabilities at September 30, 2019 and December 31, 2018 . Net Investment Hedging The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings were as follows: Gain (Loss) Recognized in Accumulated Other Comprehensive Losses Gain (Loss) Recognized in Net Earnings (1) Gain (Loss) Recognized in Accumulated Other Comprehensive Losses Gain (Loss) Recognized in Net Earnings (1) For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 2019 2018 2019 2018 (in millions) Foreign currency contracts $ 70 $ 46 $ 26 $ 26 $ 57 $ 7 $ 10 $ 10 Foreign currency denominated debt 168 — — — 200 — — — Total $ 238 $ 46 $ 26 $ 26 $ 257 $ 7 $ 10 $ 10 (1) Related to amounts excluded from effectiveness testing. The changes in the fair value of the foreign currency contracts and in the carrying value of the foreign currency denominated debt due to changes in the Euro to USD exchange rate were recognized in accumulated other comprehensive losses related to ABI. Gains on the foreign currency contracts arising from components excluded from effectiveness testing were recognized in interest and other debt expense, net in the condensed consolidated statements of earnings based on an amortization approach.

Benefit Plans

Benefit Plans	9 Months Ended
	Sep. 30, 2019
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans: Components of Net Periodic Benefit (Income) Cost Net periodic benefit (income) cost consisted of the following: For the Nine Months Ended September 30, For the Three Months Ended September 30, Pension Postretirement Pension Postretirement 2019 2018 2019 2018 2019 2018 2019 2018 (in millions) Service cost $ 52 $ 61 $ 12 $ 13 $ 17 $ 20 $ 4 $ 4 Interest cost 229 207 57 52 77 69 17 15 Expected return on plan assets (431 ) (438 ) (11 ) (14 ) (143 ) (146 ) (4 ) (5 ) Amortization: Net loss 119 168 3 16 39 56 (3 ) (1 ) Prior service cost (credit) 4 3 (22 ) (31 ) 1 1 (8 ) (10 ) Curtailment 7 — 5 — — — — — Net periodic benefit (income) cost $ (20 ) $ 1 $ 44 $ 36 $ (9 ) $ — $ 6 $ 3 Curtailment costs shown in the table above were related to the cost reduction program discussed in Note 3. Asset Impairment, Exit and Implementation Costs . Employer Contributions Altria makes contributions to the pension plans to the extent that the contributions are tax deductible and pays benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service regulations. Altria made employer contributions of $51 million to its pension plans during the nine months ended September 30, 2019 . Currently, Altria anticipates making additional employer contributions to its pension plans during the remainder of 2019 of up to approximately $10 million , based on current tax law. Altria did no t make any employer contributions to its postretirement plans during the nine months ended September 30, 2019 . Currently, Altria anticipates making no employer contributions to its postretirement plans in 2019 . Estimates for current-year contributions to Altria’s pension and postretirement plans may be subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on assets, changes in interest rates or other considerations.

Earnings (Losses) Per Share

Earnings (Losses) Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Earnings (Losses) Per Share	Earnings (Losses) Per Share: Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Net earnings (losses) attributable to Altria $ 516 $ 5,713 $ (2,600 ) $ 1,943 Less: Distributed and undistributed earnings attributable to share-based awards (5 ) (7 ) (1 ) (2 ) Earnings (losses) for basic and diluted EPS $ 511 $ 5,706 $ (2,601 ) $ 1,941 Weighted-average shares for basic and diluted EPS 1,871 1,891 1,868 1,883

Other Comprehensive Earnings_Lo

Other Comprehensive Earnings/Losses	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Other Comprehensive Earnings/Losses	Other Comprehensive Earnings/Losses: The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria: For the Nine Months Ended September 30, 2019 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, December 31, 2018 $ (2,168 ) $ (374 ) $ (5 ) $ (2,547 ) Other comprehensive earnings (losses) before reclassifications — 108 8 116 Deferred income taxes — (28 ) — (28 ) Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — 80 8 88 Amounts reclassified to net earnings (losses) 113 (35 ) — 78 Deferred income taxes (29 ) 8 — (21 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 84 (27 ) — 57 Other comprehensive earnings (losses), net of deferred income taxes 84 53 (1) 8 145 Balances, September 30, 2019 $ (2,084 ) $ (321 ) $ 3 $ (2,402 ) For the Three Months Ended September 30, 2019 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, June 30, 2019 $ (2,110 ) $ (542 ) $ 6 $ (2,646 ) Other comprehensive earnings (losses) before reclassifications — 290 (5 ) 285 Deferred income taxes — (67 ) 2 (65 ) Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — 223 (3 ) 220 Amounts reclassified to net earnings (losses) 35 (4 ) — 31 Deferred income taxes (9 ) 2 — (7 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 26 (2 ) — 24 Other comprehensive earnings (losses), net of deferred income taxes 26 221 (1) (3 ) 244 Balances, September 30, 2019 $ (2,084 ) $ (321 ) $ 3 $ (2,402 ) For the Nine Months Ended September 30, 2018 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, December 31, 2017 $ (1,839 ) $ (54 ) $ (4 ) $ (1,897 ) Other comprehensive earnings (losses) before reclassifications — (288 ) (1 ) (289 ) Deferred income taxes — 57 — 57 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — (231 ) (1 ) (232 ) Amounts reclassified to net earnings (losses) 168 (41 ) — 127 Deferred income taxes (42 ) 10 — (32 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 126 (31 ) — 95 Other comprehensive earnings (losses), net of deferred income taxes 126 (262 ) (1) (1 ) (137 ) Balances, September 30, 2018 $ (1,713 ) $ (316 ) $ (5 ) $ (2,034 ) For the Three Months Ended September 30, 2018 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, June 30, 2018 $ (1,752 ) $ 106 $ (6 ) $ (1,652 ) Other comprehensive earnings (losses) before reclassifications — (513 ) 1 (512 ) Deferred income taxes — 107 — 107 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — (406 ) 1 (405 ) Amounts reclassified to net earnings (losses) 50 (21 ) — 29 Deferred income taxes (11 ) 5 — (6 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 39 (16 ) — 23 Other comprehensive earnings (losses), net of deferred income taxes 39 (422 ) (1) 1 (382 ) Balances, September 30, 2018 $ (1,713 ) $ (316 ) $ (5 ) $ (2,034 ) (1) Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 6 . Financial Instruments. The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Benefit Plans: (1) Net loss $ 135 $ 196 $ 42 $ 59 Prior service cost/credit (22 ) (28 ) (7 ) (9 ) 113 168 35 50 ABI (2) (35 ) (41 ) (4 ) (21 ) Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses) $ 78 $ 127 $ 31 $ 29 (1) Amounts are included in net defined benefit plan costs. For further details, see Note 7 . Benefit Plans. (2) Amounts are primarily included in earnings from equity investments.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting: The products of Altria’s subsidiaries include smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA and Nat Sherman, machine-made large cigars and pipe tobacco manufactured and sold by Middleton and premium cigars sold by Nat Sherman; smokeless tobacco products, consisting of moist smokeless tobacco and snus products manufactured and sold by USSTC and oral nicotine pouches (tobacco-derived nicotine) sold by Helix; and wine produced and/or distributed by Ste. Michelle. The products and services of these subsidiaries constitute Altria’s reportable segments of smokeable products, smokeless products and wine. The financial services and the innovative tobacco products businesses are included in all other. Altria’s chief operating decision maker (the “CODM”) reviews operating companies income to evaluate the performance of, and allocate resources to, the segments. Operating companies income for the segments is defined as operating income before general corporate expenses and amortization of intangibles. Interest and other debt expense, net, net periodic benefit income/cost, excluding service cost, and provision for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by the CODM. Segment data were as follows: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Net revenues: Smokeable products $ 16,837 $ 16,995 $ 6,049 $ 6,035 Smokeless products 1,762 1,690 620 586 Wine 483 489 167 181 All other 21 76 20 35 Net revenues $ 19,103 $ 19,250 $ 6,856 $ 6,837 Earnings (losses) before income taxes: Operating companies income (loss): Smokeable products $ 6,864 $ 6,516 $ 2,561 $ 2,277 Smokeless products 1,195 1,085 417 370 Wine 50 73 16 29 All other (27 ) (121 ) 8 (38 ) Amortization of intangibles (28 ) (30 ) (12 ) (20 ) General corporate expenses (154 ) (152 ) (46 ) (61 ) Corporate asset impairment and exit costs (1 ) — — — Operating income 7,899 7,371 2,944 2,557 Interest and other debt expense, net (989 ) (503 ) (293 ) (159 ) Net periodic benefit income, excluding service cost 40 37 24 21 Earnings from equity investments 866 759 333 189 Impairment of JUUL equity securities (4,500 ) — (4,500 ) — Loss on Cronos-related financial instruments (1,327 ) — (636 ) — Loss on ABI/SABMiller business combination — (33 ) — — Earnings (losses) before income taxes $ 1,989 $ 7,631 $ (2,128 ) $ 2,608 The comparability of operating companies income for the reportable segments was affected by the following: Non-Participating Manufacturer (“NPM”) Adjustment Items - For the nine months ended September 30, 2018, pre-tax income of $145 million for NPM adjustment items was recorded by PM USA as a reduction to cost of sales, which increased operating companies income in the smokeable products segment. NPM adjustment items result from the resolutions of certain disputes with states and territories related to the NPM adjustment provision under the 1998 Master Settlement Agreement (such dispute resolutions are referred to as “NPM Adjustment Items” and are more fully described in Health Care Cost Recovery Litigation - NPM Adjustment Disputes in Note 13 . Contingencies ) . Tobacco and Health Litigation Items - Pre-tax charges related to certain tobacco and health litigation items were recorded in Altria’s condensed consolidated statements of earnings as follows: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Smokeable products segment $ 43 $ 94 $ 3 $ 10 Smokeless products segment — 10 — 10 Interest and other debt expense, net 5 15 — 1 Total $ 48 $ 119 $ 3 $ 21 The amounts shown in the table above for the smokeable and smokeless products segments were recorded in marketing, administration and research costs. For further discussion, see Note 13 . Contingencies . Asset Impairment, Exit and Implementation Costs - See Note 3 . Asset Impairment, Exit and Implementation Costs for a breakdown of these costs by segment.

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt	Debt: Short-term Borrowings and Borrowing Arrangements At September 30, 2019 , Altria had no short-term borrowings. At December 31, 2018 , Altria had $12.7 billion of short-term borrowings, net of $96 million of debt issuance costs, under the term loan agreement discussed below. On December 20, 2018, Altria entered into a senior unsecured term loan agreement in connection with its investments in JUUL and Cronos (the “Term Loan Agreement”). At December 31, 2018, Altria had aggregate short-term borrowings under the Term Loan Agreement of $12.8 billion . Borrowings under the Term Loan Agreement were set to mature on December 19, 2019. In February 2019, Altria repaid all of the outstanding $12.8 billion of short-term borrowings under the Term Loan Agreement with net proceeds from the issuance of long-term senior unsecured notes. See Long-term Debt below. Upon repayment, the Term Loan Agreement terminated in accordance with its terms. In the first quarter of 2019, Altria recorded $96 million of pre-tax acquisition-related costs for the write-off of the debt issuance costs related to the Term Loan Agreement, which were recorded in interest and other debt expense, net in Altria’s condensed consolidated statement of earnings. At December 31, 2018 , Altria’s estimate of the fair value of its short-term borrowings was derived from discounted future cash flows based on the contractual terms of the Term Loan Agreement and observable interest rates and was classified in Level 2 of the fair value hierarchy. The fair value of Altria’s short-term borrowings at December 31, 2018 approximated its carrying value. At December 31, 2018 , accrued interest on short-term borrowings of $15 million was included in other accrued liabilities on Altria’s condensed consolidated balance sheet. Long-term Debt During the third quarter of 2019, Altria repaid, in full at maturity, senior unsecured notes in the aggregate principal amount of $1,144 million . In February 2019, Altria issued USD denominated and Euro denominated long-term senior unsecured notes in the aggregate principal amounts of $11.5 billion and €4.25 billion , respectively (collectively, the “Notes”). Altria immediately converted the proceeds of the Euro denominated notes into USD of $4.8 billion . The net proceeds from the Euro notes and a portion of the net proceeds from the USD notes were used to repay in full the $12.8 billion of short-term borrowings under the Term Loan Agreement, which were incurred to fund Altria’s investment in JUUL. The remaining net proceeds from the USD notes were used to fund Altria’s investment in Cronos in the first quarter of 2019 and for other general corporate purposes. The Notes contain the following terms: USD denominated notes ▪ $1.0 billion at 3.490% , due 2022 , interest payable semiannually beginning August 14, 2019; ▪ $1.0 billion at 3.800% , due 2024 , interest payable semiannually beginning August 14, 2019; ▪ $1.5 billion at 4.400% , due 2026 , interest payable semiannually beginning August 14, 2019; ▪ $3.0 billion at 4.800% , due 2029 , interest payable semiannually beginning August 14, 2019; ▪ $2.0 billion at 5.800% , due 2039 , interest payable semiannually beginning August 14, 2019; ▪ $2.5 billion at 5.950% , due 2049 , interest payable semiannually beginning August 14, 2019; and ▪ $0.5 billion at 6.200% , due 2059 , interest payable semiannually beginning August 14, 2019. Euro denominated notes ▪ €1.25 billion at 1.000% , due 2023 , interest payable annually beginning February 15, 2020; ▪ €0.75 billion at 1.700% , due 2025 , interest payable annually beginning June 15, 2020; ▪ €1.0 billion at 2.200% , due 2027 , interest payable annually beginning June 15, 2020; and ▪ €1.25 billion at 3.125% , due 2031 , interest payable annually beginning June 15, 2020. The Notes are Altria’s senior unsecured obligations and rank equally in right of payment with all of Altria’s existing and future senior unsecured indebtedness. Upon the occurrence of both (i) a change of control of Altria and (ii) the Notes ceasing to be rated investment grade by each of Moody’s Investors Service, Inc., Standard & Poor’s Ratings Services and Fitch Ratings Ltd. within a specified time period, Altria will be required to make an offer to purchase the Notes at a price equal to 101% of the aggregate principal amount of the Notes, plus accrued and unpaid interest to the date of repurchase as and to the extent set forth in the terms of the Notes. Altria designated its Euro denominated notes as a net investment hedge of its investment in ABI. For further discussion, see Note 6 . Financial Instruments . The obligations of Altria under the Notes are guaranteed by PM USA. For further discussion, see Note 14 . Condensed Consolidating Financial Information . Altria’s estimate of the fair value of its debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy. The aggregate fair value of Altria’s total long-term debt at September 30, 2019 and December 31, 2018 , was $30.3 billion and $12.5 billion , respectively, as compared with its carrying value of $27.9 billion and $13.0 billion , respectively. At September 30, 2019 and December 31, 2018 , accrued interest on long-term debt of $241 million and $207 million , respectively, was included in other accrued liabilities on Altria’s condensed consolidated balance sheets.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes: The income tax rate for the nine and three months ended September 30, 2019 was 74.1% and (22.3)% , respectively, versus 25.1% and 25.5% for the nine and three months ended September 30, 2018, respectively. The changes in the tax rates were due primarily to the following: ▪ a full valuation allowance in 2019 attributable to the tax benefit associated with the impairment of JUUL equity securities as discussed below; partially offset by: • tax benefits of $91 million recorded in 2019 for the reversal of tax accruals no longer required. The impairment of JUUL equity securities generated a deferred tax asset of $1,040 million that if realized would be characterized as a capital loss. Altria considered all available positive and negative evidence in determining the valuation allowance, including the character of the loss, carryback and carryforward considerations, future reversals of existing temporary differences, and available tax planning strategies. Based on the weight of available evidence, it is more likely than not that the deferred tax asset will not be realized; therefore, Altria recorded a full valuation allowance of $1,040 million against this deferred tax asset. For a discussion regarding the impairment of JUUL equity securities, see Note 5 . Investments in Equity Securities . Altria is subject to income taxation in many jurisdictions. Unrecognized tax benefits reflect the difference between tax positions taken or expected to be taken on income tax returns and the amounts recognized in the financial statements. Resolution of the related tax positions with the relevant tax authorities may take many years to complete, and such timing is not entirely within the control of Altria. At September 30, 2019 , Altria’s total unrecognized tax benefits were $50 million . The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at September 30, 2019 was $43 million , along with $7 million affecting deferred taxes. It is reasonably possible that within the next 12 months certain examinations will be resolved, which could result in a decrease in unrecognized tax benefits of approximately $26 million . At December 31, 2018 , Altria’s total unrecognized tax benefits were $85 million . The amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate at December 31, 2018 was $59 million , along with $26 million affecting deferred taxes.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies: Legal proceedings covering a wide range of matters are pending or threatened in various U.S. and foreign jurisdictions against Altria and its subsidiaries, including PM USA and UST and its subsidiaries, as well as their respective indemnitees. Various types of claims may be raised in these proceedings, including product liability, consumer protection, antitrust, tax, contraband shipments, patent infringement, employment matters, claims for contribution and claims of competitors, shareholders or distributors. Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, Altria or its subsidiaries may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, Altria or its subsidiaries under certain circumstances may have to pay more than their proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, Altria or its subsidiaries may also be required to pay interest and attorneys’ fees. Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all. As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. States, including Florida, may also seek to repeal or alter bond cap statutes through legislation. Although Altria cannot predict the outcome of such challenges, it is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges. Altria and its subsidiaries record provisions in the condensed consolidated financial statements for pending litigation when they determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 13 . Contingencies : (i) management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii) accordingly, management has not provided any amounts in the condensed consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred. Altria and its subsidiaries have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain. It is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Altria and each of its subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. Each of the companies has defended, and will continue to defend, vigorously against litigation challenges. However, Altria and its subsidiaries may enter into settlement discussions in particular cases if they believe it is in the best interests of Altria to do so. Overview of Altria and/or PM USA Tobacco-Related Litigation Types and Number of Cases Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii) smoking and health cases primarily alleging personal injury or seeking court-supervised programs for ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, including cases in which the aggregated claims of a number of individual plaintiffs are to be tried in a single proceeding; (iii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iv) class action suits alleging that the uses of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”); and (v) other tobacco-related litigation described below. Plaintiffs’ theories of recovery and the defenses raised in pending smoking and health, health care cost recovery and “Lights/Ultra Lights” cases are discussed below. The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and, in some instances, Altria as of October 28, 2019, October 22, 2018 and October 23, 2017: October 28, 2019 October 22, 2018 October 23, 2017 Individual Smoking and Health Cases (1) 95 101 87 Smoking and Health Class Actions and Aggregated Claims Litigation (2) 2 2 4 Health Care Cost Recovery Actions (3) — 1 1 “Lights/Ultra Lights” Class Actions 2 2 4 (1) Includes 21 cases filed in Massachusetts and 38 non- Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action ). Also does not include 1,471 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 ( Broin ). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. In March 2018, 923 of these cases were voluntarily dismissed without prejudice. (2) The 2017 pending cases include as one case the 30 civil actions that were to be tried in six consolidated trials in West Virginia ( In re: Tobacco Litigation ). PM USA was a defendant in nine of the 30 cases. The parties resolved these cases for an immaterial amount and in the second quarter of 2018, the court dismissed all 30 cases. (3) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below. International Tobacco-Related Cases As of October 28, 2019, PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant. PM USA and Altria are also named defendants in seven smoking and health class actions filed in various Canadian provinces. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and Philip Morris International Inc. (“PMI”) that provides for indemnities for certain liabilities concerning tobacco products. E-vapor Litigation As of October 28, 2019, Altria and/or PM USA were named as defendants in 12 class action lawsuits and 26 individual lawsuits relating to JUUL e-vapor products. JUUL is also named in these lawsuits. Tobacco-Related Cases Set for Trial As of October 28, 2019, three Engle progeny cases are set for trial through December 31, 2019. In addition, there is one individual smoking and health case against PM USA set for trial during this period. Cases against other companies in the tobacco industry may also be scheduled for trial during this period. Trial dates are subject to change. Trial Results Since January 1999, excluding the Engle progeny cases (separately discussed below), verdicts have been returned in 67 smoking and health, “Lights/Ultra Lights” and health care cost recovery cases in which PM USA was a defendant. Verdicts in favor of PM USA and other defendants were returned in 43 of the 67 cases. These 43 cases were tried in Alaska ( 1 ), California ( 7 ), Connecticut ( 1 ), Florida ( 10 ), Louisiana ( 1 ), Massachusetts ( 3 ), Mississippi ( 1 ), Missouri ( 4 ), New Hampshire ( 1 ), New Jersey ( 1 ), New York ( 5 ), Ohio ( 2 ), Pennsylvania ( 1 ), Rhode Island ( 1 ), Tennessee ( 2 ) and West Virginia ( 2 ). Of the 24 non- Engle progeny cases in which verdicts were returned in favor of plaintiffs, 20 have reached final resolution, and one case ( Gentile ) that was initially returned in favor of plaintiff was reversed post-trial and remains pending. See Smoking and Health Litigation - Engle Progeny Trial Results below for a discussion of verdicts in state and federal Engle progeny cases involving PM USA as of October 28, 2019. Judgments Paid and Provisions for Tobacco and Health Litigation Items (Including Engle Progeny Litigation) After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid in the aggregate judgments and settlements (including related costs and fees) totaling approximately $701 million and interest totaling approximately $214 million as of September 30, 2019. These amounts include payments for Engle progeny judgments (and related costs and fees) totaling approximately $309 million and related interest totaling approximately $52 million . The changes in Altria’s accrued liability for tobacco and health litigation items, including related interest costs, for the periods specified below are as follows: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Accrued liability for tobacco and health litigation items at beginning of period (1) $ 112 $ 106 $ 13 $ 107 Pre-tax charges for: Tobacco and health litigation 43 104 3 20 Related interest costs 5 15 — 1 Payments (1) (151 ) (118 ) (7 ) (21 ) Accrued liability for tobacco and health litigation items at end of period (1) $ 9 $ 107 $ 9 $ 107 (1) Includes amounts related to the costs of implementing the corrective communications remedy related to the Federal Government’s Lawsuit discussed below. The accrued liability for tobacco and health litigation items, including related interest costs, was included in accrued liabilities on Altria’s condensed consolidated balance sheets. Pre-tax charges for tobacco and health litigation were included in marketing, administration and research costs on Altria’s condensed consolidated statements of earnings. Pre-tax charges for related interest costs were included in interest and other debt expense, net on Altria’s condensed consolidated statements of earnings. Security for Judgments To obtain stays of judgments pending appeal, PM USA has posted various forms of security. As of September 30, 2019 , PM USA has posted appeal bonds totaling approximately $41 million , which have been collateralized with restricted cash that are included in assets on the condensed consolidated balance sheet. Smoking and Health Litigation Overview Plaintiffs’ allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violations of deceptive trade practice laws and consumer protection statutes, and claims under the federal and state anti-racketeering statutes. Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act. Non-Engle Progeny Litigation Summarized below are the non- Engle progeny smoking and health cases pending during 2019 in which a verdict was returned in favor of plaintiff and against PM USA. Charts listing certain verdicts for plaintiffs in the Engle progeny cases can be found in Smoking and Health Litigation - Engle Progeny Trial Results below. Greene: In September 2019, a jury in a Massachusetts state court returned a verdict against PM USA, awarding plaintiffs approximately $10 million in compensatory damages. An additional claim by plaintiffs remains pending. Laramie : In August 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiff, awarding $11 million in compensatory damages and $10 million in punitive damages. PM USA’s post-trial motions were denied in October 2019. PM USA has until November 21, 2019 to appeal. Capone : In December 2018, a jury in a Florida state court returned a verdict in favor of plaintiff, awarding $225,000 in compensatory damages. In the first quarter of 2019, PM USA recorded a provision on its condensed consolidated balance sheet of approximately $325,000 for the judgment and related costs and paid this amount in April 2019, concluding this litigation. Gentile : In October 2017, a jury in a Florida state court returned a verdict in favor of plaintiff, awarding approximately $7.1 million in compensatory damages and allocating 75% of the fault to PM USA (an amount of approximately $5.3 million ). PM USA appealed. In September 2019, the Florida Fourth District Court of Appeal reversed the judgment entered by the trial court, granted PM USA judgment on certain claims and remanded for a new trial on the remaining claims. Plaintiff has filed a motion for rehearing. Federal Government’s Lawsuit : See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case. Engle Class Action In July 2000, in the second phase of the Engle smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $145 billion against various defendants, including $74 billion against PM USA. Following entry of judgment, PM USA appealed. In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class. Plaintiffs petitioned the Florida Supreme Court for further review. In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate. The court further declared the following Phase I findings are entitled to res judicata effect in such individual actions brought within one year of the issuance of the mandate: (i) that smoking causes various diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants’ cigarettes were defective and unreasonably dangerous; (iv) that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi) that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii) that all defendants sold or supplied cigarettes that were defective; and (viii) that defendants were negligent. In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion. In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to res judicata effect by excluding finding (v) listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants. In February 2008, the trial court decertified the class. Pending Engle Progeny Cases The deadline for filing Engle progeny cases expired in January 2008. As of October 28, 2019, approximately 1,700 state court cases were pending against PM USA or Altria asserting individual claims by or on behalf of approximately 2,200 state court plaintiffs. Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates. While the Federal Engle Agreement (discussed below) resolved nearly all Engle progeny cases pending in federal court, as of October 28, 2019, approximately four cases were pending against PM USA in federal court representing the cases excluded from that agreement. Agreement to Resolve Federal Engle Progeny Cases In 2015, PM USA, R.J. Reynolds Tobacco Company (“R.J. Reynolds”) and Lorillard Tobacco Company (“Lorillard”) resolved approximately 415 pending federal Engle progeny cases (the “Federal Engle Agreement”). Federal cases that were in trial and those that previously reached final verdict were not included in the Federal Engle Agreement. Engle Progeny Trial Results As of October 28, 2019, 133 federal and state Engle progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court Engle decision. Seventy-five verdicts were returned in favor of plaintiffs and seven verdicts ( Skolnick , Calloway , McCoy , Gloger , Duignan , Caprio and Oshinsky-Blacker ) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending. Forty-seven verdicts were returned in favor of PM USA, of which 42 were state cases. In addition, there have been a number of mistrials, only some of which have resulted in new trials as of October 28, 2019. Four verdicts ( Pearson, D. Cohen , Collar and Chacon ) that were returned in favor of PM USA were subsequently reversed for new trials. Juries in two cases ( Reider and Banks ) returned zero damages verdicts in favor of PM USA . Juries in two other cases ( Weingart and Hancock ) returned verdicts against PM USA awarding no damages, but the trial court in each case decided to award plaintiffs damages. One case, Pollari, resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff. Appeals by plaintiff and defendants are pending. The charts below list the verdicts and post-trial developments in certain Engle progeny cases in which verdicts were returned in favor of plaintiffs. The first chart lists such cases that are pending as of October 28, 2019 where PM USA has recorded a provision in its condensed consolidated financial statements because we have determined that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated; the second chart lists other such cases that are pending as of October 28, 2019 but where an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated; and the third chart lists other such cases that have concluded within the previous 12 months. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault (see Engle Progeny Appellate Issues below for a discussion of the Florida Supreme Court’s decision in Schoeff ). Further, the damages noted reflect adjustments based on post-trial or appellate rulings. Currently Pending Engle Cases with Accrued Liabilities (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (All Defendants) Punitive Damages (PM USA) Appeal Status Accrual (1) Berger ( Cote ) September 2014 PM USA Federal Court - Middle District of Florida $6 million $21 million The Eleventh Circuit Court of Appeals reinstated the punitive and compensatory damages awards and remanded the case to the district court. PM USA’s challenge to the punitive damages award was denied by the district court. PM USA’s appeal to the Eleventh Circuit Court of Appeals is pending. $6 million accrual in the fourth quarter of 2018 (1) Accrual amounts include interest and associated costs, if applicable. For cases with multiple defendants, if any, accrual amounts reflect the portion of compensatory damages PM USA believes it will have to pay if the case is ultimately decided in plaintiff’s favor after taking into account any portion potentially payable by the other defendant(s). Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status McCall March 2019 PM USA Broward <$1 million (<$1 million PM USA) <$1 million New trial ordered on punitive damages. Neff March 2019 PM USA and R.J. Reynolds Broward $4 million $2 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Frogel March 2019 PM USA Palm Beach <$1 million (<$1 million PM USA) $0 Appeals by plaintiff and defendant to Fourth District Court of Appeal pending. Mahfuz February 2019 PM USA and R.J. Reynolds Broward $12 million $10 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Holliman February 2019 PM USA Miami-Dade $3 million $0 Defendant’s appeal to Third District Court of Appeal pending. Chadwell September 2018 PM USA Miami-Dade $2 million $0 Appeal by defendant to Third District Court of Appeal pending. Kaplan July 2018 PM USA and R.J. Reynolds Broward $2 million $2 million Appeals by defendants to Fourth District Court of Appeal pending. Landi June 2018 PM USA and R.J. Reynolds Broward $8 million $5 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Theis May 2018 PM USA and R.J. Reynolds Sarasota $7 million $10 million Defendants’ appeal to Second District Court of Appeal pending. Freeman March 2018 PM USA Alachua $4 million $0 Defendant’s appeal to First District Court of Appeal pending. R. Douglas November 2017 PM USA Duval <$1 million $0 Awaiting entry of final judgment by the trial court. Sommers April 2017 PM USA Miami-Dade $1 million $0 New trial ordered on punitive damages; appeals by plaintiff and defendant to Third District Court of Appeal pending. Santoro March 2017 PM USA, R.J. Reynolds and Liggett Group Broward $2 million $0 Trial court set aside punitive damages award; appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Cooper (Blackwood) September 2015 PM USA and R.J. Reynolds Broward $5 million $0 Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages. McCoy July 2015 PM USA, Broward $2 million $3 million Fourth District Court of Appeal reversed judgment and ordered a new trial; plaintiff requested review by the Florida Supreme Court. D. Brown January 2015 PM USA Federal Court - Middle District of Florida $8 million $9 million Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit pending. Kerrivan October 2014 PM USA and R.J. Reynolds Federal Court - Middle District of Florida $16 million $16 million Appeal by defendants to U.S. Court of Appeals for the Eleventh Circuit pending. Harris July 2014 PM USA, Federal Court - Middle District of Florida $2 million (<$ 1 million PM USA) $0 Appeals by plaintiff and defendants to U.S. Court of Appeals for the Eleventh Circuit pending. (1 ) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies. Engle Cases Concluded Within Past 12 Months (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Accrual Date Payment Amount (if any) Payment Date Alvarez Del Real September 2019 PM USA Miami-Dade Fourth quarter of 2019 <$1 million October 2019 Zingaro May 2019 PM USA and R.J. Reynolds Broward Third quarter of 2019 <$1 million October 2019 Bryant December 2017 PM USA Escambia Second quarter of 2019 <$1 million July 2019 Wallace October 2017 PM USA and R.J. Reynolds Brevard Second quarter of 2019 $26 million May 2019 J. Brown February 2017 PM USA and R.J. Reynolds Pinellas First quarter of 2019 $4 million April 2019 L. Martin May 2017 PM USA Miami-Dade First quarter of 2019 $2 million April 2019 Danielson November 2015 PM USA Escambia First quarter of 2019 $3 million March 2019 S. Martin November 2016 PM USA and Broward First quarter of 2019 $5 million March 2019 Searcy April 2013 PM USA and Federal Court - Middle District of Florida Third quarter of 2018 $2 million March 2019 Boatright November 2014 PM USA and Liggett Group Polk Second quarter of 2018 $42 million March 2019 M. Brown May 2015 PM USA Duval Second quarter of 2018 $8 million March 2019 Jordan August 2015 PM USA Duval Second quarter of 2018 $11 million March 2019 Pardue December 2016 PM USA and Alachua Second and Third quarters of 2018 $11 million March 2019 McKeever February 2015 PM USA Broward Fourth quarter of 2017 $21 million March 2019 Boulter December 2018 PM USA and Lee Fourth quarter of 2018 <$1 million January 2019 Simon September 2018 PM USA and Broward Fourth quarter of 2018 <$1 million October 2018 Florida Bond Statute In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applies to all state Engle progeny lawsuits in the aggregate and establishes individual bond caps for individual Engle progeny cases in amounts that vary depending on the number of judgments in effect at a given time. Plaintiffs in three state Engle progeny cases against R.J. Reynolds in Alachua County ( Alexander , Townsend and Hall ) and one case in Escambia County ( Clay ) challenged the constitutionality of the bond cap statute. The Florida Attorney General intervened in these cases in defense of the constitutionality of the statute. Trial court rulings were rendered in Clay , Alexander , Townsend and Hall, rejecting plaintiffs’ bond cap statute challenges in those cases. Plaintiffs unsuccessfully appealed these rulings. In February 2016, in the Sikes case against R.J. Reynolds, the trial court held that Florida’s bond cap statute does not stay the execution of judgment after a case is final in the Florida judicial system and before the defendant files a petition for writ of certiorari with the United States Supreme Court. In April 2016, the District Court of Appeal held that the bond cap applies to the period between a Florida Supreme Court ruling and completion of United States Supreme Court writ of certiorari review. In April 2016, PM USA filed motions in the trial court in two state Engle progeny cases seeking confirmation that the stay on executing the judgment remains in effect through the completion of United States Supreme Court writ of certiorari review or until the time for moving for such review has expired, which the court granted. No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to Engle progeny cases tried in federal court. From time to time, legislation has been presented to the Florida legislature that would repeal the 2009 appeal bond cap statute; however to date, no legislation repealing the statute has passed. Other Smoking and Health Class Actions Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts. In general, these cases purport to be brought on behalf of residents of a particular state or states (although a few cases purport to be nationwide in scope) and raise addiction claims and, in many cases, claims of physical injury as well. Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas ( 1 ), California ( 1 ), Delaware ( 1 ), the District of Columbia ( 2 ), Florida ( 2 ), Illinois ( 3 ), Iowa ( 1 ), Kansas ( 1 ), Louisiana ( 1 ), Maryland ( 1 ), Michigan ( 1 ), Minnesota ( 1 ), Nevada ( 29 ), New Jersey ( 6 ), New York ( 2 ), Ohio ( 1 ), Oklahoma ( 1 ), Oregon ( 1 ), Pennsylvania ( 1 ), Puerto Rico ( 1 ), South Carolina ( 1 ), Texas ( 1 ) and Wisconsin ( 1 ). As of October 28, 2019, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario. In Saskatchewan, British Columbia ( two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants’ cigarettes. In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants’ cigarettes. In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to Altria or its subsidiaries) seeking protection under Canada’s Companies’ Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the U.S.). The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion . See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products. Health Care Cost Recovery Litigation Overview In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages. Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees. Although there have been some decisions to the contrary, most judicial decisions in the U.S. have dismissed all or most health care cost recovery claims against cigarette manufacturers. Nine federal circuit courts of appeals and eight state appellate courts, relying primarily on grounds that plaintiffs’ claims were too remote, have ordered or affirmed dismissals of health care cost recovery actions. The United States Supreme Court ha

Condensed Consolidating Financi

Condensed Consolidating Financial Information	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Information	Condensed Consolidating Financial Information: PM USA, which is a 100% owned subsidiary of Altria, has guaranteed Altria’s obligations under its outstanding debt securities, borrowings under its Credit Agreement and amounts outstanding under its commercial paper program (the “Guarantees”). Pursuant to the Guarantees, PM USA fully and unconditionally guarantees, as primary obligor, the payment and performance of Altria’s obligations under the guaranteed debt instruments (the “Obligations”), subject to release under certain customary circumstances as noted below. The Guarantees provide that PM USA guarantees the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of the Obligations. The liability of PM USA under the Guarantees is absolute and unconditional irrespective of: any lack of validity, enforceability or genuineness of any provision of any agreement or instrument relating thereto; any change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to departure from any agreement or instrument relating thereto; any exchange, release or non-perfection of any collateral, or any release or amendment or waiver of or consent to departure from any other guarantee, for all or any of the Obligations; or any other circumstance that might otherwise constitute a defense available to, or a discharge of, Altria or PM USA. The obligations of PM USA under the Guarantees are limited to the maximum amount as will not result in PM USA’s obligations under the Guarantees constituting a fraudulent transfer or conveyance, after giving effect to such maximum amount and all other contingent and fixed liabilities of PM USA that are relevant under Bankruptcy Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar federal or state law to the extent applicable to the Guarantees. For this purpose, “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors. PM USA will be unconditionally released and discharged from the Obligations upon the earliest to occur of: ▪ the date, if any, on which PM USA consolidates with or merges into Altria or any successor; ▪ the date, if any, on which Altria or any successor consolidates with or merges into PM USA; ▪ the payment in full of the Obligations pertaining to such Guarantees; and ▪ the rating of Altria’s long-term senior unsecured debt by Standard & Poor’s Ratings Services of A or higher. At September 30, 2019 , the respective principal 100% owned subsidiaries of Altria and PM USA were not limited by long-term debt or other agreements in their ability to pay cash dividends or make other distributions with respect to their equity interests. The following sets forth the condensed consolidating balance sheets as of September 30, 2019 and December 31, 2018 , condensed consolidating statements of earnings and comprehensive earnings for the nine and three months ended September 30, 2019 and 2018 , and condensed consolidating statements of cash flows for nine months ended September 30, 2019 and 2018 for Altria, PM USA and, collectively, Altria’s other subsidiaries that are not guarantors of Altria’s debt instruments (the “Non-Guarantor Subsidiaries”). The financial information may not necessarily be indicative of results of operations or financial position had PM USA and the Non-Guarantor Subsidiaries operated as independent entities. Altria and PM USA account for investments in their subsidiaries under the equity method of accounting. Condensed Consolidating Balance Sheets September 30, 2019 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Assets Cash and cash equivalents $ 1,541 $ — $ 63 $ — $ 1,604 Receivables — 16 149 — 165 Inventories: Leaf tobacco — 466 354 — 820 Other raw materials — 130 71 — 201 Work in process — 8 590 — 598 Finished product — 105 464 — 569 — 709 1,479 — 2,188 Due from Altria and subsidiaries 85 3,825 1,331 (5,241 ) — Income taxes 47 27 44 (103 ) 15 Other current assets 83 193 43 — 319 Total current assets 1,756 4,770 3,109 (5,344 ) 4,291 Property, plant and equipment, at cost — 2,940 2,069 — 5,009 Less accumulated depreciation — 2,153 894 — 3,047 — 787 1,175 — 1,962 Goodwill — — 5,262 — 5,262 Other intangible assets, net — 2 12,686 — 12,688 Investments in equity securities 17,950 — 9,396 — 27,346 Investment in consolidated subsidiaries 23,608 2,861 — (26,469 ) — Due from Altria and subsidiaries 4,790 — — (4,790 ) — Other assets 107 1,031 897 (671 ) 1,364 Total Assets $ 48,211 $ 9,451 $ 32,525 $ (37,274 ) $ 52,913 Condensed Consolidating Balance Sheets (Continued) September 30, 2019 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Liabilities Current portion of long-term debt $ 1,000 $ — $ — $ — $ 1,000 Accounts payable 1 82 163 — 246 Accrued liabilities: Marketing — 481 73 — 554 Settlement charges — 3,086 8 — 3,094 Other 346 432 520 (103 ) 1,195 Dividends payable 1,573 — — — 1,573 Due to Altria and subsidiaries 4,540 499 202 (5,241 ) — Total current liabilities 7,460 4,580 966 (5,344 ) 7,662 Long-term debt 26,903 — — — 26,903 Deferred income taxes 3,098 — 2,813 (671 ) 5,240 Accrued pension costs 146 — 206 — 352 Accrued postretirement health care costs — 1,073 691 — 1,764 Due to Altria and subsidiaries — — 4,790 (4,790 ) — Other liabilities 59 88 169 — 316 Total liabilities 37,666 5,741 9,635 (10,805 ) 42,237 Contingencies Redeemable noncontrolling interest — — 39 — 39 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,960 3,310 27,493 (30,803 ) 5,960 Earnings reinvested in the business 39,910 611 (2,937 ) 2,326 39,910 Accumulated other comprehensive losses (2,402 ) (211 ) (1,806 ) 2,017 (2,402 ) Cost of repurchased stock (33,858 ) — — — (33,858 ) Total stockholders’ equity attributable to Altria 10,545 3,710 22,759 (26,469 ) 10,545 Noncontrolling interests — — 92 — 92 Total stockholders’ equity 10,545 3,710 22,851 (26,469 ) 10,637 Total Liabilities and Stockholders’ Equity $ 48,211 $ 9,451 $ 32,525 $ (37,274 ) $ 52,913 Condensed Consolidating Balance Sheets December 31, 2018 (in millions of dollars) Altria PM USA Non- Total Consolidated Assets Cash and cash equivalents $ 1,277 $ — $ 56 $ — $ 1,333 Receivables — 18 124 — 142 Inventories: Leaf tobacco — 561 379 — 940 Other raw materials — 123 63 — 186 Work in process — 2 645 — 647 Finished product — 128 430 — 558 — 814 1,517 — 2,331 Due from Altria and subsidiaries 46 3,828 1,194 (5,068 ) — Income taxes 100 94 — (27 ) 167 Other current assets 41 167 118 — 326 Total current assets 1,464 4,921 3,009 (5,095 ) 4,299 Property, plant and equipment, at cost — 2,928 2,022 — 4,950 Less accumulated depreciation — 2,111 901 — 3,012 — 817 1,121 — 1,938 Goodwill — — 5,196 — 5,196 Other intangible assets, net — 2 12,277 — 12,279 Investments in equity securities 17,696 — 12,800 — 30,496 Investment in consolidated subsidiaries 25,996 2,825 — (28,821 ) — Due from Altria and subsidiaries 4,790 — — (4,790 ) — Other assets 193 955 952 (670 ) 1,430 Total Assets $ 50,139 $ 9,520 $ 35,355 $ (39,376 ) $ 55,638 Condensed Consolidating Balance Sheets (Continued) December 31, 2018 (in millions of dollars) Altria PM USA Non- Total Consolidated Liabilities Short-term borrowings $ 12,704 $ — $ — $ — $ 12,704 Current portion of long-term debt 1,144 — — — 1,144 Accounts payable 1 91 307 — 399 Accrued liabilities: Marketing — 483 103 — 586 Settlement charges — 3,448 6 — 3,454 Other 295 524 611 (27 ) 1,403 Dividends payable 1,503 — — — 1,503 Due to Altria and subsidiaries 4,499 407 162 (5,068 ) — Total current liabilities 20,146 4,953 1,189 (5,095 ) 21,193 Long-term debt 11,898 — — — 11,898 Deferred income taxes 3,010 — 2,832 (670 ) 5,172 Accrued pension costs 187 — 357 — 544 Accrued postretirement health care costs — 1,072 677 — 1,749 Due to Altria and subsidiaries — — 4,790 (4,790 ) — Other liabilities 111 47 96 — 254 Total liabilities 35,352 6,072 9,941 (10,555 ) 40,810 Contingencies Redeemable noncontrolling interest — — 39 — 39 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,961 3,310 25,047 (28,357 ) 5,961 Earnings reinvested in the business 43,962 359 2,201 (2,560 ) 43,962 Accumulated other comprehensive losses (2,547 ) (221 ) (1,884 ) 2,105 (2,547 ) Cost of repurchased stock (33,524 ) — — — (33,524 ) Total stockholders’ equity attributable to Altria 14,787 3,448 25,373 (28,821 ) 14,787 Noncontrolling interests — — 2 — 2 Total stockholders’ equity 14,787 3,448 25,375 (28,821 ) 14,789 Total Liabilities and Stockholders’ Equity $ 50,139 $ 9,520 $ 35,355 $ (39,376 ) $ 55,638 Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Nine Months Ended September 30, 2019 (in millions of dollars) Altria PM USA Non- Total Consolidated Net revenues $ — $ 16,140 $ 2,991 $ (28 ) $ 19,103 Cost of sales — 4,594 801 (28 ) 5,367 Excise taxes on products — 3,949 160 — 4,109 Gross profit — 7,597 2,030 — 9,627 Marketing, administration and research costs 125 1,181 348 — 1,654 Asset impairment and exit costs 1 38 35 — 74 Operating income (expense) (126 ) 6,378 1,647 — 7,899 Interest and other debt expense (income), net 892 (64 ) 161 — 989 Net periodic benefit (income) cost, excluding service cost 1 (32 ) (9 ) — (40 ) Earnings from equity investments (640 ) — (226 ) — (866 ) Impairment of JUUL equity securities — — 4,500 — 4,500 Loss on Cronos-related financial instruments — — 1,327 — 1,327 Earnings (losses) before income taxes and equity earnings of subsidiaries (379 ) 6,474 (4,106 ) — 1,989 Provision (benefit) for income taxes (180 ) 1,610 43 — 1,473 Equity earnings of subsidiaries 715 326 — (1,041 ) — Net earnings (losses) 516 5,190 (4,149 ) (1,041 ) 516 Net (earnings) losses attributable to noncontrolling interests — — — — — Net earnings (losses) attributable to Altria $ 516 $ 5,190 $ (4,149 ) $ (1,041 ) $ 516 Net earnings (losses) $ 516 $ 5,190 $ (4,149 ) $ (1,041 ) $ 516 Other comprehensive earnings (losses), net of deferred income taxes 145 10 78 (88 ) 145 Comprehensive earnings (losses) 661 5,200 (4,071 ) (1,129 ) 661 Comprehensive (earnings) losses attributable to noncontrolling interests — — — — — Comprehensive earnings (losses) attributable to Altria $ 661 $ 5,200 $ (4,071 ) $ (1,129 ) $ 661 Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Nine Months Ended September 30, 2018 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Net revenues $ — $ 16,339 $ 2,938 $ (27 ) $ 19,250 Cost of sales — 4,666 870 (27 ) 5,509 Excise taxes on products — 4,245 164 — 4,409 Gross profit — 7,428 1,904 — 9,332 Marketing, administration and research costs 122 1,400 437 — 1,959 Asset impairment and exit costs — — 2 — 2 Operating income (expense) (122 ) 6,028 1,465 — 7,371 Interest and other debt expense (income), net 378 (37 ) 162 — 503 Net periodic benefit (income) cost, excluding service cost 3 (33 ) (7 ) — (37 ) Earnings from equity investments (759 ) — — — (759 ) Loss on ABI/SABMiller business combination 33 — — — 33 Earnings (losses) before income taxes and equity earnings of subsidiaries 223 6,098 1,310 — 7,631 Provision (benefit) for income taxes 67 1,537 311 — 1,915 Equity earnings of subsidiaries 5,557 310 — (5,867 ) — Net earnings (losses) 5,713 4,871 999 (5,867 ) 5,716 Net (earnings) losses attributable to noncontrolling interests — — (3 ) — (3 ) Net earnings (losses) attributable to Altria $ 5,713 $ 4,871 $ 996 $ (5,867 ) $ 5,713 Net earnings (losses) $ 5,713 $ 4,871 $ 999 $ (5,867 ) $ 5,716 Other comprehensive earnings (losses), net of deferred income taxes (137 ) 10 109 (119 ) (137 ) Comprehensive earnings (losses) 5,576 4,881 1,108 (5,986 ) 5,579 Comprehensive (earnings) losses attributable to noncontrolling interests — — (3 ) — (3 ) Comprehensive earnings (losses) attributable to Altria $ 5,576 $ 4,881 $ 1,105 $ (5,986 ) $ 5,576 Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Three Months Ended September 30, 2019 (in millions of dollars) Altria PM USA Non- Total Consolidated Net revenues $ — $ 5,804 $ 1,062 $ (10 ) $ 6,856 Cost of sales — 1,644 281 (10 ) 1,915 Excise taxes on products — 1,391 53 — 1,444 Gross profit — 2,769 728 — 3,497 Marketing, administration and research costs 41 392 119 — 552 Asset impairment and exit costs — — 1 — 1 Operating income (expense) (41 ) 2,377 608 — 2,944 Interest and other debt expense (income), net 258 (20 ) 55 — 293 Net periodic benefit (income) cost, excluding service cost — (19 ) (5 ) — (24 ) Earnings from equity investments (252 ) — (81 ) — (333 ) Impairment of JUUL equity securities — — 4,500 — 4,500 Loss on Cronos-related financial instruments — — 636 — 636 Earnings (losses) before income taxes and equity earnings of subsidiaries (47 ) 2,416 (4,497 ) — (2,128 ) Provision (benefit) for income taxes (93 ) 590 (23 ) — 474 Equity earnings of subsidiaries (2,646 ) 117 — 2,529 — Net earnings (losses) (2,600 ) 1,943 (4,474 ) 2,529 (2,602 ) Net (earnings) losses attributable to noncontrolling interests — — 2 — 2 Net earnings (losses) attributable to Altria $ (2,600 ) $ 1,943 $ (4,472 ) $ 2,529 $ (2,600 ) Net earnings (losses) $ (2,600 ) $ 1,943 $ (4,474 ) $ 2,529 $ (2,602 ) Other comprehensive earnings (losses), net of deferred income taxes 244 1 20 (21 ) 244 Comprehensive earnings (losses) (2,356 ) 1,944 (4,454 ) 2,508 (2,358 ) Comprehensive (earnings) losses attributable to noncontrolling interests — — 2 — 2 Comprehensive earnings (losses) attributable to Altria $ (2,356 ) $ 1,944 $ (4,452 ) $ 2,508 $ (2,356 ) Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Three Months Ended September 30, 2018 (in millions of dollars) Altria PM USA Non- Total Consolidated Net revenues $ — $ 5,811 $ 1,035 $ (9 ) $ 6,837 Cost of sales — 1,736 310 (9 ) 2,037 Excise taxes on products — 1,491 54 — 1,545 Gross profit — 2,584 671 — 3,255 Marketing, administration and research costs 45 491 164 — 700 Asset impairment and exit costs — — (2 ) — (2 ) Operating income (expense) (45 ) 2,093 509 — 2,557 Interest and other debt expense (income), net 127 (20 ) 52 — 159 Net periodic benefit (income) cost, excluding service cost 1 (18 ) (4 ) — (21 ) Earnings from equity investments (189 ) — — — (189 ) Earnings (losses) before income taxes and equity earnings of subsidiaries 16 2,131 461 — 2,608 Provision (benefit) for income taxes 21 539 104 — 664 Equity earnings of subsidiaries 1,948 119 — (2,067 ) — Net earnings (losses) 1,943 1,711 357 (2,067 ) 1,944 Net (earnings) losses attributable to noncontrolling interests — — (1 ) — (1 ) Net earnings (losses) attributable to Altria $ 1,943 $ 1,711 $ 356 $ (2,067 ) $ 1,943 Net earnings (losses) $ 1,943 $ 1,711 $ 357 $ (2,067 ) $ 1,944 Other comprehensive earnings (losses), net of deferred income taxes (382 ) 2 36 (38 ) (382 ) Comprehensive earnings (losses) 1,561 1,713 393 (2,105 ) 1,562 Comprehensive (earnings) losses attributable to noncontrolling interests — — (1 ) — (1 ) Comprehensive earnings (losses) attributable to Altria $ 1,561 $ 1,713 $ 392 $ (2,105 ) $ 1,561 Condensed Consolidating Statements of Cash Flows For the Nine Months Ended September 30, 2019 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 5,330 $ 4,862 $ 1,009 $ (5,927 ) $ 5,274 Cash Provided by (Used in) Investing Activities Capital expenditures — (26 ) (134 ) — (160 ) Investment in Cronos — — (1,863 ) — (1,863 ) Acquisition of businesses and assets — — (421 ) — (421 ) Investment in consolidated subsidiaries (2,446 ) — — 2,446 — Other, net 22 1 9 — 32 Net cash provided by (used in) investing activities (2,424 ) (25 ) (2,409 ) 2,446 (2,412 ) Cash Provided by (Used in) Financing Activities Repayment of short-term borrowings (12,800 ) — — — (12,800 ) Long-term debt issued 16,265 — — — 16,265 Long-term debt repaid (1,144 ) — — — (1,144 ) Repurchases of common stock (346 ) — — — (346 ) Dividends paid on common stock (4,498 ) — — — (4,498 ) Changes in amounts due to/from Altria and subsidiaries 3 42 2,401 (2,446 ) — Cash dividends paid to parent — (4,938 ) (989 ) 5,927 — Other, net (122 ) — (5 ) — (127 ) Net cash provided by (used in) financing activities (2,642 ) (4,896 ) 1,407 3,481 (2,650 ) Cash, cash equivalents and restricted cash (1) : Increase (decrease) 264 (59 ) 7 — 212 Balance at beginning of period 1,277 100 56 — 1,433 Balance at end of period $ 1,541 $ 41 $ 63 $ — $ 1,645 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 13 . Contingencies . Condensed Consolidating Statements of Cash Flows For the Nine Months Ended September 30, 2018 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 4,806 $ 5,801 $ 1,123 $ (5,164 ) $ 6,566 Cash Provided by (Used in) Investing Activities Capital expenditures — (33 ) (99 ) — (132 ) Acquisition of businesses and assets — — (15 ) — (15 ) Investment in consolidated subsidiaries (191 ) — — 191 — Other, net 8 — 2 — 10 Net cash provided by (used in) investing activities (183 ) (33 ) (112 ) 191 (137 ) Cash Provided by (Used in) Financing Activities Repurchases of common stock (1,317 ) — — — (1,317 ) Dividends paid on common stock (3,909 ) — — — (3,909 ) Changes in amounts due to/from Altria and subsidiaries 1,767 (1,565 ) (11 ) (191 ) — Cash dividends paid to parent — (4,166 ) (998 ) 5,164 — Other (21 ) — (4 ) — (25 ) Net cash provided by (used in) financing activities (3,480 ) (5,731 ) (1,013 ) 4,973 (5,251 ) Cash, cash equivalents and restricted cash (1) : Increase (decrease) 1,143 37 (2 ) — 1,178 Balance at beginning of period 1,203 62 49 — 1,314 Balance at end of period $ 2,346 $ 99 $ 47 $ — $ 2,492 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 13 . Contingencies .

New Accounting Guidance Not Yet

New Accounting Guidance Not Yet Adopted	9 Months Ended
	Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Guidance Not Yet Adopted	New Accounting Guidance Not Yet Adopted: The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria: Standards Description Effective Date for Public Entity Effect on Financial Statements ASU Nos. 2016-13; 2018-19; 2019-04; 2019-05 Measurement of Credit Losses on Financial Instruments (Topic 326) The guidance replaces the current incurred loss impairment methodology for recognizing credit losses for financial assets with a methodology that reflects the entity’s current estimate of all expected credit losses and requires consideration of a broader range of reasonable and supportable information for estimating credit losses. The guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period. Early adoption is permitted only as of annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Altria’s adoption of this guidance is not expected to have a material impact on Altria’s consolidated financial statements. ASU No. 2018-15 Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Subtopic 350-40) The guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. Altria’s adoption of this guidance is not expected to have a material impact on Altria’s consolidated financial statements.

Background and Basis of Prese_2

Background and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements	On January 1, 2019, Altria adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) Standards Description Effective Date for Public Entity Effect on Financial Statements ASU Nos. 2016-13; 2018-19; 2019-04; 2019-05 Measurement of Credit Losses on Financial Instruments (Topic 326) The guidance replaces the current incurred loss impairment methodology for recognizing credit losses for financial assets with a methodology that reflects the entity’s current estimate of all expected credit losses and requires consideration of a broader range of reasonable and supportable information for estimating credit losses. The guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period. Early adoption is permitted only as of annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Altria’s adoption of this guidance is not expected to have a material impact on Altria’s consolidated financial statements. ASU No. 2018-15 Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Subtopic 350-40) The guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. Altria’s adoption of this guidance is not expected to have a material impact on Altria’s consolidated financial statements.
Equity Method Investments	Altria reviews its investment in ABI for impairment by comparing the fair value of its investment to its carrying value. If the carrying value of Altria’s investment exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired and impairment is recognized in the period identified. The factors used to make this determination include the duration and magnitude of the fair value decline, ABI’s financial condition and near-term prospects, and Altria’s intent and ability to hold its investment in ABI until recovery. The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria may, in certain instances, pledge or otherwise grant a security interest in all or part of its Restricted Shares. In the event the pledgee or security interest holder forecloses on the Restricted Shares, the relevant Restricted Shares will be automatically converted, one-for-one, into ordinary shares. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share.
Equity Securities Without Readily Determinable Fair Value	Altria accounted for its investment in JUUL as an investment in an equity security. Since the JUUL shares do not have a readily determinable fair value, Altria has elected to measure its investment in JUUL at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There have been no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through September 30, 2019. Altria reviews its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators. If a qualitative assessment indicates that Altria’s investment in JUUL may be impaired, a quantitative assessment is performed. If the quantitative assessment indicates the fair value of the investment is less than its carrying value, the investment is written down to its fair value.

Background and Basis of Prese_3

Background and Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Share Repurchase Activity	Altria’s share repurchase activity was as follows: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions, except per share data) Total number of shares repurchased 6.4 21.8 — 6.2 Aggregate cost of shares repurchased $ 346 $ 1,317 $ — $ 367 Average price per share of shares repurchased $ 54.36 $ 60.53 $ — $ 59.18

Asset Impairment, Exit and Im_2

Asset Impairment, Exit and Implementation Costs (Tables)	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Pre-tax asset impairment, exit and implementation costs consisted of the following: For the Nine Months Ended September 30, 2019 For the Nine Months Ended September 30, 2018 Asset Impairment and Exit Costs Implementation Costs (1) Total Asset Impairment and Exit Costs Implementation Costs (2) Total (in millions) Smokeable products $ 50 $ 29 $ 79 $ (4 ) $ 1 $ (3 ) Smokeless products 9 3 12 6 3 9 All other 14 (7 ) 7 — — — General corporate 1 — 1 — — — Total 74 25 99 2 4 6 Plus amounts included in net periodic benefit income, excluding (3) 12 — 12 — — — Total $ 86 $ 25 $ 111 $ 2 $ 4 $ 6 (1) Included in cost of sales ( $1 million cost reversal) and marketing, administration and research costs ( $26 million ) in Altria’s condensed consolidated statement of earnings. (2) Included in cost of sales in Altria’s condensed consolidated statements of earnings. (3) Represents curtailment costs. See Note 7 . Benefit Plans . For the Three Months Ended September 30, 2019 For the Three Months Ended September 30, 2018 Asset Impairment and Exit Costs Implementation Costs (1) Total Asset Impairment and Exit Costs Implementation Costs (2) Total (in millions) Smokeable products $ — $ 4 $ 4 $ (5 ) $ (1 ) $ (6 ) Smokeless products 1 — 1 3 — 3 Total $ 1 $ 4 $ 5 $ (2 ) $ (1 ) $ (3 ) (1) Included in cost of sales ( $1 million ) and marketing, administration and research costs ( $3 million ) in Altria’s condensed consolidated statement of earnings. (2) Included in cost of sales in Altria’s condensed consolidated statements of earnings.
Schedule of Restructuring Reserve by Type of Cost	The movement in the restructuring liabilities, substantially all of which are severance liabilities, was as follows: For the Nine Months Ended September 30, 2019 (in millions) Balances at December 31, 2018 $ 155 Charges 52 Cash spent (119 ) Balances at September 30, 2019 $ 88

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	Goodwill and other intangible assets, net, by segment were as follows: Goodwill Other Intangible Assets, net September 30, 2019 December 31, 2018 September 30, 2019 December 31, 2018 (in millions) Smokeable products $ 99 $ 99 $ 3,077 $ 3,037 Smokeless products 5,089 5,023 9,189 8,825 Wine 74 74 238 239 Other — — 184 178 Total $ 5,262 $ 5,196 $ 12,688 $ 12,279 The change in goodwill relates to the 2019 acquisition of the Burger Group. For additional information, see Note 1 . Background and Basis of Presentation . The changes in goodwill and net carrying amount of intangible assets were as follows: For the Nine Months Ended September 30, 2019 For the Year Ended December 31, 2018 Goodwill Other Intangible Assets, net Goodwill Other Intangible Assets, net (in millions) Balance at January 1 $ 5,196 $ 12,279 $ 5,307 $ 12,400 Changes due to: Acquisitions (1) 66 437 — 15 Asset impairment (2) — — (111 ) (98 ) Amortization — (28 ) — (38 ) Balance at End of Period $ 5,262 $ 12,688 $ 5,196 $ 12,279 (1) Substantially all of the 2019 changes reflect the acquisition of the Burger Group, which held assets consisting primarily of intellectual property. (2) Reflects asset impairment of goodwill and other intangible assets, net, related to e-vapor products and the Columbia Crest trademark.
Schedule of Indefinite-Lived Intangible Assets	Other intangible assets consisted of the following: September 30, 2019 December 31, 2018 Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization (in millions) Indefinite-lived intangible assets $ 11,846 $ — $ 11,846 $ — Definite-lived intangible assets 1,090 248 654 221 Total other intangible assets $ 12,936 $ 248 $ 12,500 $ 221
Schedule of Finite-Lived Intangible Assets	Other intangible assets consisted of the following: September 30, 2019 December 31, 2018 Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization (in millions) Indefinite-lived intangible assets $ 11,846 $ — $ 11,846 $ — Definite-lived intangible assets 1,090 248 654 221 Total other intangible assets $ 12,936 $ 248 $ 12,500 $ 221

Investments in Equity Securit_2

Investments in Equity Securities Investments in Equity Securities (Tables)	9 Months Ended
	Sep. 30, 2019
Investments [Abstract]
Investment	Altria’s investments consisted of the following: Carrying Amount September 30, 2019 December 31, 2018 (in millions) ABI $ 17,950 $ 17,696 JUUL 8,305 12,800 Cronos (1) 1,091 — Total $ 27,346 $ 30,496 ( 1) Includes investment in Acquired Common Shares ( $673 million ), the Cronos warrant ( $315 million ) and the Fixed-price Preemptive Rights ( $103 million ) as discussed further below.
Equity Method Investments	Earnings from equity investments accounted for under the equity method of accounting consisted of the following: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) ABI $ 640 $ 759 $ 252 $ 189 Cronos (1) 226 — 81 — Total $ 866 $ 759 $ 333 $ 189 ( 1) Represents Altria’s share of Cronos’s earnings, substantially all of which relate to the change in fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares.

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value Measurement Inputs and Valuation Techniques	The fair values of the Fixed-price Preemptive Rights and warrant are estimated using Black-Scholes option-pricing models, adjusted for unobservable inputs, including probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at: September 30, 2019 March 8, 2019 September 30, 2019 March 8, 2019 Fixed-price Preemptive Rights Warrant Expected life (1) 1.93 years 2.32 years 3.43 years 4 years Expected volatility (2) 81.55% 93.02% 81.55% 93.02% Risk-free interest rate (3)(4) 1.61% 1.61% 1.49% 1.67% Expected dividend yield (5) —% —% —% —% (1) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 1 year to 7 years at September 30, 2019 and March 8, 2019) and the March 8, 2023 expiration date of the warrant. (2) Based on a blend of historical volatility levels of the underlying equity security and peer companies. (3) Based on the implied yield currently available on Canadian Treasury zero coupon issues weighted for the remaining expected life of the Fixed-price Preemptive Rights. (4) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the warrant. (5) Based on Cronos’s expected dividend payments .
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation	The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and warrant, which are classified in Level 3 of the fair value hierarchy: (in millions) Balance at December 31, 2018 $ — Initial investment in Fixed-price Preemptive Rights and warrant 1,736 Exercise of Preemptive Rights (22 ) Pre-tax earnings (losses) recognized in net earnings (1,296 ) Balance at September 30, 2019 $ 418
Schedule of Derivative Liabilities at Fair Value	The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows: Fair Value of Assets Fair Value of Liabilities Balance Sheet Classification September 30, 2019 December 31, 2018 Balance Sheet Classification September 30, 2019 December 31, 2018 Derivatives designated as hedging instruments: (in millions) Foreign currency contracts Other current assets $ 69 $ 37 Other accrued liabilities $ — $ — Foreign currency contracts Other assets 17 4 Other liabilities — 4 Total $ 86 $ 41 $ — $ 4 Derivatives not designated as hedging instruments: Cronos warrant Investments in equity securities $ 315 $ — Fixed-price Preemptive Rights Investments in equity securities 103 — Total $ 418 $ — Total derivatives $ 504 $ 41 $ — $ 4
Pre-tax Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses	The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings were as follows: Gain (Loss) Recognized in Accumulated Other Comprehensive Losses Gain (Loss) Recognized in Net Earnings (1) Gain (Loss) Recognized in Accumulated Other Comprehensive Losses Gain (Loss) Recognized in Net Earnings (1) For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 2019 2018 2019 2018 (in millions) Foreign currency contracts $ 70 $ 46 $ 26 $ 26 $ 57 $ 7 $ 10 $ 10 Foreign currency denominated debt 168 — — — 200 — — — Total $ 238 $ 46 $ 26 $ 26 $ 257 $ 7 $ 10 $ 10 (1) Related to amounts excluded from effectiveness testing.

Benefit Plans (Tables)

Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2019
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit (Income) Cost	Net periodic benefit (income) cost consisted of the following: For the Nine Months Ended September 30, For the Three Months Ended September 30, Pension Postretirement Pension Postretirement 2019 2018 2019 2018 2019 2018 2019 2018 (in millions) Service cost $ 52 $ 61 $ 12 $ 13 $ 17 $ 20 $ 4 $ 4 Interest cost 229 207 57 52 77 69 17 15 Expected return on plan assets (431 ) (438 ) (11 ) (14 ) (143 ) (146 ) (4 ) (5 ) Amortization: Net loss 119 168 3 16 39 56 (3 ) (1 ) Prior service cost (credit) 4 3 (22 ) (31 ) 1 1 (8 ) (10 ) Curtailment 7 — 5 — — — — — Net periodic benefit (income) cost $ (20 ) $ 1 $ 44 $ 36 $ (9 ) $ — $ 6 $ 3

Earnings (Losses) Per Share (Ta

Earnings (Losses) Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Basic and diluted earnings (losses) per share (“EPS”) were calculated using the following: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Net earnings (losses) attributable to Altria $ 516 $ 5,713 $ (2,600 ) $ 1,943 Less: Distributed and undistributed earnings attributable to share-based awards (5 ) (7 ) (1 ) (2 ) Earnings (losses) for basic and diluted EPS $ 511 $ 5,706 $ (2,601 ) $ 1,941 Weighted-average shares for basic and diluted EPS 1,871 1,891 1,868 1,883

Other Comprehensive Earnings__2

Other Comprehensive Earnings/Losses (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria: For the Nine Months Ended September 30, 2019 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, December 31, 2018 $ (2,168 ) $ (374 ) $ (5 ) $ (2,547 ) Other comprehensive earnings (losses) before reclassifications — 108 8 116 Deferred income taxes — (28 ) — (28 ) Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — 80 8 88 Amounts reclassified to net earnings (losses) 113 (35 ) — 78 Deferred income taxes (29 ) 8 — (21 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 84 (27 ) — 57 Other comprehensive earnings (losses), net of deferred income taxes 84 53 (1) 8 145 Balances, September 30, 2019 $ (2,084 ) $ (321 ) $ 3 $ (2,402 ) For the Three Months Ended September 30, 2019 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, June 30, 2019 $ (2,110 ) $ (542 ) $ 6 $ (2,646 ) Other comprehensive earnings (losses) before reclassifications — 290 (5 ) 285 Deferred income taxes — (67 ) 2 (65 ) Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — 223 (3 ) 220 Amounts reclassified to net earnings (losses) 35 (4 ) — 31 Deferred income taxes (9 ) 2 — (7 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 26 (2 ) — 24 Other comprehensive earnings (losses), net of deferred income taxes 26 221 (1) (3 ) 244 Balances, September 30, 2019 $ (2,084 ) $ (321 ) $ 3 $ (2,402 ) For the Nine Months Ended September 30, 2018 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, December 31, 2017 $ (1,839 ) $ (54 ) $ (4 ) $ (1,897 ) Other comprehensive earnings (losses) before reclassifications — (288 ) (1 ) (289 ) Deferred income taxes — 57 — 57 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — (231 ) (1 ) (232 ) Amounts reclassified to net earnings (losses) 168 (41 ) — 127 Deferred income taxes (42 ) 10 — (32 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 126 (31 ) — 95 Other comprehensive earnings (losses), net of deferred income taxes 126 (262 ) (1) (1 ) (137 ) Balances, September 30, 2018 $ (1,713 ) $ (316 ) $ (5 ) $ (2,034 ) For the Three Months Ended September 30, 2018 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, June 30, 2018 $ (1,752 ) $ 106 $ (6 ) $ (1,652 ) Other comprehensive earnings (losses) before reclassifications — (513 ) 1 (512 ) Deferred income taxes — 107 — 107 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — (406 ) 1 (405 ) Amounts reclassified to net earnings (losses) 50 (21 ) — 29 Deferred income taxes (11 ) 5 — (6 ) Amounts reclassified to net earnings (losses), net of deferred income taxes 39 (16 ) — 23 Other comprehensive earnings (losses), net of deferred income taxes 39 (422 ) (1) 1 (382 ) Balances, September 30, 2018 $ (1,713 ) $ (316 ) $ (5 ) $ (2,034 ) (1) Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 6 . Financial Instruments.
Reclassification out of Accumulated Other Comprehensive Income	The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Benefit Plans: (1) Net loss $ 135 $ 196 $ 42 $ 59 Prior service cost/credit (22 ) (28 ) (7 ) (9 ) 113 168 35 50 ABI (2) (35 ) (41 ) (4 ) (21 ) Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses) $ 78 $ 127 $ 31 $ 29 (1) Amounts are included in net defined benefit plan costs. For further details, see Note 7 . Benefit Plans. (2) Amounts are primarily included in earnings from equity investments.

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Segment data were as follows: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Net revenues: Smokeable products $ 16,837 $ 16,995 $ 6,049 $ 6,035 Smokeless products 1,762 1,690 620 586 Wine 483 489 167 181 All other 21 76 20 35 Net revenues $ 19,103 $ 19,250 $ 6,856 $ 6,837 Earnings (losses) before income taxes: Operating companies income (loss): Smokeable products $ 6,864 $ 6,516 $ 2,561 $ 2,277 Smokeless products 1,195 1,085 417 370 Wine 50 73 16 29 All other (27 ) (121 ) 8 (38 ) Amortization of intangibles (28 ) (30 ) (12 ) (20 ) General corporate expenses (154 ) (152 ) (46 ) (61 ) Corporate asset impairment and exit costs (1 ) — — — Operating income 7,899 7,371 2,944 2,557 Interest and other debt expense, net (989 ) (503 ) (293 ) (159 ) Net periodic benefit income, excluding service cost 40 37 24 21 Earnings from equity investments 866 759 333 189 Impairment of JUUL equity securities (4,500 ) — (4,500 ) — Loss on Cronos-related financial instruments (1,327 ) — (636 ) — Loss on ABI/SABMiller business combination — (33 ) — — Earnings (losses) before income taxes $ 1,989 $ 7,631 $ (2,128 ) $ 2,608
Schedule of Pre-tax Tobacco and Health Litigation Items	Tobacco and Health Litigation Items - Pre-tax charges related to certain tobacco and health litigation items were recorded in Altria’s condensed consolidated statements of earnings as follows: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Smokeable products segment $ 43 $ 94 $ 3 $ 10 Smokeless products segment — 10 — 10 Interest and other debt expense, net 5 15 — 1 Total $ 48 $ 119 $ 3 $ 21

Contingencies (Tables)

Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contingencies	Currently Pending Engle Cases with Accrued Liabilities (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (All Defendants) Punitive Damages (PM USA) Appeal Status Accrual (1) Berger ( Cote ) September 2014 PM USA Federal Court - Middle District of Florida $6 million $21 million The Eleventh Circuit Court of Appeals reinstated the punitive and compensatory damages awards and remanded the case to the district court. PM USA’s challenge to the punitive damages award was denied by the district court. PM USA’s appeal to the Eleventh Circuit Court of Appeals is pending. $6 million accrual in the fourth quarter of 2018 (1) Accrual amounts include interest and associated costs, if applicable. For cases with multiple defendants, if any, accrual amounts reflect the portion of compensatory damages PM USA believes it will have to pay if the case is ultimately decided in plaintiff’s favor after taking into account any portion potentially payable by the other defendant(s). Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status McCall March 2019 PM USA Broward <$1 million (<$1 million PM USA) <$1 million New trial ordered on punitive damages. Neff March 2019 PM USA and R.J. Reynolds Broward $4 million $2 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Frogel March 2019 PM USA Palm Beach <$1 million (<$1 million PM USA) $0 Appeals by plaintiff and defendant to Fourth District Court of Appeal pending. Mahfuz February 2019 PM USA and R.J. Reynolds Broward $12 million $10 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Holliman February 2019 PM USA Miami-Dade $3 million $0 Defendant’s appeal to Third District Court of Appeal pending. Chadwell September 2018 PM USA Miami-Dade $2 million $0 Appeal by defendant to Third District Court of Appeal pending. Kaplan July 2018 PM USA and R.J. Reynolds Broward $2 million $2 million Appeals by defendants to Fourth District Court of Appeal pending. Landi June 2018 PM USA and R.J. Reynolds Broward $8 million $5 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Theis May 2018 PM USA and R.J. Reynolds Sarasota $7 million $10 million Defendants’ appeal to Second District Court of Appeal pending. Freeman March 2018 PM USA Alachua $4 million $0 Defendant’s appeal to First District Court of Appeal pending. R. Douglas November 2017 PM USA Duval <$1 million $0 Awaiting entry of final judgment by the trial court. Sommers April 2017 PM USA Miami-Dade $1 million $0 New trial ordered on punitive damages; appeals by plaintiff and defendant to Third District Court of Appeal pending. Santoro March 2017 PM USA, R.J. Reynolds and Liggett Group Broward $2 million $0 Trial court set aside punitive damages award; appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Cooper (Blackwood) September 2015 PM USA and R.J. Reynolds Broward $5 million $0 Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages. McCoy July 2015 PM USA, Broward $2 million $3 million Fourth District Court of Appeal reversed judgment and ordered a new trial; plaintiff requested review by the Florida Supreme Court. D. Brown January 2015 PM USA Federal Court - Middle District of Florida $8 million $9 million Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit pending. Kerrivan October 2014 PM USA and R.J. Reynolds Federal Court - Middle District of Florida $16 million $16 million Appeal by defendants to U.S. Court of Appeals for the Eleventh Circuit pending. Harris July 2014 PM USA, Federal Court - Middle District of Florida $2 million (<$ 1 million PM USA) $0 Appeals by plaintiff and defendants to U.S. Court of Appeals for the Eleventh Circuit pending. (1 ) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies. Engle Cases Concluded Within Past 12 Months (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Accrual Date Payment Amount (if any) Payment Date Alvarez Del Real September 2019 PM USA Miami-Dade Fourth quarter of 2019 <$1 million October 2019 Zingaro May 2019 PM USA and R.J. Reynolds Broward Third quarter of 2019 <$1 million October 2019 Bryant December 2017 PM USA Escambia Second quarter of 2019 <$1 million July 2019 Wallace October 2017 PM USA and R.J. Reynolds Brevard Second quarter of 2019 $26 million May 2019 J. Brown February 2017 PM USA and R.J. Reynolds Pinellas First quarter of 2019 $4 million April 2019 L. Martin May 2017 PM USA Miami-Dade First quarter of 2019 $2 million April 2019 Danielson November 2015 PM USA Escambia First quarter of 2019 $3 million March 2019 S. Martin November 2016 PM USA and Broward First quarter of 2019 $5 million March 2019 Searcy April 2013 PM USA and Federal Court - Middle District of Florida Third quarter of 2018 $2 million March 2019 Boatright November 2014 PM USA and Liggett Group Polk Second quarter of 2018 $42 million March 2019 M. Brown May 2015 PM USA Duval Second quarter of 2018 $8 million March 2019 Jordan August 2015 PM USA Duval Second quarter of 2018 $11 million March 2019 Pardue December 2016 PM USA and Alachua Second and Third quarters of 2018 $11 million March 2019 McKeever February 2015 PM USA Broward Fourth quarter of 2017 $21 million March 2019 Boulter December 2018 PM USA and Lee Fourth quarter of 2018 <$1 million January 2019 Simon September 2018 PM USA and Broward Fourth quarter of 2018 <$1 million October 2018 The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and, in some instances, Altria as of October 28, 2019, October 22, 2018 and October 23, 2017: October 28, 2019 October 22, 2018 October 23, 2017 Individual Smoking and Health Cases (1) 95 101 87 Smoking and Health Class Actions and Aggregated Claims Litigation (2) 2 2 4 Health Care Cost Recovery Actions (3) — 1 1 “Lights/Ultra Lights” Class Actions 2 2 4 (1) Includes 21 cases filed in Massachusetts and 38 non- Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action ). Also does not include 1,471 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 ( Broin ). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. In March 2018, 923 of these cases were voluntarily dismissed without prejudice. (2) The 2017 pending cases include as one case the 30 civil actions that were to be tried in six consolidated trials in West Virginia ( In re: Tobacco Litigation ). PM USA was a defendant in nine of the 30 cases. The parties resolved these cases for an immaterial amount and in the second quarter of 2018, the court dismissed all 30 cases. (3) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below. The changes in Altria’s accrued liability for tobacco and health litigation items, including related interest costs, for the periods specified below are as follows: For the Nine Months Ended September 30, For the Three Months Ended September 30, 2019 2018 2019 2018 (in millions) Accrued liability for tobacco and health litigation items at beginning of period (1) $ 112 $ 106 $ 13 $ 107 Pre-tax charges for: Tobacco and health litigation 43 104 3 20 Related interest costs 5 15 — 1 Payments (1) (151 ) (118 ) (7 ) (21 ) Accrued liability for tobacco and health litigation items at end of period (1) $ 9 $ 107 $ 9 $ 107 (1) Includes amounts related to the costs of implementing the corrective communications remedy related to the Federal Government’s Lawsuit discussed below.

Condensed Consolidating Finan_2

Condensed Consolidating Financial Information (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheets September 30, 2019 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Assets Cash and cash equivalents $ 1,541 $ — $ 63 $ — $ 1,604 Receivables — 16 149 — 165 Inventories: Leaf tobacco — 466 354 — 820 Other raw materials — 130 71 — 201 Work in process — 8 590 — 598 Finished product — 105 464 — 569 — 709 1,479 — 2,188 Due from Altria and subsidiaries 85 3,825 1,331 (5,241 ) — Income taxes 47 27 44 (103 ) 15 Other current assets 83 193 43 — 319 Total current assets 1,756 4,770 3,109 (5,344 ) 4,291 Property, plant and equipment, at cost — 2,940 2,069 — 5,009 Less accumulated depreciation — 2,153 894 — 3,047 — 787 1,175 — 1,962 Goodwill — — 5,262 — 5,262 Other intangible assets, net — 2 12,686 — 12,688 Investments in equity securities 17,950 — 9,396 — 27,346 Investment in consolidated subsidiaries 23,608 2,861 — (26,469 ) — Due from Altria and subsidiaries 4,790 — — (4,790 ) — Other assets 107 1,031 897 (671 ) 1,364 Total Assets $ 48,211 $ 9,451 $ 32,525 $ (37,274 ) $ 52,913 Condensed Consolidating Balance Sheets (Continued) September 30, 2019 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Liabilities Current portion of long-term debt $ 1,000 $ — $ — $ — $ 1,000 Accounts payable 1 82 163 — 246 Accrued liabilities: Marketing — 481 73 — 554 Settlement charges — 3,086 8 — 3,094 Other 346 432 520 (103 ) 1,195 Dividends payable 1,573 — — — 1,573 Due to Altria and subsidiaries 4,540 499 202 (5,241 ) — Total current liabilities 7,460 4,580 966 (5,344 ) 7,662 Long-term debt 26,903 — — — 26,903 Deferred income taxes 3,098 — 2,813 (671 ) 5,240 Accrued pension costs 146 — 206 — 352 Accrued postretirement health care costs — 1,073 691 — 1,764 Due to Altria and subsidiaries — — 4,790 (4,790 ) — Other liabilities 59 88 169 — 316 Total liabilities 37,666 5,741 9,635 (10,805 ) 42,237 Contingencies Redeemable noncontrolling interest — — 39 — 39 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,960 3,310 27,493 (30,803 ) 5,960 Earnings reinvested in the business 39,910 611 (2,937 ) 2,326 39,910 Accumulated other comprehensive losses (2,402 ) (211 ) (1,806 ) 2,017 (2,402 ) Cost of repurchased stock (33,858 ) — — — (33,858 ) Total stockholders’ equity attributable to Altria 10,545 3,710 22,759 (26,469 ) 10,545 Noncontrolling interests — — 92 — 92 Total stockholders’ equity 10,545 3,710 22,851 (26,469 ) 10,637 Total Liabilities and Stockholders’ Equity $ 48,211 $ 9,451 $ 32,525 $ (37,274 ) $ 52,913 Condensed Consolidating Balance Sheets December 31, 2018 (in millions of dollars) Altria PM USA Non- Total Consolidated Assets Cash and cash equivalents $ 1,277 $ — $ 56 $ — $ 1,333 Receivables — 18 124 — 142 Inventories: Leaf tobacco — 561 379 — 940 Other raw materials — 123 63 — 186 Work in process — 2 645 — 647 Finished product — 128 430 — 558 — 814 1,517 — 2,331 Due from Altria and subsidiaries 46 3,828 1,194 (5,068 ) — Income taxes 100 94 — (27 ) 167 Other current assets 41 167 118 — 326 Total current assets 1,464 4,921 3,009 (5,095 ) 4,299 Property, plant and equipment, at cost — 2,928 2,022 — 4,950 Less accumulated depreciation — 2,111 901 — 3,012 — 817 1,121 — 1,938 Goodwill — — 5,196 — 5,196 Other intangible assets, net — 2 12,277 — 12,279 Investments in equity securities 17,696 — 12,800 — 30,496 Investment in consolidated subsidiaries 25,996 2,825 — (28,821 ) — Due from Altria and subsidiaries 4,790 — — (4,790 ) — Other assets 193 955 952 (670 ) 1,430 Total Assets $ 50,139 $ 9,520 $ 35,355 $ (39,376 ) $ 55,638 Condensed Consolidating Balance Sheets (Continued) December 31, 2018 (in millions of dollars) Altria PM USA Non- Total Consolidated Liabilities Short-term borrowings $ 12,704 $ — $ — $ — $ 12,704 Current portion of long-term debt 1,144 — — — 1,144 Accounts payable 1 91 307 — 399 Accrued liabilities: Marketing — 483 103 — 586 Settlement charges — 3,448 6 — 3,454 Other 295 524 611 (27 ) 1,403 Dividends payable 1,503 — — — 1,503 Due to Altria and subsidiaries 4,499 407 162 (5,068 ) — Total current liabilities 20,146 4,953 1,189 (5,095 ) 21,193 Long-term debt 11,898 — — — 11,898 Deferred income taxes 3,010 — 2,832 (670 ) 5,172 Accrued pension costs 187 — 357 — 544 Accrued postretirement health care costs — 1,072 677 — 1,749 Due to Altria and subsidiaries — — 4,790 (4,790 ) — Other liabilities 111 47 96 — 254 Total liabilities 35,352 6,072 9,941 (10,555 ) 40,810 Contingencies Redeemable noncontrolling interest — — 39 — 39 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,961 3,310 25,047 (28,357 ) 5,961 Earnings reinvested in the business 43,962 359 2,201 (2,560 ) 43,962 Accumulated other comprehensive losses (2,547 ) (221 ) (1,884 ) 2,105 (2,547 ) Cost of repurchased stock (33,524 ) — — — (33,524 ) Total stockholders’ equity attributable to Altria 14,787 3,448 25,373 (28,821 ) 14,787 Noncontrolling interests — — 2 — 2 Total stockholders’ equity 14,787 3,448 25,375 (28,821 ) 14,789 Total Liabilities and Stockholders’ Equity $ 50,139 $ 9,520 $ 35,355 $ (39,376 ) $ 55,638
Condensed Consolidating Statements of Earnings and Comprehensive Earnings	Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Nine Months Ended September 30, 2019 (in millions of dollars) Altria PM USA Non- Total Consolidated Net revenues $ — $ 16,140 $ 2,991 $ (28 ) $ 19,103 Cost of sales — 4,594 801 (28 ) 5,367 Excise taxes on products — 3,949 160 — 4,109 Gross profit — 7,597 2,030 — 9,627 Marketing, administration and research costs 125 1,181 348 — 1,654 Asset impairment and exit costs 1 38 35 — 74 Operating income (expense) (126 ) 6,378 1,647 — 7,899 Interest and other debt expense (income), net 892 (64 ) 161 — 989 Net periodic benefit (income) cost, excluding service cost 1 (32 ) (9 ) — (40 ) Earnings from equity investments (640 ) — (226 ) — (866 ) Impairment of JUUL equity securities — — 4,500 — 4,500 Loss on Cronos-related financial instruments — — 1,327 — 1,327 Earnings (losses) before income taxes and equity earnings of subsidiaries (379 ) 6,474 (4,106 ) — 1,989 Provision (benefit) for income taxes (180 ) 1,610 43 — 1,473 Equity earnings of subsidiaries 715 326 — (1,041 ) — Net earnings (losses) 516 5,190 (4,149 ) (1,041 ) 516 Net (earnings) losses attributable to noncontrolling interests — — — — — Net earnings (losses) attributable to Altria $ 516 $ 5,190 $ (4,149 ) $ (1,041 ) $ 516 Net earnings (losses) $ 516 $ 5,190 $ (4,149 ) $ (1,041 ) $ 516 Other comprehensive earnings (losses), net of deferred income taxes 145 10 78 (88 ) 145 Comprehensive earnings (losses) 661 5,200 (4,071 ) (1,129 ) 661 Comprehensive (earnings) losses attributable to noncontrolling interests — — — — — Comprehensive earnings (losses) attributable to Altria $ 661 $ 5,200 $ (4,071 ) $ (1,129 ) $ 661 Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Nine Months Ended September 30, 2018 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Net revenues $ — $ 16,339 $ 2,938 $ (27 ) $ 19,250 Cost of sales — 4,666 870 (27 ) 5,509 Excise taxes on products — 4,245 164 — 4,409 Gross profit — 7,428 1,904 — 9,332 Marketing, administration and research costs 122 1,400 437 — 1,959 Asset impairment and exit costs — — 2 — 2 Operating income (expense) (122 ) 6,028 1,465 — 7,371 Interest and other debt expense (income), net 378 (37 ) 162 — 503 Net periodic benefit (income) cost, excluding service cost 3 (33 ) (7 ) — (37 ) Earnings from equity investments (759 ) — — — (759 ) Loss on ABI/SABMiller business combination 33 — — — 33 Earnings (losses) before income taxes and equity earnings of subsidiaries 223 6,098 1,310 — 7,631 Provision (benefit) for income taxes 67 1,537 311 — 1,915 Equity earnings of subsidiaries 5,557 310 — (5,867 ) — Net earnings (losses) 5,713 4,871 999 (5,867 ) 5,716 Net (earnings) losses attributable to noncontrolling interests — — (3 ) — (3 ) Net earnings (losses) attributable to Altria $ 5,713 $ 4,871 $ 996 $ (5,867 ) $ 5,713 Net earnings (losses) $ 5,713 $ 4,871 $ 999 $ (5,867 ) $ 5,716 Other comprehensive earnings (losses), net of deferred income taxes (137 ) 10 109 (119 ) (137 ) Comprehensive earnings (losses) 5,576 4,881 1,108 (5,986 ) 5,579 Comprehensive (earnings) losses attributable to noncontrolling interests — — (3 ) — (3 ) Comprehensive earnings (losses) attributable to Altria $ 5,576 $ 4,881 $ 1,105 $ (5,986 ) $ 5,576 Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Three Months Ended September 30, 2019 (in millions of dollars) Altria PM USA Non- Total Consolidated Net revenues $ — $ 5,804 $ 1,062 $ (10 ) $ 6,856 Cost of sales — 1,644 281 (10 ) 1,915 Excise taxes on products — 1,391 53 — 1,444 Gross profit — 2,769 728 — 3,497 Marketing, administration and research costs 41 392 119 — 552 Asset impairment and exit costs — — 1 — 1 Operating income (expense) (41 ) 2,377 608 — 2,944 Interest and other debt expense (income), net 258 (20 ) 55 — 293 Net periodic benefit (income) cost, excluding service cost — (19 ) (5 ) — (24 ) Earnings from equity investments (252 ) — (81 ) — (333 ) Impairment of JUUL equity securities — — 4,500 — 4,500 Loss on Cronos-related financial instruments — — 636 — 636 Earnings (losses) before income taxes and equity earnings of subsidiaries (47 ) 2,416 (4,497 ) — (2,128 ) Provision (benefit) for income taxes (93 ) 590 (23 ) — 474 Equity earnings of subsidiaries (2,646 ) 117 — 2,529 — Net earnings (losses) (2,600 ) 1,943 (4,474 ) 2,529 (2,602 ) Net (earnings) losses attributable to noncontrolling interests — — 2 — 2 Net earnings (losses) attributable to Altria $ (2,600 ) $ 1,943 $ (4,472 ) $ 2,529 $ (2,600 ) Net earnings (losses) $ (2,600 ) $ 1,943 $ (4,474 ) $ 2,529 $ (2,602 ) Other comprehensive earnings (losses), net of deferred income taxes 244 1 20 (21 ) 244 Comprehensive earnings (losses) (2,356 ) 1,944 (4,454 ) 2,508 (2,358 ) Comprehensive (earnings) losses attributable to noncontrolling interests — — 2 — 2 Comprehensive earnings (losses) attributable to Altria $ (2,356 ) $ 1,944 $ (4,452 ) $ 2,508 $ (2,356 ) Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Three Months Ended September 30, 2018 (in millions of dollars) Altria PM USA Non- Total Consolidated Net revenues $ — $ 5,811 $ 1,035 $ (9 ) $ 6,837 Cost of sales — 1,736 310 (9 ) 2,037 Excise taxes on products — 1,491 54 — 1,545 Gross profit — 2,584 671 — 3,255 Marketing, administration and research costs 45 491 164 — 700 Asset impairment and exit costs — — (2 ) — (2 ) Operating income (expense) (45 ) 2,093 509 — 2,557 Interest and other debt expense (income), net 127 (20 ) 52 — 159 Net periodic benefit (income) cost, excluding service cost 1 (18 ) (4 ) — (21 ) Earnings from equity investments (189 ) — — — (189 ) Earnings (losses) before income taxes and equity earnings of subsidiaries 16 2,131 461 — 2,608 Provision (benefit) for income taxes 21 539 104 — 664 Equity earnings of subsidiaries 1,948 119 — (2,067 ) — Net earnings (losses) 1,943 1,711 357 (2,067 ) 1,944 Net (earnings) losses attributable to noncontrolling interests — — (1 ) — (1 ) Net earnings (losses) attributable to Altria $ 1,943 $ 1,711 $ 356 $ (2,067 ) $ 1,943 Net earnings (losses) $ 1,943 $ 1,711 $ 357 $ (2,067 ) $ 1,944 Other comprehensive earnings (losses), net of deferred income taxes (382 ) 2 36 (38 ) (382 ) Comprehensive earnings (losses) 1,561 1,713 393 (2,105 ) 1,562 Comprehensive (earnings) losses attributable to noncontrolling interests — — (1 ) — (1 ) Comprehensive earnings (losses) attributable to Altria $ 1,561 $ 1,713 $ 392 $ (2,105 ) $ 1,561
Condensed Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows For the Nine Months Ended September 30, 2019 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 5,330 $ 4,862 $ 1,009 $ (5,927 ) $ 5,274 Cash Provided by (Used in) Investing Activities Capital expenditures — (26 ) (134 ) — (160 ) Investment in Cronos — — (1,863 ) — (1,863 ) Acquisition of businesses and assets — — (421 ) — (421 ) Investment in consolidated subsidiaries (2,446 ) — — 2,446 — Other, net 22 1 9 — 32 Net cash provided by (used in) investing activities (2,424 ) (25 ) (2,409 ) 2,446 (2,412 ) Cash Provided by (Used in) Financing Activities Repayment of short-term borrowings (12,800 ) — — — (12,800 ) Long-term debt issued 16,265 — — — 16,265 Long-term debt repaid (1,144 ) — — — (1,144 ) Repurchases of common stock (346 ) — — — (346 ) Dividends paid on common stock (4,498 ) — — — (4,498 ) Changes in amounts due to/from Altria and subsidiaries 3 42 2,401 (2,446 ) — Cash dividends paid to parent — (4,938 ) (989 ) 5,927 — Other, net (122 ) — (5 ) — (127 ) Net cash provided by (used in) financing activities (2,642 ) (4,896 ) 1,407 3,481 (2,650 ) Cash, cash equivalents and restricted cash (1) : Increase (decrease) 264 (59 ) 7 — 212 Balance at beginning of period 1,277 100 56 — 1,433 Balance at end of period $ 1,541 $ 41 $ 63 $ — $ 1,645 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 13 . Contingencies . Condensed Consolidating Statements of Cash Flows For the Nine Months Ended September 30, 2018 (in millions of dollars) Altria PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 4,806 $ 5,801 $ 1,123 $ (5,164 ) $ 6,566 Cash Provided by (Used in) Investing Activities Capital expenditures — (33 ) (99 ) — (132 ) Acquisition of businesses and assets — — (15 ) — (15 ) Investment in consolidated subsidiaries (191 ) — — 191 — Other, net 8 — 2 — 10 Net cash provided by (used in) investing activities (183 ) (33 ) (112 ) 191 (137 ) Cash Provided by (Used in) Financing Activities Repurchases of common stock (1,317 ) — — — (1,317 ) Dividends paid on common stock (3,909 ) — — — (3,909 ) Changes in amounts due to/from Altria and subsidiaries 1,767 (1,565 ) (11 ) (191 ) — Cash dividends paid to parent — (4,166 ) (998 ) 5,164 — Other (21 ) — (4 ) — (25 ) Net cash provided by (used in) financing activities (3,480 ) (5,731 ) (1,013 ) 4,973 (5,251 ) Cash, cash equivalents and restricted cash (1) : Increase (decrease) 1,143 37 (2 ) — 1,178 Balance at beginning of period 1,203 62 49 — 1,314 Balance at end of period $ 2,346 $ 99 $ 47 $ — $ 2,492 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 13 . Contingencies .

New Accounting Guidance Not Y_2

New Accounting Guidance Not Yet Adopted (Tables)	9 Months Ended
	Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Guidance Not Yet Adopted	The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria: Standards Description Effective Date for Public Entity Effect on Financial Statements ASU Nos. 2016-13; 2018-19; 2019-04; 2019-05 Measurement of Credit Losses on Financial Instruments (Topic 326) The guidance replaces the current incurred loss impairment methodology for recognizing credit losses for financial assets with a methodology that reflects the entity’s current estimate of all expected credit losses and requires consideration of a broader range of reasonable and supportable information for estimating credit losses. The guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period. Early adoption is permitted only as of annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Altria’s adoption of this guidance is not expected to have a material impact on Altria’s consolidated financial statements. ASU No. 2018-15 Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Subtopic 350-40) The guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. Altria’s adoption of this guidance is not expected to have a material impact on Altria’s consolidated financial statements.

Background and Basis of Prese_4

Background and Basis of Presentation (Narrative) (Details) - USD ($)	3 Months Ended			9 Months Ended		18 Months Ended	31 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Jan. 31, 2018	Jul. 31, 2019	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	May 31, 2018	Jul. 31, 2017	Oct. 31, 2016	Jul. 31, 2015
Equity, Class of Treasury Stock [Line Items]
Common stock increase decrease in dividend rate percentage	5.00%
Dividends declared (usd per share)	$ 0.84	$ 0.80	$ 0.80	$ 2.44	$ 2.2
Common stock, dividends, per share, annualized (in usd per share)				$ 3.36
Repurchase of common stock (shares)	0		6,200,000	6,400,000	21,800,000
Average price of repurchased shares, per share (usd per share)	$ 0		$ 59.18	$ 54.36	$ 60.53
Accounting Standards Update 2016-02 [Member]
Equity, Class of Treasury Stock [Line Items]
Operating lease, liability										$ 179,000,000
Operating lease, right-of-use asset										179,000,000
Cumulative effect										$ 0
ABI [Member]
Equity, Class of Treasury Stock [Line Items]
Equity method investment, ownership percentage	10.10%			10.10%
JUUL [Member]
Equity, Class of Treasury Stock [Line Items]
Equity securities, ownership percentage	35.00%			35.00%							35.00%
Equity securities Fv-Ni, purchase price											$ 12,800,000,000
Cronos [Member]
Equity, Class of Treasury Stock [Line Items]
Equity method investment, ownership percentage	45.00%			45.00%					45.00%
July 2015 Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Planned share repurchase program													$ 4,000,000,000	$ 3,000,000,000	$ 1,000,000,000
Repurchase of common stock (shares)							58,700,000
Average price of repurchased shares, per share (usd per share)							$ 68.15
January 2018 Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Planned share repurchase program							$ 1,000,000,000					$ 2,000,000,000
Repurchase of common stock (shares)						34,000,000
Average price of repurchased shares, per share (usd per share)						$ 58.86
July 2019 Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Planned share repurchase program								$ 1,000,000,000
Stock repurchased during period (in shares)				0
Helix Innovations LLC [Member]
Equity, Class of Treasury Stock [Line Items]
Noncontrolling interest, ownership percentage by parent		80.00%				80.00%
Business combination, consideration transferred		$ 353,000,000
Noncontrolling interest, ownership percentage by noncontrolling owners		20.00%				20.00%

Background and Basis of Prese_5

Background and Basis of Presentation (Share Repurchase Table) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Total number of shares repurchased (shares)	0	6.2	6.4	21.8
Aggregate cost of shares repurchased	$ 0	$ 367	$ 346	$ 1,317
Average price per share of shares repurchased (usd per share)	$ 0	$ 59.18	$ 54.36	$ 60.53

Revenues from Contracts with _2

Revenues from Contracts with Customers (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Allowance for sales discounts, goods	$ 0	$ 0
Deferred revenue	$ 229,000,000	288,000,000
Expected period for satisfaction of performance obligation	P3D
Receivables	$ 165,000,000	$ 142,000,000

Asset Impairment, Exit and Im_3

Asset Impairment, Exit and Implementation Costs (Pre-tax Asset Impairment, Exit and Implementation Costs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs	$ 1	$ (2)	$ 74	$ 2
Plus amounts included in net periodic benefit income, excluding service cost, Asset Impairment and Exit Costs			12	0
Total, Asset Impairment and Exit Costs	1	(2)	86	2
Implementation Costs			25	4
Plus amounts included in net period benefit income, excluding service cost, Implementation Costs			0	0
Total, Implementation Costs	(4)	1	(25)	(4)
Restructuring Charges			99	6
Plus amounts included in net periodic benefit income, excluding service cost, Total			12	0
Total restructuring	5	(3)	111	6
Operating Segments [Member] | Smokeable Products [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs	0	(5)	50	(4)
Implementation Costs	4	(1)	29	1
Restructuring Charges	4	(6)	79	(3)
Operating Segments [Member] | Smokeless Products [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs	1	3	9	6
Implementation Costs	0	0	3	3
Restructuring Charges	1	3	12	9
Operating Segments [Member] | All Other [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs			14	0
Implementation Costs			(7)	0
Restructuring Charges			7	0
Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs	0	$ 0	1	0
Implementation Costs			0	0
Restructuring Charges			1	$ 0
Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Total, Implementation Costs	1		1
Marketing Administration And Research Costs [Member]
Restructuring Cost and Reserve [Line Items]
Total, Implementation Costs	$ (3)		$ (26)

Asset Impairment, Exit and Im_4

Asset Impairment, Exit and Implementation Costs (Movement in Restructuring Liabilities) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning of period	$ 155
Charges	52
Cash spent	(119)
Restructuring reserve, end of period	$ 88

Asset Impairment, Exit and Im_5

Asset Impairment, Exit and Implementation Costs (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended		10 Months Ended	12 Months Ended
	Dec. 31, 2018	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 99,000,000	$ 6,000,000
Charges			52,000,000
Payments for restructuring			119,000,000
Cost Reduction Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost		$ 240,000,000	240,000,000		$ 240,000,000
Restructuring charges						$ 121,000,000
Charges					220,000,000
Payments for restructuring	$ 0	38,000,000	110,000,000
Refocus of Innovative Product Efforts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			12,000,000			272,000,000
Employee Severance [Member] | Cost Reduction Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost		210,000,000	210,000,000		210,000,000
Other Restructuring [Member] | Cost Reduction Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost		30,000,000	30,000,000		$ 30,000,000
Other Restructuring [Member] | Refocus of Innovative Product Efforts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges						63,000,000
Asset Impairment and Exit Costs [Member] | Cost Reduction Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 5,000,000	$ 99,000,000
Asset Impairment and Exit Costs [Member] | Refocus of Innovative Product Efforts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges						$ 209,000,000

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, net (Schedule of Goodwill and Other Intangible Assets by Segment) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill [Line Items]
Goodwill	$ 5,262	$ 5,196	$ 5,307
Other Intangible Assets, net	12,688	12,279	$ 12,400
Smokeable Products [Member]
Goodwill [Line Items]
Goodwill	99	99
Other Intangible Assets, net	3,077	3,037
Smokeless Products [Member]
Goodwill [Line Items]
Goodwill	5,089	5,023
Other Intangible Assets, net	9,189	8,825
Wine [Member]
Goodwill [Line Items]
Goodwill	74	74
Other Intangible Assets, net	238	239
All Other [Member]
Goodwill [Line Items]
Goodwill	0	0
Other Intangible Assets, net	$ 184	$ 178

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, net (Other Intangible Assets Disclosure) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Indefinite-lived intangible assets	$ 11,846	$ 11,846
Definite-lived intangible assets	1,090	654
Accumulated Amortization	248	221
Total other intangible assets	$ 12,936	$ 12,500

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, net (Changes in Goodwill and Net Carrying Amount of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Goodwill [Roll Forward]
Goodwill, beginning of period			$ 5,196	$ 5,307	$ 5,307
Acquisitions			66		0
Asset impairment			0		(111)
Goodwill, end of period	$ 5,262		5,262		5,196
Intangible Assets [Roll Forward]
Intangible assets, net, beginning of period			12,279	12,400	12,400
Acquisitions			437		15
Asset impairment			0		(98)
Amortization	(12)	$ (20)	(28)	$ (30)	(38)
Intangible assets, net, end of period	$ 12,688		$ 12,688		$ 12,279

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets, net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Loss Contingencies [Line Items]
Amortization of intangible assets	$ 12	$ 20	$ 28	$ 30	$ 38
Finite-lived intangible assets, amortization expense, next twelve months	63		63
Finite-lived intangible assets, amortization expense, year two	63		63
Finite-lived intangible assets, amortization expense, year three	63		63
Finite-lived intangible assets, amortization expense, year four	63		63
Finite-lived intangible assets, amortization expense, year five	63		63
UST Litigation [Member]
Loss Contingencies [Line Items]
Indefinite-lived trademarks	9,000		9,000
Middleton [Member]
Loss Contingencies [Line Items]
Indefinite-lived trademarks	$ 2,600		$ 2,600
Definite Lived Intangible Assets [Member]
Loss Contingencies [Line Items]
Finite-lived intangible asset, useful life			19 years

Investments in Equity Securit_3

Investments in Equity Securities (Summary of Investments) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Investment [Line Items]
Investments	$ 27,346	$ 30,496
ABI [Member]
Investment [Line Items]
Investments in equity securities	17,950	17,696
JUUL [Member]
Investment [Line Items]
Equity securities, Fv-Ni	8,305	12,800
Cronos [Member]
Investment [Line Items]
Investments in equity securities	1,091	$ 0
Equity Contract, Warrant [Member] | Cronos [Member]
Investment [Line Items]
Derivative asset, fair value, gross asset	315
Equity Contract, Preemptive Rights [Member] | Cronos [Member]
Investment [Line Items]
Derivative asset, fair value, gross asset	103
Common Stock [Member] | Cronos [Member]
Investment [Line Items]
Investments in equity securities	$ 673

Investments in Equity Securit_4

Investments in Equity Securities (Earnings in Equity Securities) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Investment [Line Items]
Earnings from equity investments	$ 333	$ 189	$ 866	$ 759
ABI [Member]
Investment [Line Items]
Earnings from equity investments	252	189	640	759
Cronos [Member]
Investment [Line Items]
Earnings from equity investments	$ 81	$ 0	$ 226	$ 0

Investments in Equity Securit_5

Investments in Equity Securities (Investment in ABI Narrative) (Details) - ABI [Member] - USD ($) shares in Millions, $ in Millions	Dec. 31, 2018	Sep. 30, 2019
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		10.10%
Number of restricted shares owned (in shares)		185
Number of ordinary shares owned (in shares)		12
Fair value of equity investment	$ 13,100	$ 18,800
Investments in equity securities	$ 17,696	$ 17,950
Difference between carrying amount and fair value, percentage	(26.00%)	(4.00%)

Investments in Equity Securit_6

Investments in Equity Securities (Investment in JUUL Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Schedule of Equity Method Investments [Line Items]
Impairment of JUUL equity securities		$ 4,500	$ 0	$ 4,500	$ 0
JUUL [Member]
Schedule of Equity Method Investments [Line Items]
Payments to acquire equity securities	$ 12,800
Equity securities, ownership percentage	35.00%	35.00%		35.00%
Equity securities, ownership percentage upon conversion		35.00%		35.00%
Equity securities, threshold for downward adjustment of board election		30.00%		30.00%
Equity securities without readily determinable fair value, fair value disclosure		$ 8,300		$ 8,300
Equity securities without readily determinable fair value, quantitative assessment adjustment, annual amount	$ 12,800
Equity securities without readily determinable fair value, quantitative assessment adjustment, percent				35.00%
Impairment of JUUL equity securities		$ 4,500

Investments in Equity Securit_7

Investments in Equity Securities (Investment in Cronos Narrative) (Details) - Cronos Group Inc. [Member] $ / shares in Units, shares in Millions, $ in Billions, $ in Billions	Mar. 31, 2019USD ($)shares	Mar. 31, 2019CAD ($)	Mar. 07, 2019CAD ($)	Sep. 30, 2019directorboard_membershares	Mar. 31, 2019$ / shares
Investment [Line Items]
Number of ordinary shares owned (approximately) (in shares) | shares	149.8
Ownership percentage (approximately)	45.00%			45.00%
Equity method investments, purchase price	$ 1.8	$ 2.4	$ 2.4
Equity method investment, warrant exercised, ownership percentage (approximately)	55.00%	55.00%
Payments to acquire equity method investments	$ 0.4
Payments for deferred tax liability	0.3
Number of directors nominated | director				4
Number of members on the Board of Directors | board_member				7
Equity Contract, Preemptive Rights [Member]
Investment [Line Items]
Equity method investment, shares purchased, (CAD per share) | $ / shares					$ 16.25
Equity method investment, number of shares eligible for purchase (in shares) | shares				37
Payments for derivative instrument, investing activities	$ 0.5
Equity Contract, Warrant [Member]
Investment [Line Items]
Equity method investment, shares purchased, (CAD per share) | $ / shares					$ 19
Equity method investment, number of shares eligible for purchase (in shares) | shares				76
Equity method investment, percentage of shares eligible for purchase	10.00%
Payments for derivative instrument, investing activities	$ 1.2

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) $ in Billions	Mar. 31, 2019USD ($)	Mar. 31, 2019CAD ($)	Mar. 07, 2019CAD ($)	Sep. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Mar. 07, 2019USD ($)	Mar. 07, 2019CAD ($)	Dec. 31, 2018USD ($)
Derivative [Line Items]
Unrealized gain (loss) on derivatives				$ (636,000,000)			$ (1,296,000,000)
Derivative, gain (loss) on derivative, net				(636,000,000)		$ 0	(1,327,000,000)	$ 0
Equity Contract, Preemptive Rights [Member]
Derivative [Line Items]
Unrealized gain (loss) on derivatives				(188,000,000)			(400,000,000)
Equity Contract, Warrant [Member]
Derivative [Line Items]
Unrealized gain (loss) on derivatives				(448,000,000)			(896,000,000)
Not Designated as Hedging Instrument [Member] | Forward Contracts [Member]
Derivative [Line Items]
Derivative asset, notional amount									$ 1,800,000,000	$ 2.4
Derivative, gain (loss) on derivative, net					$ (31,000,000)
Cronos Group Inc. [Member]
Derivative [Line Items]
Equity method investments, purchase price	$ 1,800,000,000	$ 2.4	$ 2.4
Foreign Currency Denominated Debt [Member]
Derivative [Line Items]
Debt instrument, fair value disclosure				4,937,000,000			4,937,000,000
Long-term debt				4,608,000,000			4,608,000,000				$ 0
Net Investment Hedging [Member] | Foreign currency contracts [Member]
Derivative [Line Items]
Derivative, notional amount				$ 1,391,000,000			$ 1,391,000,000				$ 1,226,000,000

Financial Instruments (Fair Val

Financial Instruments (Fair Value Using Black-Scholes Option-Pricing Model) (Details)	Sep. 30, 2019year	Mar. 08, 2019year
Expected Life [Member] | Equity Contract, Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	1.93	2.32
Expected Life [Member] | Equity Contract, Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	3.43	4
Expected Volatility [Member] | Equity Contract, Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.8155	0.9302
Expected Volatility [Member] | Equity Contract, Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.8155	0.9302
Risk Free Interest Rate [Member] | Equity Contract, Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.0161	0.0161
Risk Free Interest Rate [Member] | Equity Contract, Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.0149	0.0167
Expected Dividend Yield [Member] | Equity Contract, Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0	0
Expected Dividend Yield [Member] | Equity Contract, Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0	0
Weighted Average Expected Term [Member] | Equity Contract, Preemptive Rights [Member] | Minimum [Member]
Derivative [Line Items]
Derivative asset, measurement input	1
Weighted Average Expected Term [Member] | Equity Contract, Preemptive Rights [Member] | Maximum [Member]
Derivative [Line Items]
Derivative asset, measurement input	7

Financial Instruments (Beginnin

Financial Instruments (Beginning and Ending Balances of Fixed-price Preemptive Rights and Warrants) (Details) - Fair Value, Inputs, Level 3 [Member] - Equity Contract [Member] $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at begging of period	$ 0
Initial investment in Fixed-price Preemptive Rights and warrant	1,736
Exercise of Preemptive Rights	(22)
Pre-tax earnings (losses) recognized in net earnings	(1,296)
Balance at end of period	$ 418

Financial Instruments (Fair V_2

Financial Instruments (Fair Value Derivative Financial Instruments) (Details) - Net Investment Hedging [Member] - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Fair Value of Assets	$ 504	$ 41
Fair Value of Liabilities	0	4
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	86	41
Fair Value of Liabilities	0	4
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	69	37
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	17	4
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Liabilities	0	0
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Liabilities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Liabilities	0	4
Equity Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	418	0
Equity Contract, Warrant [Member] | Not Designated as Hedging Instrument [Member] | Investments In Equity Securities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	315	0
Equity Contract, Preemptive Rights [Member] | Not Designated as Hedging Instrument [Member] | Investments In Equity Securities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	$ 103	$ 0

Financial Instruments (Effects

Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details) - Net Investment Hedging [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	$ 257	$ 7	$ 238	$ 46
Gain Recognized in Net Earnings	10	10	26	26
Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	57	7	70	46
Gain Recognized in Net Earnings	10	10	26	26
Foreign Currency Denominated Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	200	0	168	0
Gain Recognized in Net Earnings	$ 0	$ 0	$ 0	$ 0

Benefit Plans (Schedule Of Comp

Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 17	$ 20	$ 52	$ 61
Interest cost	77	69	229	207
Expected return on plan assets	(143)	(146)	(431)	(438)
Amortization:
Net loss	39	56	119	168
Prior service cost (credit)	1	1	4	3
Curtailment	0	0	7	0
Net periodic benefit (income) cost	(9)	0	(20)	1
Postretirement [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	4	4	12	13
Interest cost	17	15	57	52
Expected return on plan assets	(4)	(5)	(11)	(14)
Amortization:
Net loss	(3)	(1)	3	16
Prior service cost (credit)	(8)	(10)	(22)	(31)
Curtailment	0	0	5	0
Net periodic benefit (income) cost	$ 6	$ 3	$ 44	$ 36

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, employer contributions	$ 51,000,000
Pension [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Anticipated additional employer contributions	10,000,000
Postretirement [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, employer contributions	0
Postretirement [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Anticipated additional employer contributions	$ 0

Earnings (Losses) Per Share (Ba

Earnings (Losses) Per Share (Basic and Diluted Earnings Per Share) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net earnings (losses) attributable to Altria	$ (2,600)	$ 1,943	$ 516	$ 5,713
Less: Distributed and undistributed earnings attributable to share-based awards	(1)	(2)	(5)	(7)
Earnings (losses) for basic and diluted EPS	$ (2,601)	$ 1,941	$ 511	$ 5,706
Weighted-average shares for basic and diluted EPS (in shares)	1,868	1,883	1,871	1,891

Other Comprehensive Earnings__3

Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	$ 14,466	$ 15,798	$ 14,789	$ 15,380
Other comprehensive earnings (losses), net of deferred income taxes	244	(382)	145	(137)
Ending balance	10,637	15,496	10,637	15,496
Accumulated Other Comprehensive Losses [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(2,646)	(1,652)	(2,547)	(1,897)
Other comprehensive earnings (losses) before reclassifications	285	(512)	116	(289)
Deferred income taxes	(65)	107	(28)	57
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	220	(405)	88	(232)
Amounts reclassified to net earnings (losses)	31	29	78	127
Deferred income taxes	(7)	(6)	(21)	(32)
Amounts reclassified to net earnings (losses), net of deferred income taxes	24	23	57	95
Other comprehensive earnings (losses), net of deferred income taxes	244	(382)	145	(137)
Ending balance	(2,402)	(2,034)	(2,402)	(2,034)
Benefit Plans [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(2,110)	(1,752)	(2,168)	(1,839)
Other comprehensive earnings (losses) before reclassifications	0	0	0	0
Deferred income taxes	0	0	0	0
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	0	0	0	0
Amounts reclassified to net earnings (losses)	35	50	113	168
Deferred income taxes	(9)	(11)	(29)	(42)
Amounts reclassified to net earnings (losses), net of deferred income taxes	26	39	84	126
Other comprehensive earnings (losses), net of deferred income taxes	26	39	84	126
Ending balance	(2,084)	(1,713)	(2,084)	(1,713)
ABI [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(542)	106	(374)	(54)
Other comprehensive earnings (losses) before reclassifications	290	(513)	108	(288)
Deferred income taxes	(67)	107	(28)	57
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	223	(406)	80	(231)
Amounts reclassified to net earnings (losses)	(4)	(21)	(35)	(41)
Deferred income taxes	2	5	8	10
Amounts reclassified to net earnings (losses), net of deferred income taxes	(2)	(16)	(27)	(31)
Other comprehensive earnings (losses), net of deferred income taxes	221	(422)	53	(262)
Ending balance	(321)	(316)	(321)	(316)
Currency Translation Adjustments and Other [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	6	(6)	(5)	(4)
Other comprehensive earnings (losses) before reclassifications	(5)	1	8	(1)
Deferred income taxes	2	0	0	0
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	(3)	1	8	(1)
Amounts reclassified to net earnings (losses)	0	0	0	0
Deferred income taxes	0	0	0	0
Amounts reclassified to net earnings (losses), net of deferred income taxes	0	0	0	0
Other comprehensive earnings (losses), net of deferred income taxes	(3)	1	8	(1)
Ending balance	$ 3	$ (5)	$ 3	$ (5)

Other Comprehensive Earnings__4

Other Comprehensive Earnings/Losses (Reclassifications) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit income, excluding service cost	$ (24)	$ (21)	$ (40)	$ (37)
ABI	(333)	(189)	(866)	(759)
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)	2,602	(1,944)	(516)	(5,716)
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
ABI	(4)	(21)	(35)	(41)
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings (losses)	31	29	78	127
Benefit Plans [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit income, excluding service cost	35	50	113	168
Net loss [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit income, excluding service cost	42	59	135	196
Prior service cost/credit [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit income, excluding service cost	$ (7)	$ (9)	$ (22)	$ (28)

Segment Reporting (Segment Data

Segment Reporting (Segment Data Schedule) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net revenues	$ 6,856	$ 6,837	$ 19,103	$ 19,250
Operating income	2,944	2,557	7,899	7,371
Amortization of intangibles	(12)	(20)	(28)	(30)	$ (38)
Corporate asset impairment and exit costs	(1)	2	(74)	(2)
Interest and other debt expense, net	(293)	(159)	(989)	(503)
Net periodic benefit income, excluding service cost	24	21	40	37
Earnings from equity investments	333	189	866	759
Impairment of JUUL equity securities	(4,500)	0	(4,500)	0
Loss on Cronos-related financial instruments	(636)	0	(1,327)	0
Loss on ABI/SABMiller business combination	0	0	0	(33)
Earnings (losses) before income taxes and equity earnings of subsidiaries	(2,128)	2,608	1,989	7,631
Smokeable Products [Member]
Segment Reporting Information [Line Items]
Net revenues	6,049	6,035	16,837	16,995
Smokeless Products [Member]
Segment Reporting Information [Line Items]
Net revenues	620	586	1,762	1,690
Wine [Member]
Segment Reporting Information [Line Items]
Net revenues	167	181	483	489
All Other [Member]
Segment Reporting Information [Line Items]
Net revenues	20	35	21	76
Operating Segments [Member] | Smokeable Products [Member]
Segment Reporting Information [Line Items]
Operating income	2,561	2,277	6,864	6,516
Corporate asset impairment and exit costs	0	5	(50)	4
Operating Segments [Member] | Smokeless Products [Member]
Segment Reporting Information [Line Items]
Operating income	417	370	1,195	1,085
Corporate asset impairment and exit costs	(1)	(3)	(9)	(6)
Operating Segments [Member] | Wine [Member]
Segment Reporting Information [Line Items]
Operating income	16	29	50	73
Operating Segments [Member] | All Other [Member]
Segment Reporting Information [Line Items]
Operating income	8	(38)	(27)	(121)
Corporate asset impairment and exit costs			(14)	0
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Amortization of intangibles	(12)	(20)	(28)	(30)
General corporate [Member]
Segment Reporting Information [Line Items]
General corporate expenses	(46)	(61)	(154)	(152)
Corporate asset impairment and exit costs	$ 0	$ 0	$ (1)	$ 0

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2018USD ($)
NPM Adjustment to Cost of Sales [Member] | Smokeable Products [Member] | Operating Income (Loss) [Member] | PM USA [Member] | NPM [Member]
Segment Reporting Information [Line Items]
Gain (loss) related to litigation settlement	$ 145

Segment Reporting (Schedule of

Segment Reporting (Schedule of Tobacco and Health Litigation Items) (Details) - PM USA [Member] - Tobacco and Health Litigation Cases [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded	$ 3	$ 21	$ 48	$ 119
Marketing Administration And Research Costs [Member] | Operating Segments [Member] | Smokeable Products [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded	3	10	43	94
Marketing Administration And Research Costs [Member] | Operating Segments [Member] | Smokeless Products [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded	0	10	0	10
Interest and Other Debt Expense, Net [Member] | Segment Reconciling Items [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded	$ 0	$ 1	$ 5	$ 15

Debt (Narrative) (Details)

Debt (Narrative) (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2019USD ($)	Sep. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Feb. 28, 2019EUR (€)	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Short-term borrowings		$ 0		$ 0			$ 12,704,000,000
Debt issuance costs							96,000,000
Repayment of short-term borrowings				12,800,000,000	$ 0
Accrued interest on short-term borrowings							15,000,000
Long-term debt repaid				1,144,000,000	0
Long-term debt issued				16,265,000,000	$ 0
Accrued interest on long-term debt		241,000,000		241,000,000			207,000,000
Reported Value Measurement [Member]
Debt Instrument [Line Items]
Long-term debt		27,900,000,000		27,900,000,000			13,000,000,000
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Debt Instrument [Line Items]
Long-term debt		30,300,000,000		$ 30,300,000,000			12,500,000,000
Term Loan Agreement, JUUL and Cronos [Member]
Debt Instrument [Line Items]
Face amount							$ 12,800,000,000
Repayment of short-term borrowings	$ 12,800,000,000
Pre-tax acquisition-related costs			$ 96,000,000
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt repaid		$ 1,144,000,000
Redemption price, percentage				101.00%
Senior Notes [Member] | USD Denominated Notes [Member]
Debt Instrument [Line Items]
Face amount	11,500,000,000
Senior Notes [Member] | Euro Denominated Notes [Member]
Debt Instrument [Line Items]
Face amount | €						€ 4,250,000,000
Long-term debt issued	4,800,000,000
Senior Notes [Member] | USD Denominated Notes Due 2022 [Member]
Debt Instrument [Line Items]
Face amount	$ 1,000,000,000
Stated interest rate	3.49%					3.49%
Senior Notes [Member] | USD Denominated Notes Due 2024 [Member]
Debt Instrument [Line Items]
Face amount	$ 1,000,000,000
Stated interest rate	3.80%					3.80%
Senior Notes [Member] | USD Denominated Notes Due 2026 [Member]
Debt Instrument [Line Items]
Face amount	$ 1,500,000,000
Stated interest rate	4.40%					4.40%
Senior Notes [Member] | USD Denominated Notes Due 2029 [Member]
Debt Instrument [Line Items]
Face amount	$ 3,000,000,000
Stated interest rate	4.80%					4.80%
Senior Notes [Member] | USD Denominated Notes Due 2039 [Member]
Debt Instrument [Line Items]
Face amount	$ 2,000,000,000
Stated interest rate	5.80%					5.80%
Senior Notes [Member] | USD Denominated Notes Due 2049 [Member]
Debt Instrument [Line Items]
Face amount	$ 2,500,000,000
Stated interest rate	5.95%					5.95%
Senior Notes [Member] | USD Denominated Notes Due 2059 [Member]
Debt Instrument [Line Items]
Face amount	$ 500,000,000
Stated interest rate	6.20%					6.20%
Senior Notes [Member] | Euro Denominated Notes Due 2023 [Member]
Debt Instrument [Line Items]
Face amount | €						€ 1,250,000,000
Stated interest rate	1.00%					1.00%
Senior Notes [Member] | Euro Denominated Notes Due 2025 [Member]
Debt Instrument [Line Items]
Face amount | €						€ 750,000,000
Stated interest rate	1.70%					1.70%
Senior Notes [Member] | Euro Denominated Notes Due 2027 [Member]
Debt Instrument [Line Items]
Face amount | €						€ 1,000,000,000
Stated interest rate	2.20%					2.20%
Senior Notes [Member] | Euro Denominated Notes Due 2031 [Member]
Debt Instrument [Line Items]
Face amount | €						€ 1,250,000,000
Stated interest rate	3.125%					3.125%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Investment [Line Items]
Income tax rate	(22.30%)	25.50%	74.10%	25.10%
Effective income tax rate reconciliation adjustments to tax accruals			$ 91
Unrecognized tax benefits	$ 50		50		$ 85
Unrecognized tax benefits that would impact the effective tax rate	43		43		59
Possible decrease in unrecognized tax benefits	26		26
Unrecognized tax benefits that would impact deferred taxes	7		7		$ 26
JUUL [Member]
Investment [Line Items]
Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount			1,040
Deferred tax assets, net	$ 1,040		$ 1,040

Contingencies (General Informat

Contingencies (General Information) (Details)	Sep. 30, 2019state
Commitments and Contingencies Disclosure [Abstract]
Number of states that cap bond or require no bond	47

Contingencies (Schedule of Pend

Contingencies (Schedule of Pending Cases) (Details)	Oct. 28, 2019case	Mar. 31, 2018case	Dec. 31, 2017casetrialplantiff	Oct. 22, 2018case	Oct. 23, 2017case
Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending				101	87
ETS Smoking and Health Case, Flight Attendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of claims dismissed		923
Smoking and Health Class Actions and Aggregated Claims Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending				2	4
Smoking and Health Class Actions and Aggregated Claims Litigation [Member] | Pending Litigation [Member] | West Virginia [Member]
Loss Contingencies [Line Items]
Number of cases			30
Number of plaintiffs | plantiff			30
Number of consolidated trials | trial			6
Smoking and Health Class Actions and Aggregated Claims Litigation [Member] | Pending Litigation [Member] | West Virginia [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of cases			9
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending				1	1
Lights Ultra Lights Class Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending				2	4
Subsequent Event [Member] | Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending	95
Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Massachusetts [Member]
Loss Contingencies [Line Items]
Number of cases pending	21
Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Florida [Member]
Loss Contingencies [Line Items]
Number of cases pending	38
Subsequent Event [Member] | ETS Smoking and Health Case, Flight Attendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of cases	1,471
Subsequent Event [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending	2
Subsequent Event [Member] | Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending	0
Subsequent Event [Member] | Lights Ultra Lights Class Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending	2

Contingencies (Overview of Altr

Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details) - case	Oct. 28, 2019	Oct. 28, 2019	Oct. 22, 2018	Oct. 23, 2017
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending			1	1
Smoking and Health Class Actions and Aggregated Claims Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending			2	4
Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending			101	87
Subsequent Event [Member] | Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending	0	0
Subsequent Event [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending	2	2
Subsequent Event [Member] | Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending	95	95
Subsequent Event [Member] | PM USA [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	10	10
Subsequent Event [Member] | PM USA [Member] | Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	3	3
Number of verdicts returned	133
Number of favorable verdicts	47
Number of unfavorable verdicts	75
Subsequent Event [Member] | PM USA [Member] | Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	1	1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Number of verdicts returned		67
Number of favorable verdicts		43
Number of unfavorable verdicts		24
Number of claims resolved		20
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Alaska [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | California [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		7
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Connecticut [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Florida [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		10
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Louisiana [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Massachusetts [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		3
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Mississippi [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Missouri [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		4
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Hampshire [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Jersey [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New York [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		5
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Ohio [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Pennsylvania [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Rhode Island [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Tennessee [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | West Virginia [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	8	8
Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	7	7

Contingencies (Judgments Paid a

Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		180 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019
Loss Contingency Accrual [Roll Forward]
Accrued liability for tobacco and health litigation items at beginning of period	$ 13	$ 107	$ 107	$ 112	$ 106
Payments	(7)		(21)	(151)	(118)
Accrued liability for tobacco and health litigation items at end of period	9	$ 112	107	9	107	$ 9
Interest Expense Related to Litigation [Member]
Loss Contingency Accrual [Roll Forward]
Provision related to litigation recorded	0		1	5	15
Tobacco and Health Judgment [Member]
Loss Contingencies [Line Items]
Judgments paid (approximately)						701
Litigation settlement interest expense (income)						214
Tobacco and Health Judgment [Member] | Litigation Cases Results [Member]
Loss Contingency Accrual [Roll Forward]
Provision related to litigation recorded	3		$ 20	43	$ 104
Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Judgments paid (approximately)						309
Litigation settlement interest expense (income)						52
Assets [Member] | Pending Litigation [Member] | PM USA [Member]
Loss Contingency Accrual [Roll Forward]
Security posted for appeal of judgments	$ 41			$ 41		$ 41

Contingencies (Non-Engle Progen

Contingencies (Non-Engle Progeny Litigation) (Details) - USD ($)	1 Months Ended
	Apr. 30, 2019	Sep. 30, 2019	Aug. 31, 2019	Dec. 31, 2018	Oct. 31, 2017
Non-Engle Progeny Smoking and Health Case, Greene [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded		$ 10,000,000
Non-Engle Progeny Smoking and Health Case, Laramie [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded			$ 11,000,000
Punitive damages awarded			$ 10,000,000
Non-Engle Progeny Smoking and Health Case, Capone [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded				$ 225,000
Provision related to litigation recorded	$ 325,000
Non-Engle Progeny Smoking and Health Case, Gentile [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded					$ 7,100,000
Non-Engle Progeny Smoking and Health Case, Gentile [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded					$ 5,300,000
Compensatory damages award, allocation percentage					75.00%

Contingencies (Engle Class Acti

Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)	Oct. 28, 2019USD ($)caseplantiff	Jul. 31, 2006	Dec. 31, 2015case	Jul. 31, 2000USD ($)
Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Punitive damages awarded | $				$ 145,000,000,000
Engle Progeny Cases [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Punitive damages awarded | $				$ 74,000,000,000
Period for decertified class members could file individual actions		1 year
Engle Progeny Cases, Federal [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of claims resolved			415
Subsequent Event [Member] | Engle Progeny Cases [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of verdicts returned	133
Number of unfavorable verdicts	75
Number of claims with unfavorable verdicts pending/reversed	7
Number of favorable verdicts	47
Subsequent Event [Member] | Engle Progeny Cases, State [Member]
Loss Contingencies [Line Items]
Number of cases pending	1,700
Number of plaintiffs | plantiff	2,200
Subsequent Event [Member] | Engle Progeny Cases, State [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	42
Subsequent Event [Member] | Engle Progeny Cases, Federal [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of cases pending	4
Subsequent Event [Member] | Engle Progeny Cases, D Cohen, Collar, Chacon [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of verdicts reversed	4
Subsequent Event [Member] | Engle Progeny Cases, Reider and Banks [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Zero damages verdicts	2
Damages awarded, value | $	$ 0
Subsequent Event [Member] | Engle Progeny Cases, Weingart and Hancock [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Zero damages verdict modified	2
Damages awarded, value | $	$ 0
Subsequent Event [Member] | Engle Progeny Cases, Pollari [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	1

Contingencies (Engle Progeny Ca

Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details) - USD ($) $ in Millions

Jul. 30, 2019

Oct. 31, 2019

May 31, 2019

Apr. 30, 2019

Mar. 31, 2019

Jan. 31, 2019

Oct. 31, 2018

Sep. 30, 2019

Dec. 31, 2018

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Feb. 28, 2019

Jul. 31, 2018

May 31, 2018

Mar. 31, 2018

Nov. 30, 2017

Apr. 30, 2017

Mar. 31, 2017

Sep. 30, 2015

Jul. 31, 2015

Jan. 31, 2015

Oct. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 7

$ 21

$ 151

$ 118

Engle Progeny Cases, Berger [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 6

Provision related to litigation recorded

$ 6

Engle Progeny Cases, Berger [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 21

Engle Progeny Cases, McCall [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 1

Engle Progeny Cases, McCall [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

1

Engle Progeny Cases, Neff [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

4

Engle Progeny Cases, Neff [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

2

Engle Progeny Cases, Frogel [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Engle Progeny Cases, Frogel [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

0

Engle Progeny Cases, Mahfuz [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 12

Engle Progeny Cases, Mahfuz [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

10

Engle Progeny Cases, Holliman [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

3

Engle Progeny Cases, Holliman [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

2

2

Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

0

0

Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 2

Engle Progeny Cases, Landi [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

8

8

Engle Progeny Cases, Landi [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 5

$ 5

Engle Progeny Cases, Theis [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 7

Engle Progeny Cases, Theis [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 10

Engle Progeny Cases, Freeman [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 4

Engle Progeny Cases, Freeman [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, R. Douglas [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 1

Engle Progeny Cases, R. Douglas [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Sommers [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 1

Engle Progeny Cases, Sommers [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Santoro [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, Santoro [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 5

Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

$ 0

Engle Progeny Cases, McCoy [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, McCoy [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

$ 3

Engle Progeny Cases, D. Brown [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 8

Engle Progeny Cases, D. Brown [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 9

Engle Progeny Cases, Kerrivan [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 16

Engle Progeny Cases, Kerrivan [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 16

Engle Progeny Cases, Harris [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, Harris [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

$ 0

Engle Progeny Cases, Bryant [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 1

Engle Progeny Cases, Wallace [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 26

Engle Progeny Cases, J. Brown [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 4

Engle Progeny Cases, L. Martin [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 2

Engle Progeny Cases, Danielson [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

3

Engle Progeny Cases, S. Martin [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

5

Engle Progeny Cases, Searcy [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

2

Engle Progeny Cases, Boatright [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

42

Engle Progeny Cases, M. Brown [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

8

Engle Progeny Cases, Jordan [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

11

Engle Progeny Cases, Pardue [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

11

Engle Progeny Cases, McKeever [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 21

Engle Progeny Cases, Boulter [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 1

Engle Progeny Cases, Simon [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 1

Subsequent Event [Member] | Engle Progeny Cases, Alvarez del Real [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 1

Subsequent Event [Member] | Engle Progeny Cases, Zingaro [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Loss contingency accrual, payments

$ 1

Contingencies (Florida Bond Sta

Contingencies (Florida Bond Statute) (Details) - Engle Progeny Cases, State [Member]	1 Months Ended
	Apr. 30, 2016case	Jun. 30, 2009USD ($)case
Loss Contingencies [Line Items]
Number of cases in which seeking confirmation	2
Florida [Member]
Loss Contingencies [Line Items]
Maximum bond for all defendants | $		$ 200,000,000
Alachua County, Florida [Member]
Loss Contingencies [Line Items]
Number of cases in which plaintiffs that challenged constitutionality of bond cap statute		3
Escambia County, Florida [Member]
Loss Contingencies [Line Items]
Number of cases in which plaintiffs that challenged constitutionality of bond cap statute		1

Contingencies (Other Smoking an

Contingencies (Other Smoking and Health Class Actions) (Details) - Smoking and Health Class Actions and Aggregated Claims Litigation [Member] $ in Billions	1 Months Ended	281 Months Ended
	Mar. 31, 2019CAD ($)rulingmanufacture	Sep. 30, 2019case	Oct. 28, 2019case	Oct. 22, 2018case	Oct. 23, 2017case
Loss Contingencies [Line Items]
Number of cases pending				2	4
PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		61
Arkansas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
California [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Delaware [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
District of Columbia [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Florida [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Illinois [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		3
Iowa [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Kansas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Louisiana [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Maryland [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Michigan [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Minnesota [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Nevada [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		29
New Jersey [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		6
New York [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Ohio [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Oklahoma [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Oregon [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Pennsylvania [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Puerto Rico [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
South Carolina [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Texas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Wisconsin [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Canada [Member] | Canadian Tobacco Manufacturers [Member]
Loss Contingencies [Line Items]
Number of manufacturers | manufacture	3
Number of verdicts upheld | ruling	2
Amount awarded to other party | $	$ 13
Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of cases pending			2
Subsequent Event [Member] | Canada [Member] | Philip Morris USA and Altria Group [Member]
Loss Contingencies [Line Items]
Number of cases pending			7
Subsequent Event [Member] | British Columbia and Saskatchewan [Member] | Philip Morris USA and Altria Group [Member]
Loss Contingencies [Line Items]
Number of cases pending			2

Contingencies (Health Care Cost

Contingencies (Health Care Cost Recovery Litigation) (Details) - Health Care Cost Recovery Actions [Member]	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 30, 1998USD ($)state	Sep. 30, 2019USD ($)case	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)case	Oct. 22, 2018case	Oct. 23, 2017case
Loss Contingencies [Line Items]
Number of cases pending | case					1	1
Number of states with settled litigation | state	46
State settlement agreements annual payments	$ 9,400,000,000
State settlement agreements attorney fees annual cap	$ 500,000,000
Litigation settlement		$ 1,100,000,000	$ 1,200,000,000	$ 3,200,000,000
Threatened Litigation [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending | case		10		10

Contingencies (NPM Adjustment D

Contingencies (NPM Adjustment Disputes - Settlement with 20 States and Territories and Settlement with New York) (Details) $ in Millions	1 Months Ended					3 Months Ended		9 Months Ended	12 Months Ended
	Apr. 30, 2019USD ($)	Apr. 30, 2018USD ($)	Oct. 31, 2017USD ($)state	Sep. 30, 2013USD ($)state	Nov. 30, 1998state	Mar. 31, 2019USD ($)	Mar. 31, 2018state	Sep. 30, 2019USD ($)stateclaim	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018settlement_development
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of states with settled litigation | state					46
PM USA [Member] | Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Loss contingency, reduction to cost of sales						$ 52			$ 209	$ 39
PM USA [Member] | Health Care Cost Recovery Actions [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states with settled litigation including New York, subsequent expansion | state								36
Settlement agreements, number | claim								2
Number of states with settled litigation | state								37
PM USA [Member] | Health Care Cost Recovery Actions, 2003-2015 NPM Adjustments [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states with settled litigation including New York, subsequent expansion | state			26
​Proceeds from legal settlements			$ 740
Loss contingency, number of settlement developments									2		2
PM USA [Member] | Health Care Cost Recovery Actions, 2004-2017 [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of additional states added | state							10
Payments received from litigation settlement	$ 121	$ 68						$ 248
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Number of states with settled litigation | state				2
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states | state				15
Number of states without defense | state				6
Loss contingency, number of disputes outstanding | state				2
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member] | Cost of Sales [Member]
Loss Contingencies [Line Items]
Loss contingency, reduction to cost of sales				$ 74
PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								388
PM USA [Member] | Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								181
PM USA [Member] | Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								154
PM USA [Member] | Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								185
PM USA [Member] | Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								250
PM USA [Member] | Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								211
PM USA [Member] | Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								218
PM USA [Member] | Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								166
PM USA [Member] | Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								214
PM USA [Member] | Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								224
PM USA [Member] | Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								258
PM USA [Member] | Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								299
PM USA [Member] | Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								292
PM USA [Member] | Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								285
PM USA [Member] | Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain								332
New York [Member] | PM USA [Member] | Health Care Cost Recovery Actions, Transition Years 2004-2017 [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
​Proceeds from legal settlements								$ 265
Maryland, Missouri, New Mexico and Pennsylvania [Member] | PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states remaining | state				4

Contingencies (Other Disputes U

Contingencies (Other Disputes Under the State Settlement Agreements) (Details) $ in Millions	1 Months Ended
	Aug. 31, 2018USD ($)
PM USA [Member] | Other Disputes Under the State Settlement Agreements [Member]
Loss Contingencies [Line Items]
Amount ordered to be paid from other party	$ 9.8

Contingencies (Federal Governme

Contingencies (Federal Government's Lawsuit) (Details) - Federal Governments Lawsuit [Member] - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Aug. 31, 2006	Dec. 31, 2014
Loss Contingencies [Line Items]
Disclosure period	10 years
Implementation of Corrective Communications [Member]
Loss Contingencies [Line Items]
Provision related to litigation recorded		$ 31

Contingencies (Lights_Ultra Lig

Contingencies (Lights/Ultra Lights Cases) (Details)	Oct. 28, 2019casecourt	Oct. 22, 2018case	Oct. 23, 2017case
Lights Ultra Lights Class Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending		2	4
Subsequent Event [Member] | Lights Ultra Lights Class Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending	2
Subsequent Event [Member] | Lights [Member]
Loss Contingencies [Line Items]
Claims not certified, number	23
Subsequent Event [Member] | Lights [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of state courts | court	21

Contingencies (E-vapor Litigati

Contingencies (E-vapor Litigation) (Details) - Subsequent Event [Member] - E-vapor Litigation [Member]	Oct. 28, 2019claim
Pending Class Action Lawsuits [Member]
Loss Contingencies [Line Items]
Number of cases pending	12
Pending Individual Lawsuits [Member]
Loss Contingencies [Line Items]
Number of cases pending	26

Contingencies (UST Litigations

Contingencies (UST Litigations Narrative) (Details)	Oct. 28, 2019claim
Pending Individual Lawsuits [Member] | Subsequent Event [Member] | UST Litigation [Member]
Loss Contingencies [Line Items]
Claims filed, number	1

Contingencies (Guarantees and O

Contingencies (Guarantees and Other Similar Matters Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Loss Contingencies [Line Items]
Contingent liability related to performance surety bonds	$ 27,000,000
Redeemable noncontrolling interest	39,000,000	$ 39,000,000
Letter of Credit [Member]
Loss Contingencies [Line Items]
Credit line available under the agreement	51,000,000
Revolving Credit Facility [Member] | Credit Agreement [Member]
Loss Contingencies [Line Items]
Credit line available under the agreement	$ 3,000,000,000
Debt instrument, term	5 years

Condensed Consolidating Finan_3

Condensed Consolidating Financial Information (Condensed Consolidating Balance Sheets) (Details) - USD ($)	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 1,604,000,000		$ 1,333,000,000
Receivables	165,000,000		142,000,000
Inventories:
Leaf tobacco	820,000,000		940,000,000
Other raw materials	201,000,000		186,000,000
Work in process	598,000,000		647,000,000
Finished product	569,000,000		558,000,000
Inventory, net	2,188,000,000		2,331,000,000
Due from Altria and subsidiaries	0		0
Income taxes	15,000,000		167,000,000
Other current assets	319,000,000		326,000,000
Total current assets	4,291,000,000		4,299,000,000
Property, plant and equipment, at cost	5,009,000,000		4,950,000,000
Less accumulated depreciation	3,047,000,000		3,012,000,000
Property, plant and equipment, net	1,962,000,000		1,938,000,000
Goodwill	5,262,000,000		5,196,000,000			$ 5,307,000,000
Other intangible assets, net	12,688,000,000		12,279,000,000			12,400,000,000
Investments in equity securities	27,346,000,000		30,496,000,000
Investment in consolidated subsidiaries	0		0
Due from Altria and subsidiaries	0		0
Other assets	1,364,000,000		1,430,000,000
Total Assets	52,913,000,000		55,638,000,000
Liabilities
Short-term borrowings	0		12,704,000,000
Current portion of long-term debt	1,000,000,000		1,144,000,000
Accounts payable	246,000,000		399,000,000
Accrued liabilities:
Marketing	554,000,000		586,000,000
Settlement charges	3,094,000,000		3,454,000,000
Other	1,195,000,000		1,403,000,000
Dividends payable	1,573,000,000		1,503,000,000
Due to Altria and subsidiaries	0		0
Total current liabilities	7,662,000,000		21,193,000,000
Long-term debt	26,903,000,000		11,898,000,000
Deferred income taxes	5,240,000,000		5,172,000,000
Accrued pension costs	352,000,000		544,000,000
Accrued postretirement health care costs	1,764,000,000		1,749,000,000
Due to Altria and subsidiaries	0		0
Other liabilities	316,000,000		254,000,000
Total liabilities	42,237,000,000		40,810,000,000
Contingencies
Redeemable noncontrolling interest	39,000,000		39,000,000
Stockholders’ Equity
Common stock	935,000,000		935,000,000
Additional paid-in capital	5,960,000,000		5,961,000,000
Earnings reinvested in the business	39,910,000,000		43,962,000,000
Accumulated other comprehensive losses	(2,402,000,000)		(2,547,000,000)
Cost of repurchased stock	(33,858,000,000)		(33,524,000,000)
Total stockholders’ equity attributable to Altria	10,545,000,000		14,787,000,000
Noncontrolling interests	92,000,000		2,000,000
Total stockholders’ equity	10,637,000,000	$ 14,466,000,000	14,789,000,000	$ 15,496,000,000	$ 15,798,000,000	$ 15,380,000,000
Total Liabilities and Stockholders’ Equity	52,913,000,000		55,638,000,000
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Assets
Cash and cash equivalents	1,541,000,000		1,277,000,000
Receivables	0		0
Inventories:
Leaf tobacco	0		0
Other raw materials	0		0
Work in process	0		0
Finished product	0		0
Inventory, net	0		0
Due from Altria and subsidiaries	85,000,000		46,000,000
Income taxes	47,000,000		100,000,000
Other current assets	83,000,000		41,000,000
Total current assets	1,756,000,000		1,464,000,000
Property, plant and equipment, at cost	0		0
Less accumulated depreciation	0		0
Property, plant and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Investments in equity securities	17,950,000,000		17,696,000,000
Investment in consolidated subsidiaries	23,608,000,000		25,996,000,000
Due from Altria and subsidiaries	4,790,000,000		4,790,000,000
Other assets	107,000,000		193,000,000
Total Assets	48,211,000,000		50,139,000,000
Liabilities
Short-term borrowings			12,704,000,000
Current portion of long-term debt	1,000,000,000		1,144,000,000
Accounts payable	1,000,000		1,000,000
Accrued liabilities:
Marketing	0		0
Settlement charges	0		0
Other	346,000,000		295,000,000
Dividends payable	1,573,000,000		1,503,000,000
Due to Altria and subsidiaries	4,540,000,000		4,499,000,000
Total current liabilities	7,460,000,000		20,146,000,000
Long-term debt	26,903,000,000		11,898,000,000
Deferred income taxes	3,098,000,000		3,010,000,000
Accrued pension costs	146,000,000		187,000,000
Accrued postretirement health care costs	0		0
Due to Altria and subsidiaries	0		0
Other liabilities	59,000,000		111,000,000
Total liabilities	37,666,000,000		35,352,000,000
Contingencies
Redeemable noncontrolling interest	0		0
Stockholders’ Equity
Common stock	935,000,000		935,000,000
Additional paid-in capital	5,960,000,000		5,961,000,000
Earnings reinvested in the business	39,910,000,000		43,962,000,000
Accumulated other comprehensive losses	(2,402,000,000)		(2,547,000,000)
Cost of repurchased stock	(33,858,000,000)		(33,524,000,000)
Total stockholders’ equity attributable to Altria	10,545,000,000		14,787,000,000
Noncontrolling interests	0		0
Total stockholders’ equity	10,545,000,000		14,787,000,000
Total Liabilities and Stockholders’ Equity	48,211,000,000		50,139,000,000
Reportable Legal Entities [Member] | PM USA [Member]
Assets
Cash and cash equivalents	0		0
Receivables	16,000,000		18,000,000
Inventories:
Leaf tobacco	466,000,000		561,000,000
Other raw materials	130,000,000		123,000,000
Work in process	8,000,000		2,000,000
Finished product	105,000,000		128,000,000
Inventory, net	709,000,000		814,000,000
Due from Altria and subsidiaries	3,825,000,000		3,828,000,000
Income taxes	27,000,000		94,000,000
Other current assets	193,000,000		167,000,000
Total current assets	4,770,000,000		4,921,000,000
Property, plant and equipment, at cost	2,940,000,000		2,928,000,000
Less accumulated depreciation	2,153,000,000		2,111,000,000
Property, plant and equipment, net	787,000,000		817,000,000
Goodwill	0		0
Other intangible assets, net	2,000,000		2,000,000
Investments in equity securities	0		0
Investment in consolidated subsidiaries	2,861,000,000		2,825,000,000
Due from Altria and subsidiaries	0		0
Other assets	1,031,000,000		955,000,000
Total Assets	9,451,000,000		9,520,000,000
Liabilities
Short-term borrowings			0
Current portion of long-term debt	0		0
Accounts payable	82,000,000		91,000,000
Accrued liabilities:
Marketing	481,000,000		483,000,000
Settlement charges	3,086,000,000		3,448,000,000
Other	432,000,000		524,000,000
Dividends payable	0		0
Due to Altria and subsidiaries	499,000,000		407,000,000
Total current liabilities	4,580,000,000		4,953,000,000
Long-term debt	0		0
Deferred income taxes	0		0
Accrued pension costs	0		0
Accrued postretirement health care costs	1,073,000,000		1,072,000,000
Due to Altria and subsidiaries	0		0
Other liabilities	88,000,000		47,000,000
Total liabilities	5,741,000,000		6,072,000,000
Contingencies
Redeemable noncontrolling interest	0		0
Stockholders’ Equity
Common stock	0		0
Additional paid-in capital	3,310,000,000		3,310,000,000
Earnings reinvested in the business	611,000,000		359,000,000
Accumulated other comprehensive losses	(211,000,000)		(221,000,000)
Cost of repurchased stock	0		0
Total stockholders’ equity attributable to Altria	3,710,000,000		3,448,000,000
Noncontrolling interests	0		0
Total stockholders’ equity	3,710,000,000		3,448,000,000
Total Liabilities and Stockholders’ Equity	9,451,000,000		9,520,000,000
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	63,000,000		56,000,000
Receivables	149,000,000		124,000,000
Inventories:
Leaf tobacco	354,000,000		379,000,000
Other raw materials	71,000,000		63,000,000
Work in process	590,000,000		645,000,000
Finished product	464,000,000		430,000,000
Inventory, net	1,479,000,000		1,517,000,000
Due from Altria and subsidiaries	1,331,000,000		1,194,000,000
Income taxes	44,000,000		0
Other current assets	43,000,000		118,000,000
Total current assets	3,109,000,000		3,009,000,000
Property, plant and equipment, at cost	2,069,000,000		2,022,000,000
Less accumulated depreciation	894,000,000		901,000,000
Property, plant and equipment, net	1,175,000,000		1,121,000,000
Goodwill	5,262,000,000		5,196,000,000
Other intangible assets, net	12,686,000,000		12,277,000,000
Investments in equity securities	9,396,000,000		12,800,000,000
Investment in consolidated subsidiaries	0		0
Due from Altria and subsidiaries	0		0
Other assets	897,000,000		952,000,000
Total Assets	32,525,000,000		35,355,000,000
Liabilities
Short-term borrowings			0
Current portion of long-term debt	0		0
Accounts payable	163,000,000		307,000,000
Accrued liabilities:
Marketing	73,000,000		103,000,000
Settlement charges	8,000,000		6,000,000
Other	520,000,000		611,000,000
Dividends payable	0		0
Due to Altria and subsidiaries	202,000,000		162,000,000
Total current liabilities	966,000,000		1,189,000,000
Long-term debt	0		0
Deferred income taxes	2,813,000,000		2,832,000,000
Accrued pension costs	206,000,000		357,000,000
Accrued postretirement health care costs	691,000,000		677,000,000
Due to Altria and subsidiaries	4,790,000,000		4,790,000,000
Other liabilities	169,000,000		96,000,000
Total liabilities	9,635,000,000		9,941,000,000
Contingencies
Redeemable noncontrolling interest	39,000,000		39,000,000
Stockholders’ Equity
Common stock	9,000,000		9,000,000
Additional paid-in capital	27,493,000,000		25,047,000,000
Earnings reinvested in the business	(2,937,000,000)		2,201,000,000
Accumulated other comprehensive losses	(1,806,000,000)		(1,884,000,000)
Cost of repurchased stock	0		0
Total stockholders’ equity attributable to Altria	22,759,000,000		25,373,000,000
Noncontrolling interests	92,000,000		2,000,000
Total stockholders’ equity	22,851,000,000		25,375,000,000
Total Liabilities and Stockholders’ Equity	32,525,000,000		35,355,000,000
Total Consolidating Adjustments [Member]
Assets
Cash and cash equivalents	0		0
Receivables	0		0
Inventories:
Leaf tobacco	0		0
Other raw materials	0		0
Work in process	0		0
Finished product	0		0
Inventory, net	0		0
Due from Altria and subsidiaries	(5,241,000,000)		(5,068,000,000)
Income taxes	(103,000,000)		(27,000,000)
Other current assets	0		0
Total current assets	(5,344,000,000)		(5,095,000,000)
Property, plant and equipment, at cost	0		0
Less accumulated depreciation	0		0
Property, plant and equipment, net	0		0
Goodwill	0		0
Other intangible assets, net	0		0
Investments in equity securities	0		0
Investment in consolidated subsidiaries	(26,469,000,000)		(28,821,000,000)
Due from Altria and subsidiaries	(4,790,000,000)		(4,790,000,000)
Other assets	(671,000,000)		(670,000,000)
Total Assets	(37,274,000,000)		(39,376,000,000)
Liabilities
Short-term borrowings			0
Current portion of long-term debt	0		0
Accounts payable	0		0
Accrued liabilities:
Marketing	0		0
Settlement charges	0		0
Other	(103,000,000)		(27,000,000)
Dividends payable	0		0
Due to Altria and subsidiaries	(5,241,000,000)		(5,068,000,000)
Total current liabilities	(5,344,000,000)		(5,095,000,000)
Long-term debt	0		0
Deferred income taxes	(671,000,000)		(670,000,000)
Accrued pension costs	0		0
Accrued postretirement health care costs	0		0
Due to Altria and subsidiaries	(4,790,000,000)		(4,790,000,000)
Other liabilities	0		0
Total liabilities	(10,805,000,000)		(10,555,000,000)
Contingencies
Redeemable noncontrolling interest	0		0
Stockholders’ Equity
Common stock	(9,000,000)		(9,000,000)
Additional paid-in capital	(30,803,000,000)		(28,357,000,000)
Earnings reinvested in the business	2,326,000,000		(2,560,000,000)
Accumulated other comprehensive losses	2,017,000,000		2,105,000,000
Cost of repurchased stock	0		0
Total stockholders’ equity attributable to Altria	(26,469,000,000)		(28,821,000,000)
Noncontrolling interests	0		0
Total stockholders’ equity	(26,469,000,000)		(28,821,000,000)
Total Liabilities and Stockholders’ Equity	$ (37,274,000,000)		$ (39,376,000,000)

Condensed Consolidating Finan_4

Condensed Consolidating Financial Information (Condensed Consolidating Statements of Earnings and Comprehensive Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 6,856	$ 6,837	$ 19,103	$ 19,250
Cost of sales	1,915	2,037	5,367	5,509
Excise taxes on products	1,444	1,545	4,109	4,409
Gross profit	3,497	3,255	9,627	9,332
Marketing, administration and research costs	552	700	1,654	1,959
Asset impairment and exit costs	1	(2)	74	2
Operating income (expense)	2,944	2,557	7,899	7,371
Interest and other debt expense (income), net	293	159	989	503
Net periodic benefit (income) cost, excluding service cost	(24)	(21)	(40)	(37)
Earnings from equity investments	(333)	(189)	(866)	(759)
Impairment of JUUL equity securities	4,500	0	4,500	0
Loss on Cronos-related financial instruments	636		1,327
Loss on ABI/SABMiller business combination	0	0	0	33
Earnings (losses) before income taxes and equity earnings of subsidiaries	(2,128)	2,608	1,989	7,631
Provision (benefit) for income taxes	474	664	1,473	1,915
Equity earnings of subsidiaries	0	0	0	0
Net earnings (losses)	(2,602)	1,944	516	5,716
Net (earnings) losses attributable to noncontrolling interests	2	(1)	0	(3)
Net earnings (losses) attributable to Altria	(2,600)	1,943	516	5,713
Net earnings (losses)	(2,602)	1,944	516	5,716
Other comprehensive earnings (losses), net of deferred income taxes	244	(382)	145	(137)
Comprehensive earnings (losses)	(2,358)	1,562	661	5,579
Comprehensive (earnings) losses attributable to noncontrolling interests	2	(1)	0	(3)
Comprehensive earnings (losses) attributable to Altria	(2,356)	1,561	661	5,576
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0	0	0
Cost of sales	0	0	0	0
Excise taxes on products	0	0	0	0
Gross profit	0	0	0	0
Marketing, administration and research costs	41	45	125	122
Asset impairment and exit costs	0	0	1	0
Operating income (expense)	(41)	(45)	(126)	(122)
Interest and other debt expense (income), net	258	127	892	378
Net periodic benefit (income) cost, excluding service cost	0	1	1	3
Earnings from equity investments	(252)	(189)	(640)	(759)
Impairment of JUUL equity securities	0		0
Loss on Cronos-related financial instruments	0		0
Loss on ABI/SABMiller business combination				33
Earnings (losses) before income taxes and equity earnings of subsidiaries	(47)	16	(379)	223
Provision (benefit) for income taxes	(93)	21	(180)	67
Equity earnings of subsidiaries	(2,646)	1,948	715	5,557
Net earnings (losses)	(2,600)	1,943	516	5,713
Net (earnings) losses attributable to noncontrolling interests	0	0	0	0
Net earnings (losses) attributable to Altria	(2,600)	1,943	516	5,713
Net earnings (losses)	(2,600)	1,943	516	5,713
Other comprehensive earnings (losses), net of deferred income taxes	244	(382)	145	(137)
Comprehensive earnings (losses)	(2,356)	1,561	661	5,576
Comprehensive (earnings) losses attributable to noncontrolling interests	0	0	0	0
Comprehensive earnings (losses) attributable to Altria	(2,356)	1,561	661	5,576
Reportable Legal Entities [Member] | PM USA [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	5,804	5,811	16,140	16,339
Cost of sales	1,644	1,736	4,594	4,666
Excise taxes on products	1,391	1,491	3,949	4,245
Gross profit	2,769	2,584	7,597	7,428
Marketing, administration and research costs	392	491	1,181	1,400
Asset impairment and exit costs	0	0	38	0
Operating income (expense)	2,377	2,093	6,378	6,028
Interest and other debt expense (income), net	(20)	(20)	(64)	(37)
Net periodic benefit (income) cost, excluding service cost	(19)	(18)	(32)	(33)
Earnings from equity investments	0	0	0	0
Impairment of JUUL equity securities	0		0
Loss on Cronos-related financial instruments	0		0
Loss on ABI/SABMiller business combination				0
Earnings (losses) before income taxes and equity earnings of subsidiaries	2,416	2,131	6,474	6,098
Provision (benefit) for income taxes	590	539	1,610	1,537
Equity earnings of subsidiaries	117	119	326	310
Net earnings (losses)	1,943	1,711	5,190	4,871
Net (earnings) losses attributable to noncontrolling interests	0	0	0	0
Net earnings (losses) attributable to Altria	1,943	1,711	5,190	4,871
Net earnings (losses)	1,943	1,711	5,190	4,871
Other comprehensive earnings (losses), net of deferred income taxes	1	2	10	10
Comprehensive earnings (losses)	1,944	1,713	5,200	4,881
Comprehensive (earnings) losses attributable to noncontrolling interests	0	0	0	0
Comprehensive earnings (losses) attributable to Altria	1,944	1,713	5,200	4,881
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	1,062	1,035	2,991	2,938
Cost of sales	281	310	801	870
Excise taxes on products	53	54	160	164
Gross profit	728	671	2,030	1,904
Marketing, administration and research costs	119	164	348	437
Asset impairment and exit costs	1	(2)	35	2
Operating income (expense)	608	509	1,647	1,465
Interest and other debt expense (income), net	55	52	161	162
Net periodic benefit (income) cost, excluding service cost	(5)	(4)	(9)	(7)
Earnings from equity investments	(81)	0	(226)	0
Impairment of JUUL equity securities	4,500		4,500
Loss on Cronos-related financial instruments	636		1,327
Loss on ABI/SABMiller business combination				0
Earnings (losses) before income taxes and equity earnings of subsidiaries	(4,497)	461	(4,106)	1,310
Provision (benefit) for income taxes	(23)	104	43	311
Equity earnings of subsidiaries	0	0	0	0
Net earnings (losses)	(4,474)	357	(4,149)	999
Net (earnings) losses attributable to noncontrolling interests	2	(1)	0	(3)
Net earnings (losses) attributable to Altria	(4,472)	356	(4,149)	996
Net earnings (losses)	(4,474)	357	(4,149)	999
Other comprehensive earnings (losses), net of deferred income taxes	20	36	78	109
Comprehensive earnings (losses)	(4,454)	393	(4,071)	1,108
Comprehensive (earnings) losses attributable to noncontrolling interests	2	(1)	0	(3)
Comprehensive earnings (losses) attributable to Altria	(4,452)	392	(4,071)	1,105
Total Consolidating Adjustments [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	(10)	(9)	(28)	(27)
Cost of sales	(10)	(9)	(28)	(27)
Excise taxes on products	0	0	0	0
Gross profit	0	0	0	0
Marketing, administration and research costs	0	0	0	0
Asset impairment and exit costs	0	0	0	0
Operating income (expense)	0	0	0	0
Interest and other debt expense (income), net	0	0	0	0
Net periodic benefit (income) cost, excluding service cost	0	0	0	0
Earnings from equity investments	0	0	0	0
Impairment of JUUL equity securities	0		0
Loss on Cronos-related financial instruments	0		0
Loss on ABI/SABMiller business combination				0
Earnings (losses) before income taxes and equity earnings of subsidiaries	0	0	0	0
Provision (benefit) for income taxes	0	0	0	0
Equity earnings of subsidiaries	2,529	(2,067)	(1,041)	(5,867)
Net earnings (losses)	2,529	(2,067)	(1,041)	(5,867)
Net (earnings) losses attributable to noncontrolling interests	0	0	0	0
Net earnings (losses) attributable to Altria	2,529	(2,067)	(1,041)	(5,867)
Net earnings (losses)	2,529	(2,067)	(1,041)	(5,867)
Other comprehensive earnings (losses), net of deferred income taxes	(21)	(38)	(88)	(119)
Comprehensive earnings (losses)	2,508	(2,105)	(1,129)	(5,986)
Comprehensive (earnings) losses attributable to noncontrolling interests	0	0	0	0
Comprehensive earnings (losses) attributable to Altria	$ 2,508	$ (2,105)	$ (1,129)	$ (5,986)

Condensed Consolidating Finan_5

Condensed Consolidating Financial Information (Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	$ 5,274	$ 6,566
Cash Provided by (Used in) Investing Activities
Capital expenditures	(160)	(132)
Investment in Cronos	(1,863)	0
Acquisition of businesses and assets	(421)	(15)
Investment in consolidated subsidiaries	0	0
Other, net	32	10
Net cash provided by (used in) investing activities	(2,412)	(137)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	(12,800)	0
Long-term debt issued	16,265	0
Long-term debt repaid	(1,144)	0
Repurchases of common stock	(346)	(1,317)
Dividends paid on common stock	(4,498)	(3,909)
Changes in amounts due to/from Altria and subsidiaries	0	0
Cash dividends paid to parent	0	0
Other, net	(127)	(25)
Net cash provided by (used in) financing activities	(2,650)	(5,251)
Cash, cash equivalents and restricted cash:
Increase (decrease)	212	1,178
Balance at beginning of period	1,433	1,314
Balance at end of period	1,645	2,492
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	5,330	4,806
Cash Provided by (Used in) Investing Activities
Capital expenditures	0	0
Investment in Cronos	0
Acquisition of businesses and assets	0	0
Investment in consolidated subsidiaries	(2,446)	(191)
Other, net	22	8
Net cash provided by (used in) investing activities	(2,424)	(183)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	(12,800)
Long-term debt issued	16,265
Long-term debt repaid	(1,144)
Repurchases of common stock	(346)	(1,317)
Dividends paid on common stock	(4,498)	(3,909)
Changes in amounts due to/from Altria and subsidiaries	3	1,767
Cash dividends paid to parent	0	0
Other, net	(122)	(21)
Net cash provided by (used in) financing activities	(2,642)	(3,480)
Cash, cash equivalents and restricted cash:
Increase (decrease)	264	1,143
Balance at beginning of period	1,277	1,203
Balance at end of period	1,541	2,346
Reportable Legal Entities [Member] | PM USA [Member]
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	4,862	5,801
Cash Provided by (Used in) Investing Activities
Capital expenditures	(26)	(33)
Investment in Cronos	0
Acquisition of businesses and assets	0	0
Investment in consolidated subsidiaries	0	0
Other, net	1	0
Net cash provided by (used in) investing activities	(25)	(33)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	0
Long-term debt issued	0
Long-term debt repaid	0
Repurchases of common stock	0	0
Dividends paid on common stock	0	0
Changes in amounts due to/from Altria and subsidiaries	42	(1,565)
Cash dividends paid to parent	(4,938)	(4,166)
Other, net	0	0
Net cash provided by (used in) financing activities	(4,896)	(5,731)
Cash, cash equivalents and restricted cash:
Increase (decrease)	(59)	37
Balance at beginning of period	100	62
Balance at end of period	41	99
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	1,009	1,123
Cash Provided by (Used in) Investing Activities
Capital expenditures	(134)	(99)
Investment in Cronos	(1,863)
Acquisition of businesses and assets	(421)	(15)
Investment in consolidated subsidiaries	0	0
Other, net	9	2
Net cash provided by (used in) investing activities	(2,409)	(112)
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	0
Long-term debt issued	0
Long-term debt repaid	0
Repurchases of common stock	0	0
Dividends paid on common stock	0	0
Changes in amounts due to/from Altria and subsidiaries	2,401	(11)
Cash dividends paid to parent	(989)	(998)
Other, net	(5)	(4)
Net cash provided by (used in) financing activities	1,407	(1,013)
Cash, cash equivalents and restricted cash:
Increase (decrease)	7	(2)
Balance at beginning of period	56	49
Balance at end of period	63	47
Total Consolidating Adjustments [Member]
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	(5,927)	(5,164)
Cash Provided by (Used in) Investing Activities
Capital expenditures	0	0
Investment in Cronos	0
Acquisition of businesses and assets	0	0
Investment in consolidated subsidiaries	2,446	191
Other, net	0	0
Net cash provided by (used in) investing activities	2,446	191
Cash Provided by (Used in) Financing Activities
Repayment of short-term borrowings	0
Long-term debt issued	0
Long-term debt repaid	0
Repurchases of common stock	0	0
Dividends paid on common stock	0	0
Changes in amounts due to/from Altria and subsidiaries	(2,446)	(191)
Cash dividends paid to parent	5,927	5,164
Other, net	0	0
Net cash provided by (used in) financing activities	3,481	4,973
Cash, cash equivalents and restricted cash:
Increase (decrease)	0	0
Balance at beginning of period	0	0
Balance at end of period	$ 0	$ 0

Uncategorized Items - a2019form

Label	Element	Value	[1]
Restricted Cash, Noncurrent	us-gaap_RestrictedCashNoncurrent	$ 40,000,000
Restricted Cash, Noncurrent	us-gaap_RestrictedCashNoncurrent	43,000,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	57,000,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	$ 1,000,000
[1]	Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 13 . Contingencies .